Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Pacific Bridge Medical

## Sitemaps
[XML Sitemap](https://www.pacificbridgemedical.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Regulatory Considerations for In Vitro Companion Diagnostic Devices in Taiwan](https://www.pacificbridgemedical.com/uncategorized/taiwans-cdx-ivd/): Precision medicine has changed the way doctors prescribe treatments. Instead of using a one-size-fits-all approach, clinicians increasingly tailor therapies to individual patients. Companion diagnostics sit at the center of this shift. These tests help doctors determine whether a patient is likely to benefit from a specific drug, face a higher risk of adverse reactions, or require adjustments to therapy.
- [Understanding Japan’s GMP Compliance Inspection System](https://www.pacificbridgemedical.com/uncategorized/understanding-japans-gmp-compliance-inspection-system/): Good Manufacturing Practice (GMP) compliance is required for drug registration approval in Japan. The Pharmaceuticals and Medical Devices Agency (PMDA) conducts GMP inspections at foreign manufacturing sites to verify adherence to Japan’s GMP ordinance (MHLW Ordinance No. 179, 2004). This article provides an overview of Japan’s GMP inspection types, scope, and procedures, with special focus on requirements for foreign manufacturers.
- [Understanding Japan’s Quality Management System (QMS) Regulations for Medical Devices](https://www.pacificbridgemedical.com/uncategorized/understandaing-japan-qms/): Japan’s medical device regulatory landscape underwent a significant transformation with the revision of its Quality Management System (QMS) requirements under the Pharmaceutical and Medical Device Act (PMD Act) in 2015. The updated QMS ordinance introduced new inspection types, registration requirements, and harmonization with international standards, notably ISO 13485. This article provides an overview of the updated QMS regulations for medical devices and in-vitro diagnostics (IVDs) in Japan, based on the latest guidance from the Pharmaceuticals and Medical Devices Agency (PMDA).
- [India Medical Device Registration Overview](https://www.pacificbridgemedical.com/uncategorized/india-medical-device-registration-overview/): India’s rapidly growing healthcare sector and large population present significant opportunities for global medical device manufacturers. However, navigating India’s regulatory landscape, particularly the requirements of the Central Drugs Standard Control Organization (CDSCO), is critical for market entry and long-term success. As the national regulatory authority for drugs, medical devices, and cosmetics, CDSCO has taken major steps in recent years to strengthen and streamline its medical device regulatory framework to align with global best practices.
- [Indonesia Medical Device Registration Overview](https://www.pacificbridgemedical.com/uncategorized/indonesia-medical-device-registration-overview/): Indonesia’s medical devices and in vitro diagnostics (IVDs) are regulated by the Indonesian Ministry of Health (MoH), specifically its Directorate General of Pharmaceutical and Medical Devices. Registration and licensing are required for all imported or domestically manufactured medical devices before they are introduced to the market.
- [Vietnam Pharmaceutical Registration Overview](https://www.pacificbridgemedical.com/uncategorized/vietnam-pharmaceutical-registration-overview/): Vietnam’s pharmaceutical sector has experienced consistent growth over the past decade, spurred by rising healthcare demands, government initiatives to modernize the healthcare system, and increased foreign investment. For international pharmaceutical companies aiming to enter this emerging market, a deep understanding of Vietnam’s regulatory environment is essential.
- [Thailand Medical Device Registration Overview](https://www.pacificbridgemedical.com/uncategorized/thailand-medical-device-registration-overview/): As medical technologies evolve at lightning speed – integrating artificial intelligence, wearable tech, and patient-directed innovations – regulatory agencies worldwide are working to keep pace. Thailand is no exception. Over the past decade, the country has introduced reforms to its medical device regulatory framework to safeguard public health while promoting innovation and getting the best treatments for Thai citizens. If you're looking to register a medical device in Thailand, understanding the evolving regulatory landscape is essential.
- [Vietnam Medical Device Registration Overview](https://www.pacificbridgemedical.com/uncategorized/vietnam-medical-device-registration-overview/): Vietnam is one of the fastest-growing healthcare markets in Southeast Asia, making it an attractive destination for global medical device manufacturers. With a population exceeding 98 million and a healthcare system undergoing modernization, the demand for advanced medical technologies is rising steadily. Medical device imports make up more than 90% of the market, opening a significant window of opportunity for international players, provided they understand and comply with the country’s evolving regulatory landscape.
- [Japan Pharmaceutical Registration Overview and Update](https://www.pacificbridgemedical.com/uncategorized/japan-pharmaceutical-registration-overview-and-update/): Introduction
- [Thailand Pharmaceutical Registration Overview](https://www.pacificbridgemedical.com/uncategorized/thailand-pharmaceutical-registration-overview/): Thailand’s pharmaceutical sector is expanding rapidly, fueled by a growing healthcare market and an evolving regulatory environment that aims to balance safety, innovation, and accessibility. For companies seeking to enter the Thai pharmaceutical market, understanding the regulatory framework is crucial – particularly the drug classification system and product registration process administered by the Thai Food and Drug Administration (Thai FDA).
- [Medical Device Registration in Singapore: A 2025 Update](https://www.pacificbridgemedical.com/uncategorized/singapore-medical-device-2025-updates/): Singapore continues to assert itself as a regional leader in medical device regulation, innovation, and cybersecurity preparedness. Over the past year, the Health Sciences Authority (HSA), along with other regulatory and policy bodies in Singapore, introduced and revised several key platforms governing the lifecycle of medical devices. These changes reflect the city-state’s broader strategy to create a robust yet agile regulatory environment that supports rapid technological advances, especially in the domains of artificial intelligence (AI), cybersecurity, and Software as a Medical Device (SaMD). This article summarizes the most recent developments and regulatory initiatives affecting medical device registration and oversight in Singapore as of mid-2025.
- [What Documents Are Required for Medical Device Registration in Malaysia?](https://www.pacificbridgemedical.com/uncategorized/what-documents-are-required-for-medical-device-registration-in-malaysia/): Malaysia's medical device regulatory framework, governed by the Medical Device Authority (MDA), continues to evolve with increasing emphasis on pre- and post-market compliance. Whether you are registering a low-risk (Class A) product or a moderate-to-high-risk (Class B, C, or D) device, understanding the documentation requirements is essential for a smooth and timely approval process.
- [China’s Shifting Regulatory Landscape for Medical Devices: A 2025 Update](https://www.pacificbridgemedical.com/uncategorized/chinas-shifting-regulatory-landscape-for-medical-devices-a-2025-update/): In recent months, China has proposed and implemented several key reforms to its medical device regulatory framework, indicating a broader strategy to reshape how foreign and domestic medical products are evaluated, approved, and monitored. These changes reflect an ongoing effort by the Chinese government to strike a balance between encouraging innovation, bolstering domestic capabilities, and ensuring tighter regulatory compliance.
- [Japan’s Medical Device Regulatory Framework: An Update](https://www.pacificbridgemedical.com/uncategorized/japans-medical-device-regulatory-framework-an-update/): Over the past year, Japan has introduced a series of regulatory reforms aimed at modernizing and accelerating the approval and reimbursement pathways for medical devices, especially Software as a Medical Device (SaMD) products. These reforms are part of Japan’s broader effort to align its regulatory environment more closely with international norms while encouraging innovation and ensuring patient safety.
- [Korea Overhauls Drug Regulatory Landscape: Faster Reviews, More Innovation, Better Access](https://www.pacificbridgemedical.com/uncategorized/korea-overhauls-drug-regulatory-landscape-faster-reviews-more-innovation-better-access/): In the past year, Korea has launched an ambitious suite of pharmaceutical regulatory reforms designed to accelerate drug approvals, foster innovation, and improve patient access to essential medicines. As the Ministry of Food and Drug Safety (MFDS) faces criticism over protracted review timelines, the Korean government has taken bold steps to modernize its processes and harmonize its systems with international benchmarks.
- [Recent Pharmaceutical Regulatory Developments in Japan: A 2025 Update](https://www.pacificbridgemedical.com/uncategorized/recent-pharmaceutical-regulatory-developments-in-japan-a-2025-update/): Japan's pharmaceutical regulatory landscape is undergoing significant transformation in 2025, driven by a collective push to reduce Japan’s drug lag, enhance clinical trial systems, modernize post-approval processes, and support innovative therapies. These changes – initiated by the Ministry of Health, Labour and Welfare (MHLW), the Pharmaceuticals and Medical Devices Agency (PMDA), and other regulatory entities – aim to streamline drug development, accelerate access to novel therapies, and align Japan’s regulatory frameworks with global best practices.
- [China’s Pharmaceutical Regulatory Landscape: Key Developments in 2024–2025](https://www.pacificbridgemedical.com/uncategorized/chinas-pharmaceutical-regulatory-landscape-key-developments-in-2024-2025/): China’s pharmaceutical sector has been undergoing significant transformations in the past year, with sweeping reforms affecting drug reimbursement, approval processes, market access pathways, and the oversight of pharmaceutical representatives. Together, these policy shifts aim to enhance access to high-quality treatments, increase efficiency in drug registration, and strengthen compliance mechanisms. This article explores recent regulatory updates shaping the Chinese drug market and examines their potential impact on domestic and international stakeholders.
- [Japan Medical Device Reimbursement: Focus on Novel Device Reimbursement Category C2](https://www.pacificbridgemedical.com/uncategorized/japan-medical-device-reimbursement-focus-on-novel-device-reimbursement-category-c2/): Japan’s healthcare system is known for its efficiency and centralized regulation, which also extends into its medical device reimbursement process. For foreign and domestic manufacturers alike, understanding Japan medical device reimbursement framework is essential for successful market entry and sustained commercial success. Among the various reimbursement pathways, the C2 category stands out for devices that are novel and fall outside the standard classification and pricing mechanisms. This article will explore the foundational aspects of Japan's reimbursement system for novel devices and delve deeply into the C2 category – its application requirements, data needs, and pricing considerations.
- [Japan’s GMP Compliance System for Foreign Drug Manufacturers](https://www.pacificbridgemedical.com/uncategorized/japans-gmp-compliance-system-for-foreign-drug-manufacturers/): Japan maintains one of the most rigorous and structured Good Manufacturing Practice (GMP) compliance frameworks globally. Designed to ensure the safety, efficacy, and quality of drugs and quasi-drugs, Japan's GMP regime is enforced by the Pharmaceuticals and Medical Devices Agency (PMDA), under the Ministry of Health, Labour and Welfare (MHLW). For foreign manufacturers seeking to obtain or maintain market authorization in Japan, understanding and navigating this regulatory landscape is crucial.
- [South Korea: Recent Medical Device Registration Changes Reshape the Healthcare Landscape](https://www.pacificbridgemedical.com/uncategorized/south-korea-recent-medical-device-registration-changes/): South Korea has long stood at the forefront of technological advancement in Asia, with a robust healthcare system and a rapidly growing digital health ecosystem. In line with its reputation as a global innovator, South Korea has recently introduced several major regulatory reforms in the medical device sector. These changes, implemented or announced between late 2023 and early 2025, reflect the government’s intention to promote innovation, facilitate faster market access, and ensure the safety and effectiveness of new technologies.
- [Singapore Medical Device Registration: Class C Devices](https://www.pacificbridgemedical.com/uncategorized/singapore-class-c-medical-device-registration/): Singapore’s medical device regulatory framework is considered one of the most transparent and robust systems in the Asia-Pacific region. Managed by the Health Sciences Authority (HSA), the regulatory process aims to ensure the safety, efficacy, and quality of medical devices entering the market. For companies seeking to register Class C devices, the process can be navigated efficiently with a clear understanding of the available evaluation routes, eligibility criteria, and documentation requirements. This article provides a comprehensive guide to registering Class C medical devices in Singapore, based on the latest regulations outlined in HSA’s guidance documents.
- [Drug Registration in Malaysia: A Comprehensive Guide to Regulatory Compliance](https://www.pacificbridgemedical.com/uncategorized/drug-registration-in-malaysia/): Malaysia has developed a robust and evolving regulatory system to govern the safety, efficacy, and quality of medicinal products. At the core of this system is the 1984 regulation – Control of Drugs and Cosmetics Regulations (CDCR). These regulations set the legal foundation for drug registration in the country and empower the Drug Control Authority (DCA) to oversee the full lifecycle of pharmaceutical products — from registration and licensing to post-market surveillance and enforcement.
- [Navigating Medical Device Registration in Malaysia: A Comprehensive Guide](https://www.pacificbridgemedical.com/uncategorized/navigating-medical-device-registration-in-malaysia-a-comprehensive-guide/): Malaysia's healthcare sector continues to grow rapidly, supported by a robust regulatory environment aimed at ensuring the safety, quality, and performance of medical devices. Central to this framework is the Medical Device Act 2012 (Act 737. Under this Act, all medical devices must be registered with the Medical Device Authority (MDA) before they can be imported, exported, or marketed in Malaysia. This article outlines the full registration process, responsibilities, and regulatory requirements, based on the guidelines issued by the MDA.
- [Understanding Japan’s Drug Master File System: A Comprehensive Guide](https://www.pacificbridgemedical.com/uncategorized/understanding-japan-drug-master-file/): The Drug Master File (DMF) system in Japan serves as a critical regulatory mechanism enabling pharmaceutical manufacturers, both domestic and foreign, to confidentially register the quality and manufacturing data of drug substances, intermediates, and related materials with Japan’s review authority. Managed by the Pharmaceuticals and Medical Devices Agency (PMDA), this system is designed to facilitate the approval of pharmaceutical products by allowing finished drug manufacturers to reference the DMF during the drug approval process. This article provides a comprehensive overview of the DMF system, its scope, procedures, requirements, and implications for international stakeholders.
- [Understanding Singapore’s Drug Master File (DMF) Guideline: A Strategic Tool for Therapeutic Product Registration](https://www.pacificbridgemedical.com/uncategorized/understanding-singapore-drug-master-file/): Navigating regulatory landscapes can be daunting, especially when dealing with proprietary drug substance information. For pharmaceutical companies planning to register therapeutic products in Singapore, understanding the requirements of a Drug Master File (DMF) is essential. In August 2024, Singapore's Health Sciences Authority (HSA) updated its DMF guideline as part of the broader "Guidance on Therapeutic Product Registration." This blog post unpacks the purpose, structure, and lifecycle of the DMF submission process in Singapore and offers practical insights for applicants and DMF holders alike.
- [Taiwan’s Regulatory Framework for Regenerative Medicine](https://www.pacificbridgemedical.com/uncategorized/taiwan-regulatory-framework-for-regenerative-medicine/): Regenerative medicine is an innovative and rapidly evolving field that leverages genes, cells, and their derivatives to reconstruct or repair human body structures and functions, ultimately aiming to treat or prevent diseases. This field has the potential to revolutionize healthcare by offering new therapeutic options for conditions that are currently difficult or impossible to treat with conventional medicine.
- [Singapore Medical Device Registration: An Overview](https://www.pacificbridgemedical.com/uncategorized/singapore-medical-device-registration-an-overview/): The Health Sciences Authority (HSA) of Singapore is responsible for overseeing the registration of medical devices to ensure their safety, efficacy, and quality before they can be marketed and used within the country. The registration process for medical devices follows specific evaluation routes, which are determined based on multiple factors. These factors include the risk classification of the device, whether the device has received prior approvals from overseas reference regulatory agencies, and the duration for which the device has been marketed safely in other jurisdictions. The chosen evaluation route determines the required documentation, associated fees, and turnaround time (TAT) for the registration process.
- [Regulation of Software as a Medical Device in Taiwan](https://www.pacificbridgemedical.com/uncategorized/regulations-of-software-as-a-medical-device-in-taiwan/): Software as a Medical Device (SaMD) is an evolving sector within the medical device industry, providing essential tools for healthcare applications such as diagnostics, treatment planning, patient monitoring, and telemedicine. Taiwan’s regulatory framework for SaMD is overseen by the Taiwan Food and Drug Administration (TFDA) under the Ministry of Health and Welfare (MOHW). The TFDA is responsible for ensuring that all medical software products that fall within its jurisdiction meet stringent safety, quality, and effectiveness standards before they are allowed to enter the market. This article provides a comprehensive overview of Taiwan’s regulatory landscape for SaMD, covering its definition, classification, registration process, and regulatory requirements.
- [Taiwan: Registration of Medical Device and Drug Combination Products](https://www.pacificbridgemedical.com/uncategorized/taiwan-medical-device-drug-combination-products/): Combination products are classified based on the “Key Points for Combination Product Determination.” These products fall into two main categories. The first category includes a single product that integrates pharmaceuticals and medical devices, where the components are combined physically, chemically, or through other means, and are manufactured by a single entity. The second category consists of a set or package containing two or more pharmaceutical and medical device items that are intended to be used together. These products are designed to work synergistically to achieve a combined therapeutic effect, ensuring better treatment outcomes for patients. Given the complexity of combination products, regulatory frameworks must clearly define their classification and approval processes.
- [Singapore Drug Registration: A Comprehensive Guide](https://www.pacificbridgemedical.com/uncategorized/singapore-drug-registration-a-comprehensive-guide/): Singapore has a well-structured and rigorous regulatory framework for drug registration, which is overseen by the Health Sciences Authority (HSA) under the Health Products Act (HPA). The HSA is responsible for evaluating, approving, and regulating therapeutic products before they can be supplied in the country. Companies that intend to engage in the manufacturing, importing, or wholesaling of pharmaceutical products must obtain the relevant licenses to legally operate within Singapore. The entire registration process is designed to ensure that only high-quality, effective, and safe pharmaceutical products reach the market, thereby protecting public health.
- [Understanding Medical Device Registration in Japan](https://www.pacificbridgemedical.com/uncategorized/understanding-medical-device-registration-in-japan/): Japan has a well-defined regulatory framework for medical devices, ensuring their safety, efficacy, and quality before they reach the market. The process is governed by two key regulatory authorities: the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).
- [Navigating Korea’s Evolving Drug Registration Landscape](https://www.pacificbridgemedical.com/uncategorized/navigating-koreas-evolving-drug-registration-landscape/): The drug registration process in Korea is a meticulously structured system overseen by the Ministry of Food and Drug Safety (MFDS). This process is designed to ensure that all pharmaceuticals meet stringent standards of safety, efficacy, and quality before they are made available to the public. The journey from drug development to market approval involves several critical stages, including classification, data submission, comprehensive review, and post-approval obligations.
- [Understanding China’s Drug Registration Process](https://www.pacificbridgemedical.com/uncategorized/understanding-chinas-drug-registration-process/): China's pharmaceutical market, the second-largest globally, offers immense opportunities for international drug manufacturers. However, navigating the country's drug registration process requires an in-depth understanding of its regulatory framework, primarily overseen by the National Medical Products Administration (NMPA). This article explores the critical steps, classifications, and reforms in China's drug registration process, providing valuable insights for pharmaceutical companies looking to enter this rapidly evolving market.
- [Navigating Korea’s Medical Device Registration Process: A Comprehensive Guide](https://www.pacificbridgemedical.com/uncategorized/navigating-koreas-medical-device-registration-process-a-comprehensive-guide/): Korea's medical device market is one of the fastest-growing in Asia, offering significant opportunities for international manufacturers. With a healthcare system that places a strong emphasis on cutting-edge medical technologies, entering the Korean market can be highly rewarding. However, to succeed, companies must navigate a complex regulatory landscape governed by the Ministry of Food and Drug Safety (MFDS). This guide provides an in-depth look at the medical device registration process in Korea, detailing classifications, procedural steps, key documentation, and recent regulatory updates that are shaping the future of digital healthcare.
- [A Guide to Taiwan Medical Device Registration](https://www.pacificbridgemedical.com/uncategorized/a-guide-to-taiwan-medical-device-registration/): Taiwan's medical device registration system, managed by the Taiwan Food and Drug Administration (TFDA), is known for its well-defined regulatory framework and high standards for safety and efficacy. This process also encourages innovation, especially for digital and smart technology medical devices that incorporate cutting-edge technologies like artificial intelligence (AI), wearable sensors, and the Internet of Things (IoT). This guide explores the entire registration process, classifications, cybersecurity considerations, and post-market requirements to provide a comprehensive understanding for manufacturers looking to navigate the Taiwanese market.
- [Navigating China’s Drug Master File (DMF) System](https://www.pacificbridgemedical.com/uncategorized/navigating-chinas-drug-master-file-dmf-system/): China’s pharmaceutical market, the second largest in the world, continues to attract international manufacturers of active pharmaceutical ingredients (APIs), excipients, and packaging materials. While the opportunities are vast, accessing this market requires a thorough understanding of China’s Drug Master File (DMF) registration process. This process, managed by the National Medical Products Administration (NMPA), involves stringent regulatory requirements aimed at ensuring product safety and efficacy. This article explores the DMF system in China, discussing its regulatory evolution, procedural requirements, and the steps needed for successful compliance.
- [The Rise of Companion Diagnostics in China](https://www.pacificbridgemedical.com/uncategorized/the-rise-of-companion-diagnostics-in-china/): The field of companion diagnostics (CDx) is evolving rapidly in China, driven by advancements in precision medicine and targeted therapies. Companion diagnostics play a crucial role in identifying patient populations most likely to benefit from specific therapeutic agents, particularly in oncology. This synergy between diagnostics and therapeutics allows for more personalized treatment plans, improving patient outcomes and reducing unnecessary interventions. In recent years, China’s National Medical Products Administration (NMPA) has implemented a series of guidelines to regulate the development, approval, and clinical use of CDx products. These regulations reflect the country's commitment to harmonizing with international standards while addressing unique local healthcare needs. This article explores the regulatory framework, clinical requirements, market trends, and future prospects of companion diagnostics in China.
- [Companion Diagnostics (CDx) in Japan – Regulatory Pathways and Market Opportunities](https://www.pacificbridgemedical.com/uncategorized/cdx-in-japan-regulatory-pathways-market-opportunities/): Companion diagnostics (CDx) are essential tools in personalized medicine, ensuring that patients receive the most effective treatments based on their unique genetic and molecular profiles. These tests guide therapeutic decisions by identifying biomarkers, such as genetic mutations, that predict a patient's response to specific drugs. In Japan, the adoption of CDx is rapidly growing, supported by advancements in genomics, robust regulatory frameworks, and favorable reimbursement policies. This article explores the regulatory landscape, approval processes, and market opportunities for CDx in Japan, highlighting why the country remains a key market for foreign companion diagnostic manufacturers.
- [Navigating Japan’s Medical Device Market: MAH, DMAH, and Strategies for Foreign Success](https://www.pacificbridgemedical.com/uncategorized/navigating-japans-medical-device-market-mah-dmah-and-strategies-for-foreign-success/): Japan's medical device market is one of the largest and most attractive in the world, offering immense opportunities for foreign companies. However, navigating this market comes with significant challenges that demand strategic planning and a deep understanding of the regulatory environment. This article explores the size and complexity of Japan's medical device market, the various registration pathways available to foreign manufacturers, and the benefits and drawbacks of using a Marketing Authorization Holder (MAH) or a Designated Marketing Authorization Holder (DMAH).
- [Navigating China’s Drug Market Access System: A New Era of Access and Innovation](https://www.pacificbridgemedical.com/uncategorized/navigating-chinas-drug-reimbursement-system-a-new-era-of-access-and-innovation/): China’s healthcare policies have evolved rapidly over the past decade to meet the growing demand for affordable yet innovative medicines. Key reforms, including the National Reimbursement Drug List (NRDL) and the Volume-Based Procurement (VBP) initiative, aim to strike a balance between improving access to essential treatments and managing healthcare costs. These programs are reshaping the pharmaceutical industry while providing millions of Chinese citizens with access to life-saving drugs.
- [Device Reimbursement in Japan: Key to being Successful](https://www.pacificbridgemedical.com/uncategorized/device-reimbursement-in-japan-key-to-being-successful/): Many medical device companies try to get their devices into Japan. Japan is the third-largest device market in the world. It is also a very competitive market where only relatively unique and innovative products will succeed there. While many device companies focus on registering their product and finding the right distributor or sales mechanism in Japan, perhaps the most important factor is how your device will be reimbursed in Japan. Will Japan price your device so your company can make money?
- [China Market Access for Drugs is Tougher, But Some Daylight Too](https://www.pacificbridgemedical.com/uncategorized/china-market-access-for-drugs-is-tougher-but-some-daylight-too/): Over the last seven years, it is now easier to register foreign drugs in China, but drug pricing has generally gone down. China has utilized several programs to reduce drug prices including their National Essential Medicine List (NEML), the National Reimbursement Drug List (NRDL), Volume-based Procurement (VBP), Designated Reimbursement Groups (DRGs), and Diagnostic Intervention Packet (DIP). On the other hand, to counter these drug price reductions, China has also put in place some new mechanisms to increase innovative drug prices, like adding more new drugs to the NRDL list, a multi-tier payment system, the growth of commercial insurance, etc.
- [A High Level Overview of China’s Pharmaceutical Registration Process](https://www.pacificbridgemedical.com/uncategorized/a-high-level-overview-of-chinas-pharmaceutical-registration-process/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Raising the Bar: How GMP Ensures Pharmaceutical Quality in Japan](https://www.pacificbridgemedical.com/uncategorized/raising-the-bar-how-gmp-ensures-pharmaceutical-quality-in-japan/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Adhering to Good Clinical Practice (GCP) in Japan: Key Considerations](https://www.pacificbridgemedical.com/uncategorized/adhering-to-good-clinical-practice-gcp-in-japan-key-considerations/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Ensuring Quality: Key Components of Japanese GMP Compliance](https://www.pacificbridgemedical.com/uncategorized/ensuring-quality-key-components-of-japanese-gmp-compliance/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Recent Developments in China’s Pharmaceutical Regulatory Landscape](https://www.pacificbridgemedical.com/uncategorized/recent-developments-in-chinas-pharmaceutical-regulatory-landscape/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Documents Required for China Pharmaceutical Registration](https://www.pacificbridgemedical.com/uncategorized/documents-required-for-china-pharmaceutical-registration/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [The Evolution of GMP Standards for Pharmaceuticals in Japan](https://www.pacificbridgemedical.com/uncategorized/the-evolution-of-gmp-standards-for-pharmaceuticals-in-japan/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Navigating Good Clinical Practice for Pharmaceuticals in Japan: A Basic Overview](https://www.pacificbridgemedical.com/uncategorized/navigating-good-clinical-practice-for-pharmaceuticals-in-japan-a-basic-overview/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Fundamentals of Japan GMP Compliance for Pharmaceutical Manufacturers](https://www.pacificbridgemedical.com/uncategorized/fundamentals-of-japan-gmp-compliance-for-pharmaceutical-manufacturers/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Taiwan Medical Device Registration: A Complete Guide](https://www.pacificbridgemedical.com/uncategorized/taiwan-medical-device-registration-a-complete-guide/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Malaysia’s Medical Device Registration Process Explained](https://www.pacificbridgemedical.com/uncategorized/malaysias-medical-device-registration-process-explained/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [A Quick Guide To Japan’s Drug GMP Regulations](https://www.pacificbridgemedical.com/uncategorized/a-quick-guide-to-japans-drug-gmp-regulations/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Japan GMP Standards: How To Ensure Compliance](https://www.pacificbridgemedical.com/uncategorized/japan-gmp-standards-how-to-ensure-compliance/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Key Steps For Successful Medical Device Registration In Malaysia](https://www.pacificbridgemedical.com/uncategorized/key-steps-for-successful-medical-device-registration-in-malaysia/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [China GMP Audit: Essential Tips for Compliance](https://www.pacificbridgemedical.com/resources/china-gmp-audit-essential-tips-for-compliance/): China's pharmaceutical and medical device markets are rapidly growing, attracting global attention for their potential. However, navigating the regulatory landscape requires a thorough understanding of the local norms and practices, especially when it comes to compliance with Chinese GMP standards. These regulations ensure the safety, efficacy, and quality of pharmaceuticals and medical devices, which is why understanding and adhering to them is not just a regulatory requirement but a pivotal factor in the success of market entry and expansion.
- [Best Practices For Registering Medical Devices In Indonesia](https://www.pacificbridgemedical.com/resources/best-practices-for-registering-medical-devices-in-indonesia/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [How To Streamline Your Medical Device Registration In Thailand](https://www.pacificbridgemedical.com/resources/how-to-streamline-your-medical-device-registration-in-thailand/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Understanding Japan Medical Device Registration Pathways](https://www.pacificbridgemedical.com/resources/understanding-japan-medical-device-registration-pathways/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [China DMF Explained: Understanding Drug Regulations](https://www.pacificbridgemedical.com/resources/china-dmf-explained-understanding-drug-regulations/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Adapting to Japan’s Unique Drug Registration Requirements](https://www.pacificbridgemedical.com/resources/adapting-to-japans-unique-drug-registration-requirements/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Japan’s Clinical Trial Landscape for Drug Registration](https://www.pacificbridgemedical.com/uncategorized/japans-clinical-trial-landscape-for-drug-registration/): For more information on Japan's clinical trial landscape, please click here.
- [Key Steps in the China Medical Device Approval Process](https://www.pacificbridgemedical.com/uncategorized/key-steps-in-the-china-medical-device-approval-process/): For more information on China's medical device approval process, please click here. 
- [4 Potential Challenges With Japanese Drug Market Entry](https://www.pacificbridgemedical.com/uncategorized/4-potential-challenges-with-japanese-drug-market-entry/): For more information on Japanese drug market entry, please click here.
- [The Essential Steps to Ensure Seamless Japan DMF Submission](https://www.pacificbridgemedical.com/uncategorized/the-essential-steps-to-ensure-seamless-japan-dmf-submission/): To learn more about Japan DMF submission, please click here.
- [Why It’s Important to Have a DMF in Singapore](https://www.pacificbridgemedical.com/uncategorized/why-its-important-to-have-a-dmf-in-singapore/): To learn more about Singapore DMF, please click here.
- [How China DMF Standards Compare Internationally](https://www.pacificbridgemedical.com/uncategorized/how-china-dmf-standards-compare-internationally/): To learn more about China DMF, please click here.
- [Ensuring Compliance: Navigating the China DMF Process](https://www.pacificbridgemedical.com/uncategorized/ensuring-compliance-navigating-the-china-dmf-process/): To learn more about China DMF, please click here.
- [How To Adapt To China’s GMP Regulations: Tips for International Firms](https://www.pacificbridgemedical.com/uncategorized/how-to-adapt-to-chinas-gmp-regulations-tips-for-international-firms/): To learn more about China GMP, please click here.
- [Malaysia Pharma Registration: What International Firms Need to Know](https://www.pacificbridgemedical.com/uncategorized/malaysia-pharma-registration-what-international-firms-need-to-know/): To learn more about Malaysia pharmaceutical registration, please click here. 
- [Korea’s Drug Registration Process: A Primer for International Pharmaceuticals Companies](https://www.pacificbridgemedical.com/uncategorized/koreas-drug-registration-process-a-primer-for-international-pharmaceuticals-companies/): To learn more about Korea's drug registration process, please click here.
- [Clinical Trial Requirements for Pharmaceutical Registration in China](https://www.pacificbridgemedical.com/uncategorized/clinical-trial-requirements-for-pharmaceutical-registration-in-china/): To learn more about China's clinical trial requirements, please click here.
- [Understanding China’s Pharmaceutical Registration Process](https://www.pacificbridgemedical.com/uncategorized/understanding-chinas-pharmaceutical-registration-process/): To learn more about China's pharmaceutical registration process, please click here.
- [Malaysia Medical Device Registration Process: A Beginner’s Guide](https://www.pacificbridgemedical.com/uncategorized/malaysia-medical-device-registration-process-a-guide/): Source used in the article: https://mda.gov.my/industry/conformity-assessment-body-cab/application.html
- [How To Ensure Compliance in Malaysia’s Pharmaceutical Landscape](https://www.pacificbridgemedical.com/uncategorized/how-to-ensure-compliance-in-malaysias-pharmaceutical-landscape/): To learn more about Malaysia's pharmaceutical landscape, please click here.
- [5 Essential Tips for Expediting Drug Registration in Vietnam](https://www.pacificbridgemedical.com/uncategorized/5-essential-tips-for-expediting-drug-registration-in-vietnam/): To learn more about drug registration in Vietnam, please click here. 
- [The Importance Of Training In Japan’s Drug GMP Compliance](https://www.pacificbridgemedical.com/uncategorized/the-importance-of-training-in-japans-drug-gmp-compliance/): Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
- [Key Elements of Compliance with Japanese GMP Drug Regulations](https://www.pacificbridgemedical.com/uncategorized/key-elements-of-compliance-with-japanese-gmp-drug-regulations/): For more information on Japan GMP, please refer to this article.
- [The Implications of GCP and GPSP on Japan’s Drug Approval Process](https://www.pacificbridgemedical.com/uncategorized/the-implications-of-gcp-and-gpsp-on-japans-drug-approval-process/): To learn more about Japan GCP, please click here.
- [Understanding Japan’s Good Vigilance Practice For Pharmaceuticals (GVP)](https://www.pacificbridgemedical.com/uncategorized/understanding-japans-good-vigilance-practice-for-pharmaceuticals-gvp/): In the realm of international pharmaceutical regulations, Japan's Good Vigilance Practice (GVP) shines as a rigorous framework aimed at ensuring the safety and efficacy of marketed drugs. Navigating this system may appear daunting, yet its comprehension is non-negotiable for any global pharmaceutical player seeking success in the Japanese market.
- [Good Quality Practice (GQP) in Japan: A Quick Guide](https://www.pacificbridgemedical.com/uncategorized/good-quality-practice-gqp-in-japan-a-quick-guide/): Good Quality Practice in Japan, commonly abbreviated as GQP, acts as a cornerstone in maintaining the highest standards of quality and safety within the nation's thriving pharmaceutical industry. As foreign pharmaceutical firms aspire to penetrate and flourish in this robust market, comprehensive understanding and adherence to GQP is fundamental.
- [Exploring Good Clinical Practice (GCP) in the Japanese Context](https://www.pacificbridgemedical.com/uncategorized/exploring-good-clinical-practice-gcp-in-the-japanese-context/): To learn more about Japan GCP, please click here.
- [GMP: Setting the Standard for Pharmaceutical Quality in Japan](https://www.pacificbridgemedical.com/uncategorized/gmp-setting-the-standard-for-pharmaceutical-quality-in-japan/): For more information on Japan GMP, please refer to this article.
- [Navigating Regulatory Waters: A Guide to DMF Filing in Japan](https://www.pacificbridgemedical.com/uncategorized/navigating-regulatory-waters-a-guide-to-dmf-filing-in-japan/): For more information on Japan DMF, please refer to this article.
- [Japan’s Medical Device Market: Understanding DMAH Representation](https://www.pacificbridgemedical.com/uncategorized/japans-medical-device-market-understanding-dmah-representation/): To learn more about Japan's DMAH, please click here.
- [Compliant & Connected: Why DMAHs are Vital for Medical Product Exports to Japan](https://www.pacificbridgemedical.com/uncategorized/compliant-connected-why-dmahs-are-vital-for-medical-product-exports-to-japan/): To learn more about Japan's DMAH, please click here.
- [The Do’s and Don’ts of Drug Registration in Korea](https://www.pacificbridgemedical.com/uncategorized/the-dos-and-donts-of-drug-registration-in-korea/): To learn more about drug registration in Korea, please click here.
- [The Critical Role of MFDS in Korea’s Pharmaceutical Sector](https://www.pacificbridgemedical.com/uncategorized/the-critical-role-of-mfds-in-koreas-pharmaceutical-sector/): To learn more about the MFDS, please click here. 
- [Taiwan’s Medical Device Registration: A Step-By-Step Guide](https://www.pacificbridgemedical.com/uncategorized/taiwans-medical-device-registration-a-step-by-step-guide/): To learn more about Taiwan's medical device registration, please click here. 
- [Pitfalls to Avoid in Singapore’s Medical Device Registration](https://www.pacificbridgemedical.com/uncategorized/pitfalls-to-avoid-in-singapores-medical-device-registration/): To learn more about Singapore's medical device registration, please click here. 
- [Singapore’s Regulatory Landscape for Medical Device Entry](https://www.pacificbridgemedical.com/uncategorized/singapores-regulatory-landscape-for-medical-device-entry/): To learn more about Singapore's medical device registration, please click here. 
- [Essential Tips for Successful Medical Device Registration in Singapore](https://www.pacificbridgemedical.com/uncategorized/essential-tips-for-successful-medical-device-registration-in-singapore/): To learn more about Singapore's medical device registration, please click here. 
- [Understanding Taiwan’s Regulatory Framework for Medical Devices](https://www.pacificbridgemedical.com/uncategorized/understanding-taiwans-regulatory-framework-for-medical-devices/): To learn more about Taiwan's medical device registration, please click here. 
- [How MFDS is Revolutionizing Korea’s Drug Approval Process](https://www.pacificbridgemedical.com/uncategorized/how-mfds-is-revolutionizing-koreas-drug-approval-process/): To learn more about Korea's MFDS, please click here. 
- [Understanding Korea’s Drug Regulatory Requirements](https://www.pacificbridgemedical.com/uncategorized/understanding-koreas-drug-regulatory-requirements/): To learn more about Korea's drug regulatory requirements, please click here.
- [Ensuring Public Health: Role of Korea’s MFDS](https://www.pacificbridgemedical.com/uncategorized/ensuring-public-health-role-of-koreas-mfds/): To learn more about Korea's MFDS, please click here. 
- [Navigating Japanese GMP Inspections: Best Practices for Success](https://www.pacificbridgemedical.com/uncategorized/navigating-japanese-gmp-inspections-best-practices-for-success/): For more information on Japan GMP, please refer to this article.
- [QMS Compliance for Medical Devices and Drugs in Japan: An Overview of the Japanese Standard](https://www.pacificbridgemedical.com/uncategorized/qms-compliance-for-medical-devices-and-drugs-in-japan-an-overview-of-the-japanese-standard/): To learn more about QMS compliance in Japan, please click here. 
- [Mastering Japan’s Medical Device Approval Process: A Step-by-Step Guide](https://www.pacificbridgemedical.com/uncategorized/mastering-japans-medical-device-approval-process-a-step-by-step-guide/): To learn more about Japan's medical device approval process, please click here.

## Pages
- [Accessibility](https://www.pacificbridgemedical.com/accessibility/): We are committed to making this website accessible to everyone, ensuring that all features and content are accessible to every individual.
- [Drug Distributor Search in Vietnam](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-vietnam/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in Thailand](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-thailand/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in Taiwan](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-taiwan/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in Singapore](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-singapore/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in the Philippines](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-the-philippines/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in Malaysia](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-malaysia/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in Korea](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-korea/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in Indonesia](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-indonesia/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in Hong Kong](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/drug-distributor-search-in-hong-kong/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Medical Device Distributor Search in Vietnam](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-vietnam/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in Thailand](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-thailand/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in Taiwan](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-taiwan/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in Singapore](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-singapore/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in the Philippines](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-the-philippines/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in Malaysia](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-malaysia/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in Korea](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-korea/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in Indonesia](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-indonesia/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in Hong Kong](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/medical-device-distributor-search-in-hong-kong/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Vietnam Drug Registration and Approval](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/vietnam-drug-registration-and-approval-2/): To learn more about how PBM can help you register your drug products in Vietnam, please contact us.
- [Thailand Drug Registration and Approval](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/thailand-drug-registration-and-approval-2/): To learn more about how PBM can help you register your drug products in Thailand, please contact us.
- [Taiwan Drug Registration and DMFs for APIs, Excipients & Packaging Materials](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/taiwan-drug-registration-and-approval-2/): The Taiwanese Ministry of Health and Welfare (MOHW) set up the Taiwan Food and Drug Agency (TFDA) to enforce pharmaceutical regulations within Taiwan. For foreign drug companies to sell their pharmaceutical products in Taiwan, they are required to obtain TFDA registration approval, which is comparable to the mandatory approval of the U.S. FDA. Taiwan drug registration approval from the TFDA is necessary for the manufacturing and import of pharmaceuticals, and the requirements for approval differ between new drugs and generic drugs.
- [Singapore Drug Registration and DMFs for APIs, Excipients & Packaging Materials](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/singapore-drug-registration-and-approval-2/): To learn more about how PBM can help you register your drug products in Singapore, please contact us.
- [Philippines Drug Registration and Approval](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/philippines-drug-registration-and-approval-2/): To learn more about how PBM can help you register your drug products in the Philippines, please contact us.
- [Malaysia Drug Registration and Approval](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/malaysia-drug-registration-and-approval/): The Malaysian Ministry of Health is responsible for the country's healthcare system and the well-being of its citizens. The National Pharmaceutical Regulatory Agency is tasked with approving regulations, setting testing and quality control standards, as well as supervising the quality of pharmaceutical products. The Malaysian Drug Control Authority (DCA) mandates that all pharmaceutical products must meet safety, efficacy, and quality requirements. Additionally, the Malaysian Adverse Drug Reaction Advisory Committee performs pharmacovigilance on approved medications in the country, in accordance with the DCA.
- [Indonesia Drug Registration and Approval](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/indonesia-drug-registration-and-approval/): To learn more about how PBM can help you register your drug products in Indonesia, please contact us.
- [Hong Kong Drug Registration and Approval](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/hong-kong-drug-registration-and-approval/): Utilize our intimate industry knowledge and expertise to obtain Hong Kong PPB registration approval for your drug. To learn more about how PBM can help you register your drug products in Hong Kong, please contact us. The Pharmacy and Poisons Board (PPB) requires all pharmaceutical products in Hong Kong to be registered prior to being marketed in Hong Kong, according to the Pharmacy and Poisons Ordinance (PPO). During the drug registration process, the PPB evaluates the safety, effectiveness, and quality of the drug by analyzing scientific data. To register a new chemical or biological entity in Hong Kong, the applicant must provide proof of registration approval for the product from at least 2 of the 32 specified countries, which include the United States, Australia, Austria, Belgium, Bulgaria, Canada, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Holland, Hungary, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, and the UK. Recently, mainland China was included in the list of countries recognized by the PPB because China started implementing the ICH guidelines. In addition, Korea, Brazil, and Singapore have recently been added to this list too. However, these four countries are not designated as a Stringent Regulatory Authority (SRA) by the WHO. Hence, in addition to registration from 1 of these four countries, registration from 1 of the 32 countries listed above must also be provided for drug product registration in Hong Kong. The entity responsible for applying for drug registration in Hong Kong depends on the origin of the product. If the product is made in Hong Kong, the manufacturer should apply for registration. On the other hand, if the product is produced outside Hong Kong, the local importer is responsible for obtaining registration. To register your pharmaceutical product in Hong Kong, you need to use the Pharmaceuticals Registration System 2.0 (PRS 2.0) online, which can be accessed through the website of the Drug Office of the Department of Health. The essential documents necessary for the registration of a pharmaceutical product in Hong Kong consist of several items, such as a copy of the business registration certificate, free sale certificate from the country of origin, a cover letter, the manufacturer's license, the manufacturer's authorization letter, GMP certificate, etc. In addition to the basic documents required for registration of a pharmaceutical product, there are also several essential documents that need to be submitted. These include documents demonstrating conformity with the reference pharmacopoeia, certificate of analysis, stability test data, etc. To learn more about how PBM can help you register your drug products in Hong Kong, please contact us.
- [Sourcing and Manufacturing Medical Devices and Drugs in Other Southeast Asian Countries](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/sourcing-manufacturing/sourcing-and-manufacturing-medical-devices-and-drugs-in-other-southeast-asian-countries/): Contact us today to speak to our sourcing experts.
- [Sourcing and Manufacturing Medical Devices and Drugs in Vietnam](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/sourcing-manufacturing/sourcing-and-manufacturing-medical-devices-and-drugs-in-vietnam/): Contact us today to speak to our sourcing experts.
- [Sourcing and Manufacturing Medical Devices and Drugs in India](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/sourcing-manufacturing/sourcing-and-manufacturing-medical-devices-and-drugs-in-india/): Contact us today to speak to our sourcing experts.
- [Sourcing and Manufacturing Medical Devices and Drugs in China](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/sourcing-manufacturing/sourcing-and-manufacturing-medical-devices-and-drugs-in-china/): Contact us today to speak to our sourcing experts. 
- [Drug Reimbursement and Market Acess in the Other Asian Markets](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/reimbursement/asian-drug-reimbursement-in-the-other-asian-markets/): To learn more about drug reimbursement in other Asian markets, please contact us.
- [Reimbursement and Market Access for Pharmaceuticals in Taiwan](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/reimbursement/reimbursement-for-pharmaceuticals-in-taiwan/): To learn more about Taiwan drug reimbursement, please contact us.
- [Reimbursement and Market Access for Drugs in Japan](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/reimbursement/reimbursement-for-pharmaceuticals-in-japan/): To learn more about Japan drug reimbursement, please contact us.
- [Reimbursement and Market Access for Drugs in Korea](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/reimbursement/reimbursement-for-pharmaceuticals-in-korea/): To learn more about Korea drug reimbursement, please contact us.
- [Reimbursement and Market Access for Drugs in China](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/reimbursement/reimbursement-for-pharmaceuticals-in-china/): To learn more about China drug reimbursement, please contact us.
- [Market Access/Reimbursement/Health Economics for Medical Devices in Other Asian Countries](https://www.pacificbridgemedical.com/regulatory-services/medical-device/reimbursement/reimbursement-for-medical-devices-in-other-asian-countries/): The medical device reimbursement schemes in India, Singapore, Hong Kong, Thailand, Malaysia, Vietnam, the Philippines, and Indonesia will vary depending on the medical equipment used, the procedure being done, and the specific reimbursement regulations of each country. Generally, reimbursement in these countries is significantly less than in Japan, Korea, and Taiwan. In most of the less developed countries, medical device reimbursement is very low or non-existent.
- [Market Access/Reimbursement/Health Economics for Medical Devices in Taiwan](https://www.pacificbridgemedical.com/regulatory-services/medical-device/reimbursement/reimbursement-for-medical-devices-in-taiwan/): To learn more about Taiwan medical device reimbursement, please contact us.
- [Market Access/Reimbursement/Health Economics for Medical Devices in China](https://www.pacificbridgemedical.com/regulatory-services/medical-device/reimbursement/reimbursement-for-medical-devices-china/): To learn more about China medical device reimbursement, please contact us.
- [Market Access/Reimbursement/Health Economics for Medical Devices in Korea](https://www.pacificbridgemedical.com/regulatory-services/medical-device/reimbursement/reimbursement-for-medical-devices-in-korea/): To learn more about Korea medical device reimbursement, please contact us.
- [Market Access/Reimbursement/Health Economics for Medical Devices in Japan](https://www.pacificbridgemedical.com/regulatory-services/medical-device/reimbursement/reimbursement-for-medical-devices-in-japan/): To learn more about Japan medical device reimbursement, please contact us.
- [Hong Kong Pharmaceutical Registration and Approval](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/hong-kong-pharmaceutical-registration-and-approval-2/): Under Hong Kong's Department of Health (DOH), the Pharmaceuticals Service Department of Health (PSDH) regulates pharmaceuticals/drugs.
- [FAQ](https://www.pacificbridgemedical.com/faq/)
- [Quality Management for Medical Products in Korea (Korea GMP Drug/Device Audits)](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/quality-compliance/korea/): For a free consultation on your KGMP and quality management needs in Korea, contact us today.
- [Clinical Trials for Medical Products in the Other Asian Countries](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/clinical-trials/others/): Although some foreign companies may question the quality of the local clinical trials in the smaller Asian countries, they have some advantages over clinical trials in the more developed Asian countries. For example, the cost of conducting clinical trials in Thailand is much cheaper than in a country like South Korea. Furthermore, the approval times to initiate a clinical study in the smaller Asian countries are generally shorter than in some of the larger East Asian countries.
- [Clinical Trials for Medical Products in Korea](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/clinical-trials/korea/): If you are considering conducting clinical trials in Korea, contact us today to discuss your needs with our Korea experts.
- [Clinical Trials for Medical Products in India](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/clinical-trials/india/): Contact us today for a consultation with our India experts regarding conducting clinical trials in India for your product.
- [Japan Clinical Trials and CRO Services for Medical Device and Pharmaceutical Products](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/clinical-trials/japan/): Before conducting Japan clinical trials, the applicant must first submit a dossier containing operating procedures, protocol, Investigator's Brochure (IB), clinical trial contracts, and compensation outline, among other information. If the applicant plans on outsourcing the clinical trial, a contract must detail the agreement on duties for sponsoring and managing the trial.
- [China Clinical Trials and CRO Services for Medical Device and Pharmaceutical Products](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/clinical-trials/china/): Pacific Bridge Medical's China office offers comprehensive clinical trial consulting services. We can manage your clinical trials in China from start to finish as your contract research organization (CRO) and ensure that the process complies with all regulatory and quality requirements. Our experts can also assist you in finding a qualified Chinese CRO and act as your local agent and clinical trial “sponsor” to oversee your clinical trials in China, as required by China's Good Clinical Practice (GCP) guidelines.  We are well connected to both international and local CRO's in China.
- [Sign Up For Our Asia Medical Newsletter](https://www.pacificbridgemedical.com/newsletter-form/): Fill out the form below to stay up-to-date on the latest medical business and regulatory affairs in Asia. Our news briefs on medical device and pharmaceutical trends in the Asian medical markets are delivered monthly via email, free of charge.
- [Medical Device & Pharmaceutical Regulatory Services](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/)
- [Medical Device & Pharmaceutical Business Development Services](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/)
- [Sample Client List](https://www.pacificbridgemedical.com/why-choose-us/sample-client-list/): Medical Devices C.R. Bard Catheters for urology, cardiology and surgery and other products GE Healthcare General Electric's Healthcare Division, various products Intuitive Surgical Robotic surgical systems Datascope Balloon catheters and pumps Guidant Cardiovascular medical products Ultradent Dental products Pharmaceuticals Bristol Myers Squibb Multinational pharmaceutical manufacturer Medicis Dermatological, pediatric and podiatric products manufacturer Rhone Poulenc Rorer French pharmaceutical manufacturer Warner-Lambert Major U.S. pharmaceutical manufacturer C.B. Fleet OTC and Rx pharmaceutical manufacturer Biotechnology DuPont Biotech reagents QLT Phototherapeutics New cancer drug for photodynamic therapy (PDT) Universal HealthWatch Diagnostic tests for HIV, Malaria, and Cholera Genzyme Biotech and surgical products Consumer Healthcare Procter and Gamble Nutritionals and cosmetics Dow Hickam Health food products Parke Davis Antacids, cough, cold, and other OTC medicines Dewitt International Consumer and healthcare products, Chinese medicines Medical Services Hill-Rom Specialty beds and related services Schein Dental Products Largest U.S. distributor of dental products Microsoft Healthcare systems Pyxis Medication and supply dispensing solutions Vital Images, Inc Computer aided detection system for breast cancer R2 Technology Medical imaging software Asian Clients Alcare Co., Ltd. Japanese orthopedic/surgical/nursing care products company Inchcape Singaporean medical distributor Itochu (medical) Japanese trading company Chong Kun Dang Korean pharmaceutical company Terumo Japanese medical device firm Toray Industries, Inc. Japanese pharmaceutical and medical products company
- [Our Team](https://www.pacificbridgemedical.com/why-choose-us/our-team/): In addition to the team members listed above, PBM also has staff members in our Tokyo, Shanghai, Singapore, and Hong Kong offices.
- [Drug Distributor Search in the Other Asian Countries](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/others/): To find out how we can assist you with the distribution of your specific medical product, contact us today.
- [Drug Distributor Search in Japan](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/japan/): Please contact us if you are interested in discussing your specific needs with our Japan distribution consultants.
- [Drug Distributor Search in India](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/india/): For a consultation with our India distribution experts, click here to contact us.
- [Drug Distributor Search in China](https://www.pacificbridgemedical.com/business-development-services/pharmaceutical/distributor-search/china/): For a free consultation with our China distribution consultants, contact us today.
- [Medical Market Research in the Other Asian Countries](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/medical-market-research/others/): Contact us to learn more about market research in Asia and how Pacific Bridge can support your company's operations abroad.
- [Medical Market Research in Japan](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/medical-market-research/japan/): To get a better idea of how we can help your company gain competitive intelligence in Japan, contact us today!
- [Medical Market Research in India](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/medical-market-research/india/): Contact us now to find out more about how Pacific Bridge Medical can provide you with market research assistance in India.
- [Medical Market Research in China](https://www.pacificbridgemedical.com/business-development-services/medical-device-pharmaceutical/medical-market-research/china/): For more information about how our consultants can help your medical company with market research in China, contact us today.
- [Medical Device Distributor Search in the Other Asian Countries](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/others/): Contact us and learn how choosing a distributor that's right for your company can go a long way.
- [Medical Device Distributor Search in Japan](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/japan/): Pacific Bridge Medical has 30 years of experience with finding and managing highly qualified Japanese medical distributors. For more information on finding the right distributor in Japan, please contact us to discuss your specific needs.
- [Medical Device Distributor Search in India](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/india/): India's medical markets are expanding rapidly. Not only are medical consumers becoming wealthier and able to afford more treatment, Indians are also building more and more private hospitals that boast of the most modern healthcare. However, given India's unique business and social culture, finding the right medical distributor in India can be challenging.
- [Medical Device Distributor Search in China](https://www.pacificbridgemedical.com/business-development-services/medical-device/distributor-search/china/): Up until ten years ago, medical devices in China were mainly distributed via large government-owned establishments. Nowadays, there are more than 12,000 private medical distributors in China. Although the Chinese medical device market is rapidly expanding, the distributor search process can be quite complex and risky.
- [Korea Drug Registration and DMFs for APIs, Excipients & Packaging Materials](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/korea/): Pacific Bridge can act as an In-Country Caretaker (ICC) and register your pharmaceutical product under our name. To discuss your specific needs with our Korea regulatory consultants, contact us now.
- [Japan Drug Registration and DMFs for APIs, Excipients & Packaging Materials](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/japan/): If your medical company requires assistance with drug or API registration in Japan, contact us here for a free consultation to discuss your specific needs.
- [India Drug Registration and DMFs for APIs, Excipients & Packaging Materials](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/india/): Contact us today to discuss your needs with our India pharmaceutical consultants.
- [Pharmaceutical and API Product Registration in the Other Asian Countries](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/others/): Southeast Asia:
- [China Drug Registration and DMFs for APIs, Excipients & Packaging Materials](https://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/china/): Contact us today for a free consultation with a China regulatory affairs consultant to discuss your specific needs.
- [Local Agent Representation for Medical Device and Drug Products in Vietnam](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/vietnam/): For more information on the Vietnamese in-country caretaker system and medical product regulations, please contact us.
- [Local Agent Representation for Medical Device and Drug Products in Thailand](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/thailand/): To speak with our expert consultants about independent third party license holding and the medical markets in Thailand, contact us today.
- [Local Agent Representation for Medical Device and Drug Products in Taiwan](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/taiwan/): For a free consultation with our regulatory experts, contact us and learn more about the independent third party system and medical regulations in Taiwan.
- [Local Agent Representation for Medical Device and Drug Products in Singapore](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/singapore/): To find out more about the Singaporean medical regulations and local representation system, contact us for a free consultation with our expert regulatory consultants.
- [Local Agent Representation for Medical Device and Drug Products in the Philippines](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/philippines/): To find out more about the independent third-party system and medical regulations in the Philippines, please contact us to discuss your company's needs.
- [Local Agent Representation for Medical Device and Drug Products in Malaysia](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/malaysia/): Please contact us today to learn more about the services we can provide as your Malaysian local agent.
- [Local Agent Representation for Medical Device and Drug Products in Korea](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/korea/): Pacific Bridge Medical can act as your ICC in Korea. Contact us for a free consultation to discuss your specific needs.
- [Local Agent Representation for Medical Device and Drug Products in Japan (DMAH)](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/japan/): If you need the assistance of an experienced MAH/DMAH in Japan, contact us today for a free consultation with consultants experienced in handling PMDA regulations.
- [Local Agent Representation for Medical Device and Drug Products in Indonesia](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/indonesia/): To find out more about in-country representatives or Indonesian medical regulations, please contact us today and speak with one of our expert consultants about your company's products.
- [Local Agent Representation for Medical Device and Drug Products in Hong Kong](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/hong-kong/): If you are interested in our LRP services, contact us for a free consultation with our expert regulatory consultants now.
- [Local Agent Representation for Medical Device and Drug Products in China](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/local-agent-representation/china/): If you are interested in our local agent representation services, contact us now for a free consultation with our expert Asia consultants.
- [Quality Management for Medical Products in the Other Asian Countries (Drug/Device GMP Audits)](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/quality-compliance/others/): Most Asian countries will have their own specific form of Good Manufacturing Practice (GMP) standards. Some will be closer to international standards than others. Taiwan, Singapore, and Hong Kong quality assurance/quality control systems will usually be much more developed than in the other Southeast Asian countries. For example, in Taiwan, applicants registering their medical device must also submit Quality System Documentation (QSD) to receive product registration approval. Singapore requires companies involved in the wholesale or import of medical devices to obtain Good Distribution Practice for Medical Devices (GDPMDS) certification, which regulates how the devices are stored, transported, and handled.
- [Quality Management for Medical Products in Japan (Japan GMP Drug/Device Audits)](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/quality-compliance/japan/): Contact us today for a free consultation on your specific Japan quality control/quality assurance needs.
- [Quality Management for Medical Products in India (India GMP Drug/Device Audits)](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/quality-compliance/india/): Pacific Bridge Medical has extensive experience with helping a number of international medical companies set up their quality management systems in India. Our India quality control/quality assurance experts can help your medical company's Indian operations and suppliers ensure compliance with all relevant quality standards.
- [Quality Management for Medical Products in China (China GMP Drug/Device Audits)](https://www.pacificbridgemedical.com/regulatory-services/medical-device-pharmaceutical/quality-compliance/china/): If you have a specific need related to quality issues for medical products in China, contact us today for a free consultation with our China quality control/quality assurance experts.
- [Medical Device Registration in Vietnam](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/vietnam/): Contact us today for a consultation with our Vietnam medical device regulatory consultants.
- [Medical Device Registration in Thailand](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/thailand/): Read more about Thailand medical device registration requirements and application process by clicking on the following questions.
- [Medical Device Registration in Taiwan](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/taiwan/): Contact us today to discuss your medical device registration strategy and solution with our Taiwan regulatory experts.
- [Medical Device Registration in Singapore](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/singapore/): Ready to get your medical device approved in Singapore? Contact us today for a free consultation with our Singapore regulatory compliance consultants.
- [Medical Device Registration in the Philippines](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/philippines/): To find out more information on the proposed outline for Philippines medical device registration, click on the questions below.
- [Medical Device Registration in Malaysia](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/malaysia/): If you are ready to begin your medical device registration process in Malaysia, please contact us today.
- [Medical Device Registration in Korea](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/korea/): Contact us today for a free consultation with our Korea regulatory affairs specialists.
- [Medical Device Registration in Japan](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/japan/): We recently did a webcast about Japan Medical Device Registration and Reimbursement.
- [Medical Device Registration in Indonesia](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/indonesia/): Contact us today for a free consultation with our Indonesia medical device regulation experts regarding Indonesia medical device registration for your product.
- [Medical Device Registration in India](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/india/): Contact us today for a free consultation with our expert regulatory consultants regarding your specific India medical device registration needs.
- [Medical Device Registration in Hong Kong](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/hong-kong/): Click on the following questions to learn more about the regulatory process for Hong Kong medical device registration.
- [Medical Device Registration in China](https://www.pacificbridgemedical.com/regulatory-services/medical-device/product-registration/china/): We recently did a webcast about China Medical Device Registration and Reimbursement.

## FAQs
- [How Do Medical Device Distributors In Japan Handle Product Launches?](https://www.pacificbridgemedical.com/ufaq/how-do-medical-device-distributors-in-japan-handle-product-launches/): Distributors handle product launches by coordinating marketing, sales, & training efforts. They ensure regulatory compliance, conduct market research, & create localized strategies to promote devices effectively. Leveraging their networks helps reach target customers efficiently.
- [How Can I Compare Different Medical Device Distributors In Japan?](https://www.pacificbridgemedical.com/ufaq/how-can-i-compare-different-medical-device-distributors-in-japan/): Compare distributors by analyzing their market expertise, networks, client feedback, & service offerings. Request detailed proposals & evaluate their regulatory knowledge, sales support, & logistics capabilities to determine the best fit for your needs.
- [Are There Medical Device Distributors In Japan Specializing In Hospital Equipment?](https://www.pacificbridgemedical.com/ufaq/are-there-medical-device-distributors-in-japan-specializing-in-hospital-equipment/): Yes, some distributors specialize in hospital equipment, such as Terumo or Nipro. Researching their product focus & market reach through industry events, directories, or expert consultations can help identify partners aligned with your product category.
- [How Do I Partner With A Medical Device Distributor In Japan For Long-Term Growth?](https://www.pacificbridgemedical.com/ufaq/how-do-i-partner-with-a-medical-device-distributor-in-japan-for-long-term-growth/): Focus on building trust, aligning goals, & fostering collaboration through transparent communication. Provide ongoing support, regularly review performance, & invest in joint marketing or training initiatives to ensure mutual success & long-term growth in the market.
- [What Are The Common Challenges Faced By Medical Device Distributors In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-common-challenges-faced-by-medical-device-distributors-in-japan/): Challenges include meeting strict regulatory standards, managing high market competition, & adapting to changing healthcare demands. Balancing relationships with manufacturers & customers while maintaining profitability also poses significant hurdles in the industry.
- [How Do Medical Device Distributors In Japan Manage Inventory?](https://www.pacificbridgemedical.com/ufaq/how-do-medical-device-distributors-in-japan-manage-inventory/): Inventory management involves real-time tracking, proper storage, & timely replenishment. Distributors use advanced systems to avoid shortages, ensure compliance with storage regulations, & maintain quality control throughout the supply chain.
- [How Do Medical Device Distributors In Japan Handle After-Sales Support?](https://www.pacificbridgemedical.com/ufaq/how-do-medical-device-distributors-in-japan-handle-after-sales-support/): After-sales support involves maintenance, troubleshooting, & addressing customer concerns. Distributors may provide spare parts, repairs, & replacements, often coordinating with manufacturers to meet service standards & ensure customer satisfaction.
- [Are Medical Device Distributors In Japan Involved In Customer Training?](https://www.pacificbridgemedical.com/ufaq/are-medical-device-distributors-in-japan-involved-in-customer-training/): Yes, many distributors provide customer training to ensure proper usage & maintenance of devices. Training can include on-site demonstrations, workshops, or online sessions tailored to the needs of hospitals, clinics, or end-users, ensuring product efficiency & safety.
- [How Do Medical Device Distributors In Japan Support Marketing Activities?](https://www.pacificbridgemedical.com/ufaq/how-do-medical-device-distributors-in-japan-support-marketing-activities/): Distributors support marketing by organizing product launches, demos, & training sessions. They utilize their networks for promotions & attend trade shows to showcase devices. Collaborating on localized campaigns tailored to Japan’s healthcare market is common.
- [Are There Exclusive Medical Device Distributors In Japan For Certain Products?](https://www.pacificbridgemedical.com/ufaq/are-there-exclusive-medical-device-distributors-in-japan-for-certain-products/): Yes, exclusive agreements exist for specific products or manufacturers. Such distributors focus solely on promoting & selling designated devices. While this offers greater focus, exclusivity requires trust, strong collaboration, & clear contract terms to ensure mutual success.
- [How Do I Check A Medical Device Distributor’s Market Reputation In Japan?](https://www.pacificbridgemedical.com/ufaq/how-do-i-check-a-medical-device-distributors-market-reputation-in-japan/): Assess a distributor’s reputation by seeking references, reviewing client feedback, & consulting trade associations like JFMDA. Attending industry events & leveraging local contacts can provide further insights into their reliability, market performance, & industry standing.
- [What Are The Key Distribution Channels For Medical Device Distributors In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-key-distribution-channels-for-medical-device-distributors-in-japan/): Key distribution channels include direct sales to hospitals, clinics, & wholesalers. Some distributors leverage group purchasing organizations, e-commerce platforms, or strategic partnerships to expand market reach & improve access to healthcare providers.
- [How Can I Find A Medical Device Distributor In Japan With Nationwide Coverage?](https://www.pacificbridgemedical.com/ufaq/how-can-i-find-a-medical-device-distributor-in-japan-with-nationwide-coverage/): Large distributors like Medtronic Japan or Nipro Corporation have nationwide networks. Partnering with such companies ensures wide coverage. Research their regional capabilities & customer bases to confirm alignment with your distribution goals.
- [How Do I Negotiate Contracts With Medical Device Distributors In Japan?](https://www.pacificbridgemedical.com/ufaq/how-do-i-negotiate-contracts-with-medical-device-distributors-in-japan/): Negotiations should include pricing, exclusivity terms, service scope, & performance expectations. Understanding Japanese business etiquette & building trust are crucial. Consulting legal experts familiar with Japanese distribution laws is recommended.
- [What Are The Legal Requirements For Medical Device Distributors In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-legal-requirements-for-medical-device-distributors-in-japan/): Distributors must comply with Japan’s PMDA regulations, including proper licensing, quality management systems, & adherence to Good Distribution Practices (GDP). Some require MAH designation to import & distribute certain devices.
- [How Do Medical Device Distributors In Japan Address Warehousing?](https://www.pacificbridgemedical.com/ufaq/how-do-medical-device-distributors-in-japan-address-warehousing/): Distributors often manage warehousing to comply with Japan’s stringent storage regulations, ensuring proper temperature control & inventory tracking. Warehouses must meet quality standards to maintain device safety & performance.
- [What Are The Costs Involved In Working With A Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-costs-involved-in-working-with-a-medical-device-distributor-in-japan/): Costs typically include distributor margins, regulatory compliance fees, logistics expenses, & marketing costs. These vary depending on the distributor’s services, product type, & market reach. Contract terms should outline all financial details.
- [How Do I Identify The Right Medical Device Distributor For My Product In Japan?](https://www.pacificbridgemedical.com/ufaq/how-do-i-identify-the-right-medical-device-distributor-for-my-product-in-japan/): Evaluate distributors’ experience with similar products, market reach, regulatory expertise, & customer networks. Request references, assess their reputation, & ensure their values align with your company’s goals for a strong partnership.
- [How Do I Establish A Long-Term Partnership With A Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/how-do-i-establish-a-long-term-partnership-with-a-medical-device-distributor-in-japan/): To build long-term partnerships, ensure clear communication, establish trust, align on business goals, & respect Japanese business etiquette. Regular visits, transparent agreements, & joint planning on growth strategies can strengthen the relationship.
- [How Does The Distribution Process Work For Medical Device Distributors In Japan?](https://www.pacificbridgemedical.com/ufaq/how-does-the-distribution-process-work-for-medical-device-distributors-in-japan/): The process involves manufacturers partnering with distributors who handle imports, regulatory compliance, storage, & delivery to end-users like hospitals or clinics. Distributors may also support sales, marketing, & after-sales services depending on agreements.
- [How Do Medical Device Distributors In Japan Handle Imports?](https://www.pacificbridgemedical.com/ufaq/how-do-medical-device-distributors-in-japan-handle-imports/): Japanese medical device distributors often work with import agents or manufacturers to handle regulatory compliance, customs clearance, & logistics. The importer must ensure products meet PMDA regulations, including proper labeling & certification.
- [How Can I Locate A Specialized Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/how-can-i-locate-a-specialized-medical-device-distributor-in-japan/): Top medical device distributors in Japan include prominent companies like Medtronic Japan, Terumo Corporation, Olympus Medical, & Nipro Corporation. These distributors offer extensive networks & services, with some focusing on specific device types or healthcare sectors.
- [Are Medical Device Distributors In Japan Responsible For Product Registration?](https://www.pacificbridgemedical.com/ufaq/are-medical-device-distributors-in-japan-responsible-for-product-registration/): Medical device distributors in Japan are not typically responsible for product registration. This process is usually handled by the manufacturer or a Marketing Authorization Holder (MAH), who must ensure compliance with Japan’s Pharmaceutical & Medical Device Act (PMDA) regulations.
- [What Are The Best Practices For Working With A Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-best-practices-for-working-with-a-medical-device-distributor-in-japan/): Best practices for working with a medical device distributor in Japan include thoroughly vetting their expertise, ensuring alignment on goals, and establishing clear contracts detailing responsibilities. Maintain open communication, provide necessary training on your product, and stay informed about regulatory changes. Regularly review performance and collaborate on strategies for market growth and reimbursement success.
- [How Can A Foreign Company Connect With A Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/how-can-a-foreign-company-connect-with-a-medical-device-distributor-in-japan/): A foreign company can connect with a medical device distributor in Japan through trade shows, industry associations, or consulting firms specializing in Japan's market. Partnering with local agents or chambers of commerce is helpful. Evaluate potential distributors' expertise, network, and track record in regulatory compliance, market entry, and NHI reimbursement processes.
- [How Do Medical Device Distributors In Japan Handle Regulatory Compliance?](https://www.pacificbridgemedical.com/ufaq/how-do-medical-device-distributors-in-japan-handle-regulatory-compliance/): Medical device distributors in Japan handle regulatory compliance by ensuring products meet PMDA standards and obtaining necessary approvals before market entry. They manage labeling, documentation, and adherence to the Pharmaceutical and Medical Device Act (PMDA Act). Distributors often collaborate with manufacturers to align with MHLW requirements, ensuring smooth NHI reimbursement and market integration.
- [Are There Regional Medical Device Distributors In Japan?](https://www.pacificbridgemedical.com/ufaq/are-there-regional-medical-device-distributors-in-japan/): Yes, Japan has regional medical device distributors that focus on specific geographic areas. These distributors leverage local networks and relationships with hospitals, clinics, and healthcare providers. They are valuable for manufacturers targeting specific regions, offering localized expertise, regulatory compliance support, and tailored strategies for navigating the unique needs of Japan’s healthcare market.
- [What Is The Role Of A Medical Device Distributor In Japan’s Market?](https://www.pacificbridgemedical.com/ufaq/what-is-the-role-of-a-medical-device-distributor-in-japans-market/): A medical device distributor in Japan facilitates product importation, regulatory compliance, market entry, and distribution to healthcare providers. They manage sales, logistics, and post-market activities, including customer support and maintenance. Distributors often assist with NHI reimbursement processes by navigating MHLW and Chuikyo requirements, ensuring products align with Japanese healthcare standards.
- [How Can I Evaluate A Medical Device Distributor’s Network In Japan?](https://www.pacificbridgemedical.com/ufaq/how-can-i-evaluate-a-medical-device-distributors-network-in-japan/): To evaluate a medical device distributor's network in Japan, assess their market reach, experience with similar products, regulatory expertise, and relationships with healthcare providers. Verify their compliance with Japanese laws, NHI reimbursement knowledge, and ability to provide post-market support. Conduct due diligence on their reputation, logistics capabilities, and sales performance.
- [How Do I Verify The Credentials Of A Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/how-do-i-verify-the-credentials-of-a-medical-device-distributor-in-japan/): Verify credentials by checking their PMDA licenses, references from manufacturers they’ve worked with, & membership in trade associations like JFMDA. Conduct interviews, review their market history, & consult local experts or business directories for additional validation.
- [What Should I Consider When Choosing A Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/what-should-i-consider-when-choosing-a-medical-device-distributor-in-japan/): Consider their market experience, distribution network, regulatory expertise, & reputation. Evaluate their alignment with your product type & business goals. Strong customer relationships, warehousing capabilities, & a proven track record in handling similar devices are essential factors.
- [How Does The Process Of Partnering With A Medical Device Distributor In Japan Work?](https://www.pacificbridgemedical.com/ufaq/how-does-the-process-of-partnering-with-a-medical-device-distributor-in-japan-work/): Partnership involves identifying the right distributor, negotiating terms, & finalizing contracts. Ensure the distributor aligns with your business goals, understands regulatory requirements, & provides services like marketing & after-sales support. Regular communication & collaboration are key to success.
- [What Are The Steps To Identify A Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-steps-to-identify-a-medical-device-distributor-in-japan/): Steps include researching potential distributors, assessing their experience with similar devices, verifying their credentials, & conducting interviews. Attend trade events, network with industry professionals, & review their market presence, customer base, & compliance expertise.
- [How Can I Find A Reliable Medical Device Distributor In Japan?](https://www.pacificbridgemedical.com/ufaq/how-can-i-find-a-reliable-medical-device-distributor-in-japan/): Use trade directories, industry events like MEDTEC Japan, or platforms like JETRO to identify distributors. Seek referrals from industry peers & evaluate distributors’ experience, regulatory knowledge, & market reach. Consulting local experts or agencies familiar with Japan’s medical market can also help.
- [What Is The Outlook For Medical Device Reimbursement Policies In Japan?](https://www.pacificbridgemedical.com/ufaq/what-is-the-outlook-for-medical-device-reimbursement-policies-in-japan/): The outlook is positive, with policies adapting to support innovation, digital health, & aging population needs. Japan is focusing on expedited reviews for breakthrough devices & enhancing collaboration between regulators & manufacturers. Emphasis on cost control & evidence-based pricing will continue.
- [How Does Japan Ensure Cost-Effective Reimbursement Decisions For Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-ensure-cost-effective-reimbursement-decisions-for-devices/): Japan’s reimbursement process emphasizes balancing innovation with cost-effectiveness. MHLW evaluates clinical outcomes, cost-benefit ratios, & real-world performance to determine fair pricing. Health technology assessments (HTAs) are increasingly used to support this approach.
- [What Are The Most Common Reasons For Reimbursement Denials In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-most-common-reasons-for-reimbursement-denials-in-japan/): Common reasons include insufficient clinical evidence, non-compliance with PMDA standards, inadequate cost-effectiveness data, or misalignment with existing reimbursement classifications. Language errors or incomplete submissions can also result in application rejections.
- [How Does Japan Treat Reimbursement For Telemedicine Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-treat-reimbursement-for-telemedicine-devices/): Telemedicine devices are gradually gaining reimbursement recognition in Japan. Devices that support remote monitoring or diagnostics are reviewed based on clinical utility, safety, & cost-effectiveness. MHLW continues to update reimbursement guidelines for these technologies as adoption increases.
- [What Are The Major Trends In Medical Device Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-major-trends-in-medical-device-reimbursement-in-japan/): Trends include growing support for digital health technologies, simplified pathways for innovative devices, & increasing focus on cost-effectiveness. Reimbursement policies are also evolving to accommodate telemedicine, AI-driven tools, & minimally invasive technologies.
- [How Does Japan Promote Transparency In Medical Device Reimbursement?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-promote-transparency-in-medical-device-reimbursement/): Japan promotes transparency by publishing reimbursement policies, pricing decisions, & assessment criteria through the MHLW. Stakeholders, including manufacturers & healthcare providers, are engaged during advisory panel reviews, ensuring open communication throughout the process.
- [What Are The Language Requirements For Reimbursement Submissions In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-language-requirements-for-reimbursement-submissions-in-japan/): All submissions, including clinical data, technical documentation, & pricing applications, must be in Japanese. Manufacturers typically work with local consultants or translation services familiar with medical terminology to ensure accuracy & compliance with Japan’s regulatory standards.
- [How Are Hospitals In Japan Involved In The Reimbursement Process?](https://www.pacificbridgemedical.com/ufaq/how-are-hospitals-in-japan-involved-in-the-reimbursement-process/): Hospitals play a crucial role by providing feedback on device utility, conducting clinical trials, & supporting cost-effectiveness studies. Their input is often crucial during advisory panel discussions, as they validate a device's clinical value & practical benefits for reimbursement applications.
- [How Does Japan Manage Risk Categorization In Reimbursement Applications?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-manage-risk-categorization-in-reimbursement-applications/): Japan categorizes devices by risk level, clinical importance, & innovation. High-risk devices, like Class III & IV, undergo stricter scrutiny, requiring robust clinical evidence. The reimbursement classification determines if the device qualifies for existing pricing categories or if a new category & price need to be established.
- [What Are The Key Milestones In Japan’s Medical Device Reimbursement Process?](https://www.pacificbridgemedical.com/ufaq/what-are-the-key-milestones-in-japans-medical-device-reimbursement-process/): The key milestones include obtaining PMDA approval, assigning a reimbursement classification, securing pricing from the MHLW, & listing the product on the National Health Insurance (NHI) system. The process involves regulatory submissions, pricing negotiations, & establishing clinical evidence for the device.
- [How Does Japan Handle Reimbursement For AI-Driven Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-handle-reimbursement-for-ai-driven-medical-devices/): Japan handles reimbursement for AI-driven medical devices by evaluating their clinical effectiveness, safety, and cost-effectiveness under MHLW and Chuikyo. Devices must demonstrate clear healthcare benefits, such as improved diagnostics or efficiency. Regulatory approval by PMDA is required, and innovative AI devices may receive premium reimbursement under the NHI system if they provide significant advancements.
- [What Are The Pricing Regulations For Reimbursed Devices In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-pricing-regulations-for-reimbursed-devices-in-japan/): Pricing regulations for reimbursed devices in Japan are managed by MHLW and Chuikyo. Prices are determined through reference pricing (comparison with similar devices) or cost-based methods. Innovative devices may qualify for premium pricing if they demonstrate significant clinical benefits. Regular NHI fee schedule revisions adjust prices based on market trends and healthcare priorities.
- [How Does Japan Encourage The Development Of Reimbursable Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-encourage-the-development-of-reimbursable-medical-devices/): Japan encourages the development of reimbursable medical devices through R&D grants, tax incentives, and expedited regulatory pathways for innovative technologies. Programs like the Sakigake Designation and consultation support from MHLW and PMDA assist manufacturers. Premium pricing for cutting-edge devices under the NHI system further incentivizes innovation while addressing healthcare needs.
- [How Are Cross-Border Medical Devices Addressed In Japan’s Reimbursement Policies?](https://www.pacificbridgemedical.com/ufaq/how-are-cross-border-medical-devices-addressed-in-japans-reimbursement-policies/): Cross-border medical devices in Japan must comply with PMDA regulatory requirements and NHI reimbursement policies. Local agents often facilitate the process, ensuring alignment with Japanese standards. Reimbursement decisions by MHLW and Chuikyo consider clinical data, cost-effectiveness, and market relevance. Foreign pricing may influence negotiations, but devices must fit Japan’s healthcare system needs.
- [How Does Japan Monitor The Performance Of Reimbursed Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-monitor-the-performance-of-reimbursed-medical-devices/): Japan monitors the performance of reimbursed medical devices through mandatory post-market surveillance, requiring manufacturers to report adverse events, conduct post-market studies, and submit periodic safety updates to MHLW and PMDA. This process ensures devices maintain safety, efficacy, and quality while aligning with reimbursement criteria under the NHI system for continued market access.
- [What Is The Role Of The PMDA In Japan’s Medical Device Reimbursement?](https://www.pacificbridgemedical.com/ufaq/what-is-the-role-of-the-pmda-in-japans-medical-device-reimbursement/): The PMDA (Pharmaceuticals and Medical Devices Agency) plays a crucial role in Japan's medical device reimbursement by overseeing regulatory approval. Devices must pass PMDA safety, efficacy, and quality evaluations before reimbursement applications to MHLW and Chuikyo. PMDA’s approval ensures devices meet Japanese standards, enabling inclusion in the NHI reimbursement system.
- [How Does Japan Assess The Innovation Level Of Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-assess-the-innovation-level-of-medical-devices/): Japan assesses the innovation level of medical devices by evaluating their clinical benefits, uniqueness, and improvements over existing technologies. Chuikyo and MHLW review evidence demonstrating safety, efficacy, and cost-effectiveness. Devices offering significant advancements in patient outcomes, treatment efficiency, or healthcare impact may qualify for premium pricing or new reimbursement categories under the NHI system.
- [How Does Japan Handle Bundled Payments For Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-handle-bundled-payments-for-medical-devices/): Japan uses bundled payments for certain medical procedures, including associated devices, under the Diagnosis Procedure Combination (DPC) system. This system integrates device costs into overall procedure reimbursement, encouraging cost-efficiency. Bundled payments apply to standardized treatments, while high-cost or innovative devices may still require separate evaluation and reimbursement under the NHI fee schedule.
- [What Is The Impact Of Reimbursement Decisions On Market Access In Japan?](https://www.pacificbridgemedical.com/ufaq/what-is-the-impact-of-reimbursement-decisions-on-market-access-in-japan/): Reimbursement decisions significantly impact market access in Japan by determining a medical device’s affordability and adoption under the NHI system. Positive decisions enable widespread use in the healthcare system, while unfavorable outcomes may limit market entry. Pricing, classification, and alignment with NHI criteria influence a device’s competitiveness and accessibility in Japan.
- [How Does Japan’s Reimbursement System Treat Wearable Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japans-reimbursement-system-treat-wearable-medical-devices/): Japan’s reimbursement system evaluates wearable medical devices based on clinical efficacy, safety, and cost-effectiveness. MHLW and Chuikyo determine classification and pricing under the NHI system. Wearables must demonstrate measurable health benefits and align with healthcare needs. Innovative wearables offering significant improvements in monitoring or treatment may qualify for premium reimbursement.
- [What Are The Special Reimbursement Criteria For Cutting-Edge Devices In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-special-reimbursement-criteria-for-cutting-edge-devices-in-japan/): Cutting-edge devices in Japan may qualify for special reimbursement criteria, such as the Premium for New Technology. To qualify, devices must demonstrate significant clinical innovation, improved patient outcomes, or cost-effectiveness beyond existing technologies. MHLW and Chuikyo evaluate robust evidence during the reimbursement process, often granting higher pricing under the NHI system.
- [How Does Japan Address Reimbursement For Single-Use Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-address-reimbursement-for-single-use-medical-devices/): Japan reimburses single-use medical devices based on their classification, clinical benefits, and cost-effectiveness under the NHI system. Pricing is determined by Chuikyo, considering manufacturing costs and healthcare impact. Reimbursement encourages cost control while ensuring patient safety. Innovative single-use devices may qualify for premium pricing if they offer significant clinical advantages.
- [What Are The Submission Timelines For Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-submission-timelines-for-reimbursement-in-japan/): In Japan, reimbursement submission timelines depend on the device's classification and regulatory approval. Applications to MHLW are typically submitted post-PMDA approval. The review process by Chuikyo usually takes 6-12 months. Timelines may extend for innovative or novel devices requiring new categories or extensive evidence. Annual NHI fee schedule updates influence submission planning.
- [How Does Japan Evaluate The Economic Impact Of Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-evaluate-the-economic-impact-of-medical-devices/): Japan evaluates the economic impact of medical devices through cost-effectiveness analysis, often using metrics like quality-adjusted life years (QALYs) and cost-benefit ratios. Chuikyo and MHLW assess how devices improve healthcare outcomes while controlling costs. Evidence of long-term savings, efficiency, and value compared to existing treatments is crucial for NHI reimbursement decisions.
- [What Is The Role Of Clinical Evidence In Japan’s Reimbursement Process?](https://www.pacificbridgemedical.com/ufaq/what-is-the-role-of-clinical-evidence-in-japans-reimbursement-process/): Clinical evidence plays a critical role in Japan’s reimbursement process, demonstrating a medical device’s safety, efficacy, and clinical benefits. MHLW and Chuikyo use this evidence to assess the device’s therapeutic value, cost-effectiveness, and alignment with NHI criteria. Robust clinical data, including trial results and real-world outcomes, is essential for reimbursement approval.
- [How Are Combination Drug-Device Products Reimbursed In Japan?](https://www.pacificbridgemedical.com/ufaq/how-are-combination-drug-device-products-reimbursed-in-japan/): Combination drug-device products in Japan are reimbursed based on their primary mode of action, as determined by MHLW. If the drug is primary, the product follows pharmaceutical reimbursement rules; if the device is primary, it follows medical device rules. Chuikyo evaluates clinical effectiveness, safety, & cost-effectiveness for pricing under the NHI framework.
- [What Is The Process For Innovative Technology Add-On Payments In Japan?](https://www.pacificbridgemedical.com/ufaq/what-is-the-process-for-innovative-technology-add-on-payments-in-japan/): In Japan, innovative technology add-on payments are granted for devices with significant clinical benefits that exceed existing technologies. Manufacturers apply through MHLW, providing robust evidence of safety, efficacy, & cost-effectiveness. Chuikyo reviews the application, and if approved, the device receives premium reimbursement pricing under the NHI system to reflect its innovation.
- [What Are The Key Differences Between Reimbursement Systems In Japan And Other Countries?](https://www.pacificbridgemedical.com/ufaq/what-are-the-key-differences-between-reimbursement-systems-in-japan-and-other-countries/): Japan’s reimbursement system emphasizes cost containment, centralized decision-making, and strict evaluation by MHLW and Chuikyo. It uses the NHI fee schedule for standardized pricing. Unlike the U.S. or EU, Japan often requires separate classification for innovative devices and rigorous cost-effectiveness analysis. Annual fee revisions and strong regulatory ties also set Japan apart.
- [How Does Japan Handle Medical Devices With Multiple Indications?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-handle-medical-devices-with-multiple-indications/): Japan handles medical devices with multiple indications by evaluating each indication separately for reimbursement under the NHI system. MHLW & Chuikyo assess the clinical efficacy, safety, and cost-effectiveness for all approved indications. Pricing and classification may differ depending on the indication's value, healthcare impact, and alignment with reimbursement criteria.
- [What Is The Appeal Process For Denied Reimbursement Applications In Japan?](https://www.pacificbridgemedical.com/ufaq/what-is-the-appeal-process-for-denied-reimbursement-applications-in-japan/): The appeal process for denied reimbursement applications in Japan involves resubmitting the application with additional evidence to address MHLW or Chuikyo concerns. Manufacturers must provide stronger clinical, safety, or cost-effectiveness data. Engaging with local agents or consultants is common to navigate the process. Appeals must align with NHI guidelines for reconsideration.
- [How Does Japan Define Functional Categories For Reimbursement?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-define-functional-categories-for-reimbursement/): Japan defines functional categories for reimbursement based on a device’s clinical purpose, technological characteristics, and therapeutic application. These categories group devices with similar functions to standardize evaluation and pricing under the NHI system. New or innovative devices may require unique categories, subject to Chuikyo's assessment of their safety, efficacy, and cost-effectiveness.
- [What Documentation Is Needed For Medical Device Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/what-documentation-is-needed-for-medical-device-reimbursement-in-japan/): Documentation needed for medical device reimbursement in Japan includes regulatory approval, clinical trial data, safety & efficacy evidence, cost-effectiveness analysis, comparison with existing devices, and detailed product specifications. Additional materials like economic evaluations, post-market surveillance plans, and marketing authorization are required for submission to MHLW and Chuikyo under the NHI framework.
- [How Does Japan’s Reimbursement System Handle Imported Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japans-reimbursement-system-handle-imported-medical-devices/): Japan’s reimbursement system evaluates imported medical devices similarly to domestic ones, requiring regulatory approval from PMDA & submission to MHLW for reimbursement. Imported devices must demonstrate safety, efficacy, & cost-effectiveness. Local agents often assist with compliance, market entry, & documentation. Pricing may consider foreign market prices but adapts to Japan’s NHI system standards.
- [What Is The Role Of The Local Agent In Japan’s Reimbursement Process?](https://www.pacificbridgemedical.com/ufaq/what-is-the-role-of-the-local-agent-in-japans-reimbursement-process/): A local agent in Japan’s reimbursement process acts as a liaison for foreign manufacturers, facilitating regulatory approvals, reimbursement applications, & communication with MHLW & Chuikyo. They assist with documentation, ensure compliance with local standards, & support market access strategies. Their expertise is crucial for navigating Japan’s complex reimbursement system efficiently.
- [How Does Japan Handle Reimbursement For Diagnostic Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-handle-reimbursement-for-diagnostic-medical-devices/): Japan reimburses diagnostic medical devices under the NHI system, based on evaluations by MHLW & Chuikyo. Devices must demonstrate clinical accuracy, safety, cost-effectiveness, & healthcare utility. Reimbursement is determined through classification, pricing comparisons, or cost-based methods. Innovative diagnostics may receive premium pricing if they significantly enhance patient outcomes or healthcare efficiency.
- [What Are The Most Common Challenges With Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-most-common-challenges-with-reimbursement-in-japan/): Common challenges with reimbursement in Japan include lengthy approval timelines, stringent evidence requirements, navigating complex regulatory & reimbursement processes, & obtaining premium pricing for innovative devices. Aligning with NHI standards, addressing cost-effectiveness concerns, & adapting to periodic fee schedule revisions can also pose difficulties for manufacturers entering Japan’s healthcare market.
- [How Are Medical Device Prices Adjusted Over Time In Japan?](https://www.pacificbridgemedical.com/ufaq/how-are-medical-device-prices-adjusted-over-time-in-japan/): Medical device prices in Japan are adjusted periodically through NHI fee schedule revisions, managed by MHLW & Chuikyo. Adjustments account for market trends, technological advancements, competition, & cost-effectiveness. If a device’s price significantly decreases in the market, its reimbursement price may be lowered to reflect these changes, ensuring fair & sustainable healthcare spending.
- [What Are The Annual Updates To Japan’s Reimbursement Policies?](https://www.pacificbridgemedical.com/ufaq/what-are-the-annual-updates-to-japans-reimbursement-policies/): Japan’s reimbursement policies are updated annually through MHLW, with input from Chuikyo. These updates revise the NHI fee schedule, adjust pricing for medical devices based on market trends & clinical value, & may introduce new categories or reimbursement criteria. The goal is to reflect advancements, control costs, & maintain healthcare quality.
- [How Does Japan Determine The Cost-Effectiveness Of Medical Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-determine-the-cost-effectiveness-of-medical-devices/): Japan determines the cost-effectiveness of medical devices through Health Technology Assessment (HTA), overseen by MHLW & Chuikyo. Manufacturers submit clinical & economic evidence, including cost-benefit analyses & quality-adjusted life years (QALYs). Devices are evaluated for their impact on healthcare outcomes & costs, ensuring alignment with NHI reimbursement criteria & system sustainability.
- [How Does The Chuikyo Committee Influence Medical Device Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/how-does-the-chuikyo-committee-influence-medical-device-reimbursement-in-japan/): The Chuikyo committee plays a central role in Japan’s medical device reimbursement by reviewing applications, classifying devices, & determining reimbursement prices. It evaluates clinical efficacy, safety, cost-effectiveness, & healthcare system impact. Chuikyo ensures fair pricing, aligns devices with NHI standards, & supports sustainable healthcare through evidence-based reimbursement decisions.
- [What Is The Fee-For-Service Model In Japan’s Reimbursement System?](https://www.pacificbridgemedical.com/ufaq/what-is-the-fee-for-service-model-in-japans-reimbursement-system/): The fee-for-service model in Japan’s reimbursement system compensates healthcare providers based on individual services rendered, including medical device usage. Each service or procedure is assigned a fixed fee under the National Health Insurance (NHI) fee schedule, determined by MHLW & Chuikyo. This model ensures standardized reimbursement rates across Japan’s healthcare system.
- [How Does Japan Treat Combination Medical Products For Reimbursement?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-treat-combination-medical-products-for-reimbursement/): Japan evaluates combination medical products—those integrating drugs, devices, or biologics—based on their primary mode of action. MHLW determines regulatory pathways & reimbursement classification, with Chuikyo assessing clinical benefits, safety, & cost-effectiveness. Reimbursement aligns with the National Health Insurance (NHI) system, often requiring robust evidence for both components to justify pricing.
- [What Are The Post-Market Surveillance Requirements For Reimbursed Devices In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-post-market-surveillance-requirements-for-reimbursed-devices-in-japan/): Post-market surveillance for reimbursed devices in Japan requires manufacturers to monitor safety, efficacy, & performance. They must report adverse events, submit periodic safety updates, & conduct post-marketing studies if mandated. Compliance with PMDA & MHLW regulations ensures devices maintain their approved reimbursement status under the NHI system while safeguarding public health.
- [What Is The Pricing Process For Medical Devices Reimbursed In Japan?](https://www.pacificbridgemedical.com/ufaq/what-is-the-pricing-process-for-medical-devices-reimbursed-in-japan/): The pricing process for medical devices reimbursed in Japan involves Chuikyo evaluating the device’s clinical benefits, safety, & cost-effectiveness. Pricing is set by comparing similar devices (reference pricing) or using cost-based calculations. Devices with innovative features may qualify for premium pricing. Approved prices are included in the NHI fee schedule for reimbursement.
- [How Does Japan Handle Reimbursement For Digital Health Devices?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-handle-reimbursement-for-digital-health-devices/): Japan handles reimbursement for digital health devices through the MHLW & Chuikyo. These devices must demonstrate clinical efficacy, safety, & cost-effectiveness. They are classified under existing categories or evaluated for new classifications. Evidence from clinical trials or real-world data is essential, & reimbursement approval aligns with the NHI framework for coverage.
- [How Long Does It Take To Get Reimbursement Approval In Japan?](https://www.pacificbridgemedical.com/ufaq/how-long-does-it-take-to-get-reimbursement-approval-in-japan/): Reimbursement approval in Japan typically takes 6-12 months after regulatory approval. The process involves submitting an application to MHLW, Chuikyo review for classification & pricing, & listing in the NHI fee schedule. The timeline varies based on device complexity, evidence quality, & whether it fits existing or new reimbursement categories.
- [What Are The Differences Between New And Existing Categories In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-differences-between-new-and-existing-categories-in-japan/): In Japan, new categories are created for medical devices with novel technologies or functions not covered by existing classifications. They undergo detailed evaluation for pricing & reimbursement under NHI. Existing categories cover devices similar to those already reimbursed, often resulting in pricing based on equivalence. New categories require additional clinical & cost-effectiveness evidence.
- [What Is The Role Of MHLW In Medical Device Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/what-is-the-role-of-mhlw-in-medical-device-reimbursement-in-japan/): The Ministry of Health, Labour & Welfare (MHLW) oversees medical device reimbursement in Japan. It establishes reimbursement policies, reviews applications, & ensures devices meet safety, efficacy, & cost-effectiveness standards. MHLW works with the Chuikyo committee to evaluate pricing, classify devices, & integrate them into the National Health Insurance (NHI) system for coverage.
- [What Are The Main Steps For Submitting A Reimbursement Application In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-main-steps-for-submitting-a-reimbursement-application-in-japan/): Submitting a reimbursement application in Japan involves these steps: obtaining regulatory approval from PMDA, preparing evidence of clinical efficacy, safety, & cost-effectiveness, submitting the application to MHLW, undergoing review by Chuikyo for classification & pricing, & final inclusion in the National Health Insurance (NHI) reimbursement list. Thorough documentation is critical throughout the process.
- [How Are New Medical Devices Evaluated For Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/how-are-new-medical-devices-evaluated-for-reimbursement-in-japan/): New medical devices in Japan are evaluated for reimbursement by the Chuikyo committee under MHLW. The process involves reviewing clinical efficacy, safety, cost-effectiveness, & alignment with existing healthcare needs. Manufacturers submit evidence, including clinical trial data & economic analysis. Pricing is determined by comparing similar devices or cost-calculation methods within the NHI system.
- [What Evidence Is Required For Medical Device Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/what-evidence-is-required-for-medical-device-reimbursement-in-japan/): For medical device reimbursement in Japan, manufacturers must provide evidence of clinical efficacy, safety, cost-effectiveness, & alignment with healthcare standards. Data includes clinical trial results, real-world evidence, & comparisons to similar devices. Economic evaluations & documentation showing patient benefits are essential for approval by MHLW & Chuikyo under the NHI framework.
- [How Does Japan Classify Medical Devices For Reimbursement Purposes?](https://www.pacificbridgemedical.com/ufaq/what-are-the-functional-categories-for-medical-devices-in-japan/): Japan classifies medical devices for reimbursement based on their function, intended use, & technological features. Devices are grouped into functional categories under the NHI framework, aligning with their clinical application. Pricing tiers consider innovation, equivalence to existing devices, & therapeutic impact. The Chuikyo committee ensures classifications reflect healthcare needs & economic sustainability.
- [What Is The Role Of Health Technology Assessment In Japan’s Reimbursement System?](https://www.pacificbridgemedical.com/ufaq/what-is-the-role-of-health-technology-assessment-in-japans-reimbursement-system/): Health Technology Assessment (HTA) in Japan's reimbursement system evaluates medical devices' clinical effectiveness, safety, cost-effectiveness, & impact on healthcare. Managed by MHLW & Chuikyo, HTA informs pricing & coverage decisions within the National Health Insurance framework. It ensures resources are allocated efficiently while maintaining high-quality, patient-centered care standards in Japan’s healthcare system.
- [How Are Reimbursement Prices For Medical Devices Determined In Japan?](https://www.pacificbridgemedical.com/ufaq/how-are-reimbursement-prices-for-medical-devices-determined-in-japan/): Reimbursement prices for medical devices in Japan are determined by the Chuikyo committee under MHLW. Pricing considers clinical effectiveness, cost-effectiveness, safety, & comparison with existing devices. Manufacturers submit data for evaluation. Prices are either set based on market equivalents or through cost-calculation methods, ensuring alignment with Japan’s healthcare system & economic sustainability.
- [What Are The Key Reimbursement Agencies For Medical Devices In Japan?](https://www.pacificbridgemedical.com/ufaq/what-are-the-key-reimbursement-agencies-for-medical-devices-in-japan/): Key reimbursement agencies for medical devices in Japan include the Ministry of Health, Labour & Welfare (MHLW), which oversees reimbursement policies, & the Central Social Insurance Medical Council (Chuikyo), which evaluates reimbursement applications & determines pricing. These agencies ensure devices meet clinical, economic, & regulatory standards for inclusion in the National Health Insurance (NHI) system.
- [How Does Japan Handle Medical Device Reimbursement Applications?](https://www.pacificbridgemedical.com/ufaq/how-does-japan-handle-medical-device-reimbursement-applications/): Japan handles medical device reimbursement applications through the Ministry of Health, Labour & Welfare (MHLW). Manufacturers submit applications after regulatory approval, providing clinical evidence, cost-effectiveness, & safety data. The Chuikyo committee reviews applications, determines pricing, & assigns reimbursement classification. Successful devices are listed under the National Health Insurance (NHI) fee schedule for coverage.
- [What Is The Process For Medical Device Reimbursement In Japan?](https://www.pacificbridgemedical.com/ufaq/what-is-the-process-for-medical-device-reimbursement-in-japan/): Medical device reimbursement in Japan involves classification under the Medical Service Fee Schedule, submission for pricing approval, & obtaining reimbursement pricing through MHLW. Manufacturers must demonstrate clinical benefits, cost-effectiveness, & alignment with Japanese healthcare standards. The process requires regulatory approval, thorough documentation, & may involve negotiations for listing in the NHI reimbursement framework.
- [What Are The Best Practices For Collaborating Effectively With A Japanese Designated Marketing Authorization Holder?](https://www.pacificbridgemedical.com/ufaq/what-are-the-best-practices-for-collaborating-effectively-with-a-japanese-designated-marketing-authorization-holder/): To collaborate effectively with a Japanese Designated Marketing Authorization Holder, prioritize clear communication, respect cultural nuances, and establish mutual trust. Regularly update on project progress, adhere to timelines, and ensure compliance with local regulations. Foster a collaborative environment by valuing their expertise and maintaining open, respectful dialogue to achieve shared goals.
- [Is A Japan DMAH Required To Maintain Physical Office Space For Record-Keeping?](https://www.pacificbridgemedical.com/ufaq/is-a-japan-dmah-required-to-maintain-physical-office-space-for-record-keeping/): Yes, a Japan Designated Marketing Authorization Holder (DMAH) is required to maintain a physical office space for record-keeping. This ensures compliance with Japanese regulatory requirements, facilitates communication with authorities, and provides a secure location for storing essential documents related to product safety, quality, and regulatory compliance.
- [How Does A Japanese Designated Marketing Authorization Holder Address Cross-Border Regulatory Challenges?](https://www.pacificbridgemedical.com/ufaq/how-does-a-japanese-designated-marketing-authorization-holder-address-cross-border-regulatory-challenges/): A Japanese Designated Marketing Authorization Holder addresses cross-border regulatory challenges by collaborating with international regulatory bodies, ensuring compliance with local and global standards, leveraging local expertise, and utilizing streamlined communication channels. They also adapt strategies to meet diverse market requirements, ensuring efficient product registration and distribution across different jurisdictions.
- [Can The Japan DMAH Facilitate Regulatory Pathway Consultation With PMDA?](https://www.pacificbridgemedical.com/ufaq/can-the-japan-dmah-facilitate-regulatory-pathway-consultation-with-pmda/): Yes, the Japan DMAH (Designated Marketing Authorization Holder) can facilitate regulatory pathway consultation with the PMDA (Pharmaceuticals and Medical Devices Agency). They act as a liaison, helping foreign companies navigate Japan's regulatory requirements, ensuring compliance, and streamlining communication with the PMDA for efficient product approval processes.
- [How Often Are Japanese Designated Marketing Authorization Holders Inspected By Regulatory Authorities?](https://www.pacificbridgemedical.com/ufaq/how-often-are-japanese-designated-marketing-authorization-holders-inspected-by-regulatory-authorities/): Japanese Designated Marketing Authorization Holders (DMAHs) are typically inspected by regulatory authorities every five years. However, the frequency can vary based on risk assessments, compliance history, and specific product concerns. Authorities may conduct more frequent inspections if there are significant changes in regulations or if compliance issues are identified.
- [Does A Japan DMAH Need To Implement A Formal Quality Management System?](https://www.pacificbridgemedical.com/ufaq/does-a-japan-dmah-need-to-implement-a-formal-quality-management-system/): Yes, a Japan DMAH should implement a formal Quality Management System (QMS) to ensure compliance with regulatory requirements, enhance product safety, and improve operational efficiency. A QMS helps in maintaining consistent quality standards, facilitates continuous improvement, and builds trust with stakeholders, ultimately supporting successful market access and customer satisfaction.
- [How Does A Japanese Designated Marketing Authorization Holder Manage Confidential Information?](https://www.pacificbridgemedical.com/ufaq/how-does-a-japanese-designated-marketing-authorization-holder-manage-confidential-information/): A Japanese Designated Marketing Authorization Holder manages confidential information by implementing strict data protection protocols, adhering to regulatory requirements, and ensuring secure communication channels. They conduct regular audits, employee training, and use advanced encryption technologies to safeguard sensitive data, maintaining confidentiality and compliance with Japan's Pharmaceutical and Medical Device Act.
- [Can A Japan DMAH Handle Biologics And Advanced Therapy Products?](https://www.pacificbridgemedical.com/ufaq/can-a-japan-dmah-handle-biologics-and-advanced-therapy-products/): Yes, a Japan DMAH (Designated Marketing Authorization Holder) can handle biologics and advanced therapy products. They ensure compliance with Japanese regulations, manage product registration, and oversee post-marketing surveillance. Collaborating with local experts, they facilitate market entry and maintain product quality, safety, and efficacy in alignment with Japan's stringent standards.
- [Is The Japanese Designated Marketing Authorization Holder Involved In Secure Supply Chain Management?](https://www.pacificbridgemedical.com/ufaq/is-the-japanese-designated-marketing-authorization-holder-involved-in-secure-supply-chain-management/): Yes, the Japanese Designated Marketing Authorization Holder (DMAH) plays a crucial role in secure supply chain management. They ensure compliance with regulatory requirements, oversee product distribution, and maintain quality standards. By coordinating with manufacturers and distributors, DMAHs help safeguard the integrity and safety of pharmaceutical products throughout the supply chain.

## Regulations
- [China NMPA Medical Device and Pharmaceutical Regulations](https://www.pacificbridgemedical.com/regulation/china-medical-device-pharmaceutical-regulations/): China's medical device classification system shares some similarities with U.S. and European standards. Under the China medical device regulations, devices can be categorized into Class I, Class II, and Class III devices. Class I devices are simple devices that can be effectively monitored through regular administration, while Class III devices are complex implants or life supporting devices. Medical Device Classification rules were issued in State Drug Administration's Order Number 15.
- [Japan MHLW & PMDA Medical Device and Pharmaceutical Regulations](https://www.pacificbridgemedical.com/regulation/japan-medical-device-pharmaceutical-regulations/): For the most comprehensive and detailed overview of the Japanese medical device regulations, view the Japan Medical Device Regulations Webcast. Key topics include PMDA consultations, device classification, Foreign Manufacturer Registration, Japanese GCP, product reimbursement, how to expedite product registration and maximize the use of foreign clinical data, and more.
- [Korea Medical Device and Pharmaceutical Regulations](https://www.pacificbridgemedical.com/regulation/korea-medical-device-pharmaceutical-regulations/): Current Korea medical device regulations are covered under the Medical Device Act (MDA) that went into effect in 2004. Various amendments and modifications have been made to the MDA since its initial release. The MFDS periodically releases relevant notifications that cover more detailed technical requirements for manufacturers and importers.
- [India Medical Device and Pharmaceutical Regulations](https://www.pacificbridgemedical.com/regulation/india-medical-device-pharmaceutical-regulations/): India's Ministry of Health and Family Welfare (MoHFW) and the Central Drugs Standard Control Organization (CDSCO) are the main regulatory bodies that are responsible for overseeing pharmaceuticals and medical devices within India. The CDSCO exercises regulatory control over the import of drugs and devices, and approves new medical products and clinical trials. The CDSCO also oversees the Drugs Consultative Committee (DCC), the Drugs Technical Advisory Board (DTAB), and the Central Licensing Approving Authority (CLAA), the body responsible for ensuring medical device compliance.
- [Singapore Medical Device and Pharmaceutical Regulations](https://www.pacificbridgemedical.com/regulation/singapore-medical-device-pharmaceutical-regulations/): The Singapore Medical Device Updates Webcast provides an in-depth overview of the regulatory framework and registration process for medical device products in Singapore. The webcast highlights important regulations for importers, wholesalers, and manufacturers of medical devices, as well as post-marketing surveillance responsibilities, reimbursement, and other key topics. View the webcast for a comprehensive understanding of Singapore medical device regulations.
- [Taiwan Medical Device and Pharmaceutical Regulations](https://www.pacificbridgemedical.com/regulation/taiwan-medical-device-pharmaceutical-regulations/): Taiwan's Ministry of Health and Welfare (MOHW) is the government ministry responsible for the country's healthcare regulations. The MOHW has a broad mandate to improve the quality of healthcare, prevent and control infectious diseases, ensure food and drug safety, and facilitate technological development. Within the MOHW, the Taiwan Food and Drug Administration (TFDA) is responsible for managing the regulatory system for the safety and quality of food, drugs, medical devices, and cosmetics. The TFDA drafts and implements regulations, grants product registration and clinical trial approvals, monitors manufacturing and importation, and conducts safety surveillance activities on health products.
- [Hong Kong Medical Device and Pharmaceutical Regulations](https://www.pacificbridgemedical.com/regulation/hong-kong-medical-device-pharmaceutical-regulations/): Although Hong Kong is a Special Administrative Region of China, it does not follow the same medical device or pharmaceutical regulations as the mainland. The Medical Device Control Office (MDCO) and the Drug Office under Hong Kong's Department of Health (DH) are responsible for regulating the country's medical devices and pharmaceuticals, respectively. The MDCO is tasked with overseeing the Medical Device Administrative Control System (MDACS) and developing the regulatory framework for medical devices. The Drug Office handles the registration and import/export of drugs; the inspection and licensing of drug manufacturers, wholesalers, and retailers; and pharmacovigilance and risk management.
- [ASEAN Medical Device and Pharmaceutical Regulations](https://www.pacificbridgemedical.com/regulation/asean-medical-device-pharmaceutical-regulations/): The Association of Southeast Asian Nations (ASEAN), which is comprised of the countries Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Brunei, Laos, Myanmar, and Cambodia, was established in 1967 to promote peace and stability in the region, facilitate collaboration and mutual assistance among the member states, and accelerate regional economic growth, social progress, and cultural development. To these ends, the member nations are working to create harmonized standards in order to remove technical barriers to trade and support the establishment of an integrated market. Healthcare is one of the primary sectors identified for economic integration.

## Publications
- [Software as a Medical Device (SaMD) in Japan: What Manufacturers Need to Know](https://www.pacificbridgemedical.com/publication/software-as-a-medical-device-samd-in-japan-what-manufacturers-need-to-know/): Japan has emerged as one of the more progressive markets when it comes to SaMD. While the concept of software-based medical tools is hardly new, the country's formal regulatory recognition of SaMD reflects a deliberate effort to keep pace with the rapid convergence of healthcare and digital technology.
- [Foreign Manufacturer Accreditation (FMA) in Japan: A Step-by-Step Overview for Drug Companies](https://www.pacificbridgemedical.com/publication/foreign-manufacturer-accreditation-fma-in-japan-a-step-by-step-overview-for-drug-companies/): Japan is one of the world’s most important pharmaceutical markets, but foreign manufacturers cannot access it without first meeting Japan’s regulatory requirements. Besides submitting a Japanese drug registration dossier, clinical trial information, etc., — for drugs or quasi-drugs manufactured overseas, the applicant must obtain formal recognition from the Japanese government. This process is known as Foreign Manufacturer Accreditation (FMA). 
- [Overview of Japan’s Orphan Drug Designation System](https://www.pacificbridgemedical.com/publication/overview-of-japans-orphan-drug-designation-system/): Japan’s orphan drug designation (ODD) system is designed to promote the development of therapies for rare diseases that affect small patient populations. Because these rare diseases often lack commercially attractive markets, special regulatory and financial incentives are necessary to encourage innovation in these areas. The Ministry of Health, Labour and Welfare (MHLW) administers the ODD via the Pharmaceuticals and Medical Devices Act (PMD Act).
- [Japan Medical Device Registration Update: UDI Requirements and the Expansion of Medical DX in 2026](https://www.pacificbridgemedical.com/publication/japan-medical-device-registration-update-udi-requirements-and-the-expansion-of-medical-dx-in-2026/): Japan’s Unique Device Identification (UDI) system was formally established under the 2019 amendment to the Pharmaceutical and Medical Devices Act (PMD Act). The act was amended in 2019 as part of a major reform effort by the Japanese government. The purpose of this new system is to improve traceability, enhance access to safety information, and assist with the digitalization of health care.
- [Japan Drug Registration: Waiver of Japanese Phase 1 Studies in Multi-regional Clinical Trials](https://www.pacificbridgemedical.com/publication/japan-drug-registration-waiver-of-japanese-phase-1-studies-in-multi-regional-clinical-trials/): In December 2023, Japan introduced important regulatory changes that significantly reshape global drug development strategies. Under new guidance issued by Japan’s Ministry of Health, Labour and Welfare (MHLW), drug developers will now be allowed to include Japanese subjects in their multi-regional clinical trials (MRCT) without first conducting a stand-alone Japanese Phase I study, provided that they obtain an agreement from the Pharmaceuticals and Medical Devices Agency (PMDA) and adhere to additional restrictions. The revised framework is intended to tackle the drug lag in Japan while maintaining appropriate protection for patient safety.
- [Japan Drug Registration: How PMDA Consultation Services Provide Support](https://www.pacificbridgemedical.com/publication/japan-drug-registration-how-pmda-consultation-services-provide-support/): For drug companies planning development in Japan, consultations with the Pharmaceuticals and Medical Devices Agency (PMDA) are a practical way to align your strategy with the Japanese health authority’s expectations before you commit to costly studies and other market entry issues in Japan. The PMDA consultation services provide guidance and advice on clinical trials for drugs, data needed for regulatory submissions, and other matters.
- [Singapore’s Drug Master File System: A Regulatory Overview](https://www.pacificbridgemedical.com/publication/singapores-drug-master-file-system-a-regulatory-overview/): Singapore’s Health Sciences Authority (HSA) has a structured framework for the submission and management of Drug Master Files (DMFs) to support the registration of therapeutic products. Under the DMF system, manufacturers can submit confidential information on drug components while enabling drug product applicants to reference this information in their registration dossiers.
- [Korea Pharmaceutical Update: Registration, Policy, and Regulatory Changes](https://www.pacificbridgemedical.com/publication/korea-pharmaceutical-update-registration-policy-and-regulatory-changes/): Korea has introduced a series of regulatory measures aimed at modernizing its pharmaceutical regulatory framework and improving patient access to innovative products. Recent initiatives from the Ministry of Food and Drug Safety (MFDS) and other health agencies reflect a strategy to incorporate digital technologies into regulatory evaluation, increase transparency, and accelerate the availability of advanced treatments, especially in oncology and rare diseases.
- [Recent China Drug Registration and Regulatory Updates: Faster Innovation, Tighter Oversight, and Evolving Market Controls](https://www.pacificbridgemedical.com/publication/recent-china-drug-registration-and-regulatory-updates-faster-innovation-tighter-oversight-and-evolving-market-controls/): In late 2025, China's regulatory landscape for pharmaceuticals changed rapidly due to a number of policies that indicate the government's commitment to increasing innovation while ensuring adequate oversight and compliance. Recent reforms issued by the NMPA, the State Council, and the National Healthcare Security Administration (NHSA) have introduced new regulatory pathways for drug development, commercialization of new technological advances, and post-market surveillance.
- [China Drug Market Access Updates: NRDL, C-List, and VBP](https://www.pacificbridgemedical.com/publication/china-drug-market-access-updates-nrdl-c-list-and-vbp/): China continues to reshape its drug market access system in an effort to balance affordability with better healthcare for its citizens. At the core of this transformation are two reimbursement pathways: National Reimbursement Drug List (NRDL) and Volume-Based Procurement (VBP). Recent policy updates in 2025 indicate how the Chinese government is using these mechanisms to establish new market access pathways for innovative drug products.
- [Japan’s PMDA Expands Registration Support for Foreign Drug and Medical Device Companies](https://www.pacificbridgemedical.com/publication/japans-pmda-expands-registration-support-for-foreign-drug-and-medical-device-companies/): Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is strengthening its role as a global regulator by offering more and more registration support for foreign pharmaceutical and medical device manufacturers. The PMDA has established overseas offices, accelerated pathways for product approval, developed harmonized regulatory frameworks, and created structured consultation programs. By establishing these programs, PMDA is positioning Japan as both a strategic launch market for new products and a gateway for companies looking to gain regulatory approval throughout Asia.
- [Overview of Medical Device Registration in Indonesia](https://www.pacificbridgemedical.com/publication/overview-of-medical-device-registration-in-indonesia/): The Indonesian medical devices market is one of the largest in Southeast Asia and continues to grow at an accelerating pace as a result of the country's population growth, increased demand for sophisticated medical technologies, and improved healthcare delivery systems. Indonesia's regulation of medical devices is managed by the National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan). The BPOM oversees the registration and market release of all medical devices as well as the regulation and enforcement of medical device regulations.
- [Registering In-Vitro Diagnostics (IVD) Reagents in China: An Overview](https://www.pacificbridgemedical.com/publication/registering-in-vitro-diagnostics-ivd-reagents-in-china-an-overview/): Due to the rising prevalence of chronic conditions such as cancer and diabetes in China and the increased focus on early diagnosis and reduced treatment costs, the in vitro diagnostics (IVD) market in China is growing rapidly. The National Medical Products Administration (NMPA) of China classifies IVD reagents as medical devices. The regulatory framework for IVDs has been established in the Provisions for In-Vitro Diagnostics Reagent Registration and Filing, which describes how IVDs will be classified, reviewed, approved, and monitored throughout their lifecycle. This guidance outlines the main requirements of the regulations and some practical issues that device manufacturers must take into account when attempting to register their IVD products in China.
- [China Medical Device Registration: China Strengthens Policy Support to Advance Its Medical Device Industry](https://www.pacificbridgemedical.com/publication/china-medical-device-registration-china-strengthens-policy-support-to-advance-its-medical-device-industry/): Recent reforms to medical device registration in China are revamping how innovative products are approved for market entry. Collectively, these measures aim to reduce regulatory hurdles, enhance quality systems, encourage digital transformation, and promote international collaboration. This signals China’s ambition to move beyond low-end to mid-end device manufacturing and position itself as a global leader in high-end medical technologies.
- [Japan Drug Registration and Reimbursement Update 2026](https://www.pacificbridgemedical.com/publication/japan-drug-registration-and-reimbursement-update-2026/): Over the past year, Japan has initiated a series of regulatory and policy reforms aimed at accelerating drug development, strengthening oversight, and improving access to innovative therapies, while also reinforcing international regulatory cooperation.
- [Korea’s Medical Device Regulations: A 2025 Update](https://www.pacificbridgemedical.com/publication/koreas-medical-device-regulations-a-2025-update/): Korea has recently rolled out a more robust series of regulatory reforms and actions aimed at streamlining patient access to cutting-edge medical technologies over the past year. The advances signal Korea's growing ambition to become a global leader and incubator in the digital health and advanced medical device sectors.
- [Singapore’s Evolving Digital Health Regulatory Landscape](https://www.pacificbridgemedical.com/publication/singapores-evolving-digital-health-regulatory-landscape/): Singapore has quickly become a regional leader in digital health innovation thanks to its strong regulatory frameworks for emerging technologies, including mobile health applications, connected wearables, and AI-enabled devices. As healthcare delivery increasingly makes the transition to digital platforms over the years, the Singaporean Health Sciences Authority (HSA) has established a robust set of guidelines and pathways that protect patients while promoting innovation.
- [Taiwan Medical Device Regulations: A 2025 Update](https://www.pacificbridgemedical.com/publication/taiwan-medical-device-regulations-a-2025-update/): Over the past few years, Taiwan has enacted several significant reforms that have reshaped the regulatory framework for medical devices. These changes encompass a diverse range of topics, from regenerative medicine and digital health to product registration and classification, as well as import inspections and reimbursement policies. Each change reflects the government's commitment to enhance oversight, foster innovation, and ultimately bring new technologies to Taiwanese patients.
- [PMDA More Open to Use of Clinical Data from Other Nations](https://www.pacificbridgemedical.com/publication/pmda-more-open-to-use-of-clinical-data-from-other-nations/): Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has traditionally been less than receptive to clinical data from other nations, but that aversion is slowly giving way. Ames Gross of Pacific Bridge Medical told BioWorld that a trial conducted in another nation with significant representation of those of Japanese ancestry can go a long way toward obviating the need for a trial conducted in Japan.
- [Securing Sufficient Reimbursement in Japan With Ames Gross](https://www.pacificbridgemedical.com/publication/securing-sufficient-reimbursement-in-japan-with-ames-gross/): Japan is the third-largest medical device market in the world, so it warrants important attention by medtech companies planning their global commercial strategy for new products. But for foreign device firms the country is not an easy one in which to make inroads.
- [China Drug Quality Audits: What to Expect](https://www.pacificbridgemedical.com/publication/china-drug-quality-audits-what-to-expect/): China’s pharmaceutical/biotech market offers enormous sourcing and manufacturing opportunities for foreign companies. However, one major challenge remains – product quality is a major concern for foreign firms seeking to procure pharmaceutical products from Chinese factories. Good quality systems that meet China's National Medical Products Administration (NMPA) standards, as well as the U.S. FDA and other global regulatory standards, are essential.
- [China Medical Device GMP/Quality Audits: What to Expect](https://www.pacificbridgemedical.com/publication/what-to-expect-china-medical-device-gmp-audits/): As China’s medical device sector grows rapidly, it has become a key global manufacturing hub for a wide range of device products, from basic consumables to high-risk implantable devices. This expansion has been accompanied by more stringent regulatory control, with the National Medical Products Administration (NMPA) enforcing tighter Good Manufacturing Practice (GMP) standards, more stringent adverse event surveillance, and a more effective recall system. In parallel, NOW the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) conducts safety, certification, and inspection on some devices.
- [China Medical Device Regulations: A 2025 Update](https://www.pacificbridgemedical.com/publication/chinas-medical-device-regulatory-landscape-a-2025-update/): China Medical Device Regulatory Landscape: A 2025 Update
- [Japan’s Medical Device Regulations: A 2025 Update](https://www.pacificbridgemedical.com/publication/japan-medical-device-regulatory-landscape-a-2025-update/): Over the past year, Japan's regulatory and reimbursement environment for medical devices has been rapidly changing. These changes illustrate the government's ongoing commitment to healthcare innovation, effective reimbursement mechanisms, and expanded oversight under the updated Pharmaceutical and Medical Device Act (PMD Act). Collectively, these actions represent a remarkable change in how medical devices will be assessed, approved, and priced in Japan.
- [India’s Medical Device Regulations: A 2025 Update](https://www.pacificbridgemedical.com/publication/india-medical-device-regulations-2025-update/): Over the past year, India has enacted a series of significant regulatory reforms aimed at boosting the safety, quality, and transparency of its medical device sector. The new regulations and amendments, covering everything from risk-based quality control of imports to enhanced adverse event reporting and digitalized regulation procedures, reflect India’s commitment to align domestic practices with international norms while imposing greater accountability on manufacturers and importers.
- [Japan Medical Device Registration and Reimbursement: What Documents Are Needed?](https://www.pacificbridgemedical.com/publication/japan-medical-device-registration-and-reimbursement-what-documents-are-needed/): Japan is the world's third-largest medical device market. Thus, many foreign device companies are interested in exporting their devices there. However, being successful in Japan is a complex endeavor, and foreign device companies must consider several key factors before moving forward.
- [How to Increase Japan Reimbursement After Receiving Initial Japan Pricing](https://www.pacificbridgemedical.com/publication/how-to-increase-japan-reimbursement-after-receiving-initial-japan-pricing/): This article was originally published on MedTech Intelligence
- [What Do You Need to Know About Getting Your Medical Device Reimbursed in Japan?](https://www.pacificbridgemedical.com/publication/what-do-you-need-to-know-about-getting-your-medical-device-reimbursed-in-japan/): This article was originally posted on MedTech Intellligence
- [Korean Medical Device Registration: What Documents are Needed?](https://www.pacificbridgemedical.com/publication/korea-what-documents-are-needed-to-register-a-medical-device-in-korea/): Registering a medical device in Korea involves navigating a stringent regulatory process governed by the Ministry of Food and Drug Safety (MFDS). While much has been written about Korea's classification system and regulatory pathways, one critical aspect often overlooked is the documentation itself. For manufacturers aiming to bring their medical devices to market in Korea, understanding the exact documentation required is just as important as understanding the process. This article offers a detailed look at the types of documents typically required during the MFDS registration process.
- [Korea: What Documents Are Needed for medical device KGMP Certification?](https://www.pacificbridgemedical.com/publication/korea-what-documents-are-needed-for-medical-device-kgmp-certification/): Securing Korea Good Manufacturing Practice (KGMP) certification is a key regulatory milestone for medical device registration in Korea. The KGMP system, overseen by the Ministry of Food and Drug Safety (MFDS), ensures that medical devices are consistently produced and controlled according to quality standards. One of the most critical but often misunderstood parts of the KGMP application is documentation. This article outlines the required documents for KGMP certification based on a real-world checklist, split into two parts –1. Manufacturer-level documentation and 2. Product-specific documentation.
- [Medical Device GMP and QMS Frameworks in China, Japan and Korea](https://www.pacificbridgemedical.com/publication/medical-device-quality-frameworks-in-china-japan-and-korea/): In the fast-paced medical device industry, product quality is essential to guaranteeing patient safety and public confidence. Across the world, regulatory bodies have established stringent quality systems to manage and enforce standards throughout the life cycle of a device. In Asia, three major medical device markets – China, Japan, and Korea – have developed their own systems for managing medical device manufacturing quality. Whereas China and Korea have Good Manufacturing Practice (GMP) frameworks, Japan has a Quality Management System (QMS) system governed by a unique ordinance.
- [Medical Device Reimbursement in Asia: A Closer Look at China, Korea, and Japan](https://www.pacificbridgemedical.com/publication/medical-device-reimbursement-in-asia-a-closer-look-at-china-korea-and-japan/): Asia's growing healthcare needs and aging populations offer a significant opportunity for medical device manufacturers from around the world. However, market access to the biggest economies in Asia – China, Korea, and Japan – usually entails navigating complicated and rapidly changing reimbursement frameworks. Knowledge about how these countries assess, value, and pay for medical technology is critical for business success.
- [Drug Market Access in China, Korea, and Japan: Challenges and Reforms](https://www.pacificbridgemedical.com/publication/drug-market-access-in-china-korea-and-japan-challenges-and-reforms/): As global drug companies look to expand into Asia, having insight into the drug market access environment in China, Korea, and Japan is more important than ever. Although the drug registration procedure is getting less complicated in these markets, market access in terms of reimbursement and pricing is harder to attain. This article examines how changing reimbursement mechanisms, price management strategies, and access methods drive the life sciences sector in Asia’s three largest markets.
- [Drug GMP Systems in China, Japan, and Korea](https://www.pacificbridgemedical.com/publication/drug-gmp-systems-in-china-japan-and-korea/): In the international pharmaceuticals industry, Good Manufacturing Practice (GMP) compliance is a fundamental foundation for the safety, quality, and efficacy of drugs. With expanding supply chains and more complex global partnerships, knowledge of the quality compliance environments of leading Asian pharmaceutical markets is a prerequisite. China, Japan, and Korea are particularly noteworthy drug markets, not only due to the size of their markets and enhanced R&D capacities, but also because of the alignment of their GMP systems with global standards.
- [Drug Master File (DMF) Systems in Asia](https://www.pacificbridgemedical.com/publication/drug-master-file-dmf-systems-in-asia/): Quality, safety, and efficacy are of the utmost importance for drug products. A vital part in achieving this is having a Drug Master File (DMF). A DMF is a confidential submission to a health authority to provide detailed information about the manufacturing, processing, packaging, and storing of the drug substance/drug product components.
- [Japan Medical Device Reimbursement Update 2024](https://www.pacificbridgemedical.com/publication/japan-medical-device-reimbursement-update-2024/): This article was originally posted on MedTech Intelligence.
- [India Drug Regulations Update](https://www.pacificbridgemedical.com/publication/india-drug-regulations-update/): With over 1.4 billion people, India is currently the 3rd largest market in Asia after China and Japan. With geo-political tensions mounting between the US and China, more Western drug companies are thinking about manufacturing and sourcing drugs and drug components from India. Accordingly, India is implementing some new drug regulations to upgrade its drug quality.
- [Japan Orphan Drug Update](https://www.pacificbridgemedical.com/publication/japan-orphan-drug-update/): Japan has always been a good market for orphan drugs. The Japanese organizations that are involved in the process include the MHLW, PMDA and the National Institute of Biomedical Innovation (NIBIO). Orphan drugs must meet the following requirements – 1. less than 50,000 patients, 2. there is no applicable substitute drug and the drug has high efficacy, and 3. there is a development plan for the drug and the disease.
- [Malaysia Medical Device Update 2024](https://www.pacificbridgemedical.com/publication/malaysia-medical-device-update-2024/): Malaysia, with close to 34 million people, is a good market for Western medical device exporters. The Malay Medical Device Authority (MDA), which falls under the Ministry of Health (MoH), registers devices.
- [Korea Drug Reimbursement Update 2024](https://www.pacificbridgemedical.com/publication/korea-drug-reimbursement-update-2024/): Korea Drug Reimbursement Update 2024
- [India’s Medical Device Regulatory Update 2024](https://www.pacificbridgemedical.com/publication/indias-medical-device-regulatory-update-2024/): In recent months, India has made significant strides in reshaping the regulatory framework of its medical device industry. These initiatives are designed to improve the Indian medical device market and contain healthcare costs.
- [Korea Medical Device Registration: Digital Healthcare Update 2024](https://www.pacificbridgemedical.com/publication/korea-medical-device-registration-digital-healthcare-update-2024/): Recently, South Korea has been making significant progress in transforming its approach to healthcare, specifically through the integration of AI and digital technologies in medical devices. The Ministry of Food and Drug Safety (MFDS) is at the forefront of these efforts and paves the way for a potentially transformative period for the Korean healthcare system.
- [Japan Medical Device Registration: Digital Healthcare Update 2024](https://www.pacificbridgemedical.com/publication/japan-medical-device-registration-digital-healthcare-update-2024/): Japan Advances Regulatory and Reimbursement Frameworks for SaMD Products
- [Hong Kong Medical Device Regulatory Update 2024](https://www.pacificbridgemedical.com/publication/hong-kong-medical-device-regulatory-update-2024/): The Hong Kong government has been updating its regulatory framework for medical devices, with a number of key changes that seek to enhance safety, efficacy, and compliance.
- [Japan Drug Registration: New GMP Requirements](https://www.pacificbridgemedical.com/publication/japan-drug-registration-new-gmp-requirements/): Registering drugs in Japan can be a very tedious process, but the benefits can also be quite large. Japan has a large aging population that heavily relies on new and innovative drugs. Besides a dossier product submission, drug companies need to obtain GMP approval per MHLW's Ordinance 179 (2004) for drug approval. A GMP audit is usually needed for a new drug approval, a partial change submission and after a drug is appoved every 5 years. All documents submitted for your GMP must be in Japanese and include many documents covering – 1. Quality sytems, 2. Facility/Equipment systems, 3. Storage systems for finished Products, intermediates and raw materials, 4, Analytical testing systems, etc.
- [2024 Thailand Pharmaceutical Regulatory Update](https://www.pacificbridgemedical.com/publication/2024-thailand-pharmaceutical-regulatory-update/): In recent years, Thailand, a Southeast Asian country with 70 million people, has been consistent in its commitment to improving the regulation of pharmaceuticals, ensuring the safety, efficacy, and accessibility of drugs in the market. Two significant developments include the initiation of the initial review period for drug market authorizations (MAs) and the introduction of new regulations governing drugs imported for clinical trials.
- [2024 Singapore Drug Registration Update](https://www.pacificbridgemedical.com/publication/2024-singapore-drug-registration-update/): Singapore is an important drug market in Asia. Not because of the market size which is rather small, but because it is the second best overall healthcare market in Asia, after Japan. Getting drug approval and being successful in the Singapore market often leads to success in other Asian markets – especially in ASEAN.
- [2024 Vietnam Medical Device Regulations](https://www.pacificbridgemedical.com/publication/2024-vietnam-medical-device-regulations/): In an effort to streamline and modernize its medical device regulations, Vietnam has recently implemented significant updates, aiming to enhance efficiency while ensuring the safety and efficacy of medical devices. Two key developments, Circular 10/2023/TT-BY and Decree #07 mark, substantial shifts in Vietnam's medical device regulatory landscape.
- [Singapore Medical Device Regulations and Cybersecurity Update 2024](https://www.pacificbridgemedical.com/publication/singapore-medical-device-regulations-and-cybersecurity-update-2024/): Singapore has the second best healthcare system in Asia after Japan. Thus, as a healthcare leader, Singapore constantly updates its regulations to adapt to new technologies. Singapore is working towards enhancing the cybersecurity and regulatory compliance of medical devices. With the increasing integration of technology in healthcare, the city-state's health authorities are implementing trials and updating guidelines to safeguard against cybersecurity risks and ensure rigorous clinical evaluation of medical devices.
- [China Drug Clinical Trial Update 2024](https://www.pacificbridgemedical.com/publication/china-drug-clinical-trial-update-2024/): Chinese patients want more drugs to treat their diseases. With over 1.4 billion Chinese people and with more than 350 million people in China's middle class, there is enough disposable money to pay for them. To get more drugs approved in China, more clinical trials will need to be done there.
- [Japan Drug Registration Continues to Improve](https://www.pacificbridgemedical.com/publication/japan-drug-registration-continues-to-improve/): The Japanese government is very aware that many drugs approved in the West are not approved in Japan. The issue of drug lag in Japan is significant as it deprives Japanese citizens of access to the same cutting-edge pharmaceuticals that benefit people elsewhere in the world. Thus, the Japanese government has started a number of initiatives to make things better and reduce the lag.
- [Japan Medical Device Registration Being Expedited](https://www.pacificbridgemedical.com/publication/japan-medical-device-registration-being-expedited/): Japan's medical device market is the third largest medical device market in the world, after the US and China. While it is a highly competitive market, unique products with good value propositions can be very successful there.
- [2024 China Drug Market Access Update](https://www.pacificbridgemedical.com/publication/2024-china-drug-pricing-update/): Over the last 5 years, getting drugs registered in China and available for sale has become more efficient, easier, and a lot quicker. However, China drug pricing is still a major concern. Two drug price reduction schemes are outlined below.  First, one of the most detrimental systems for China drug pricing is Volume Based Procurement (VBP). Over the last year or so, China has implemented the 8th and 9th round of VBP. VBP normally starts only when sales of a specific drug reach about $75 million per year. Before that sales volume is reached, at least for now, VBP will not affect drug prices. The goal of VBP is to reduce drug prices in exchange for a large sale opportunity. These last 2 VBP programs reduced certain drug prices by about 50% for close to 100 drugs.
- [Japan Drug Market Access: Strategic Moves to Improve it and Foster Innovation](https://www.pacificbridgemedical.com/publication/japans-strategic-moves-to-revamp-drug-pricing-and-foster-innovation/): Hoping to revamp its pharmaceutical landscape, Japan is trying to balance the scales of drug pricing, innovation, and access to cutting-edge medications. These efforts, led by the Ministry of Health, Labour and Welfare (MHLW) and the Drug Pricing Organization (DPO), reflect a multifaceted approach to address the challenges of drug lag, supply shortages, and the need for innovation within the pharmaceutical sector.
- [Japan IVD Reimbursement Update](https://www.pacificbridgemedical.com/publication/japan-ivd-reimbursement-update/): IVDs, drugs and medical devices have different reimbursement pathways in Japan. Normally, for all these paths, a reimbursement application is submitted after product approval. Reimbursement is then normally determined within 3-6 months. However,  the MHLW is allowing some companies to have a pre-reimbursement meeting.
- [Japan Drug Clinical Trial Update](https://www.pacificbridgemedical.com/publication/japan-drug-clinical-trial-update-2/): Successful clinical trials in Japan are key to drug registration. There have been several regulations and guidelines for Japanese clinical trials over the years. Japan's clinical trial regulations are regulated by the MHLW and outlined in the PMD Act as well as in several other regulations. In 1997, the MHLW issued the – Ordinance on Standards of Implementation of Clinical Studies on Drugs. The PMDA, under the MHLW, is responsible for Japanese GCP standards. Two other important clinical trial regulations include – 1. The Clinical Trials Act for Interventional Research in 2018 and 2. the Ethical Guidelines for Medical and Biological Research Involving Human Subjects in 2021.
- [Indian Clinical Trials and First in Human (FIH) Update](https://www.pacificbridgemedical.com/publication/indian-clinical-trials-and-first-in-human-fih-update/): With political tensions in China growing and more companies trying to reduce costs, more and more Western drug and device companies will look to do clinical studies in India. While India accounts for close to 18% of the world's population, its share of the global clinical trials market is less than 2%. Experts believe that the number of Indian clinical trials will grow close to 10% over the next decade.
- [Companion Diagnostics Regulations are Evolving in Asia](https://www.pacificbridgemedical.com/publication/companion-diagnostics-regulations-are-evolving-in-asia/): This article was originally published on MedTech Intelligence.
- [Hong Kong’s Medical Device Control Office and Department of Health](https://www.pacificbridgemedical.com/publication/hong-kongs-medical-device-control-office-and-department-of-health/): 1. Overview
- [Philippines Food and Drug Administration (Philippines FDA)](https://www.pacificbridgemedical.com/publication/philippines-food-and-drug-administration-philippines-fda/): 1. Overview
- [India’s Central Drugs Standard Control Organization (CDSCO)](https://www.pacificbridgemedical.com/publication/indias-central-drugs-standard-control-organization-cdsco/): 1. Overview
- [Indonesia’s National Agency of Drug and Food Control (BPOM)](https://www.pacificbridgemedical.com/publication/indonesias-national-agency-of-drug-and-food-control-bpom/): 1. Overview
- [Thai Food and Drug Administration (Thai FDA)](https://www.pacificbridgemedical.com/publication/thai-food-and-drug-administration-thai-fda/): 1. Overview
- [Korea Drug GMP Requirements and Audits](https://www.pacificbridgemedical.com/publication/korea-drug-gmp-requirements-and-audits/): Korea is currently the 10th largest drug market in the world. While in the past, Korean drug companies mostly made generic drugs, today, they are making new chemical and biological products. Korean drug companies and foreign drug companies looking to sell their finished or API products in Korea must meet Korean GMP standards.
- [Vietnam’s Ministry of Health](https://www.pacificbridgemedical.com/publication/vietnams-ministry-of-health/): 1. Overview
- [China’s Second List of Rare Diseases](https://www.pacificbridgemedical.com/publication/chinas-second-list-of-rare-diseases/): On September 18, China's National Health Commission, released their second list of rare diseases. This list includes 86 rare diseases including Giant Cell arteritis, Gorlin Syndrome, Fragile X Syndrome, etc.
- [China Drug GMP Update](https://www.pacificbridgemedical.com/publication/china-drug-gmp-update/): Despite the ongoing political frictions between the US and China, many Western pharmaceutical companies still rely heavily on Chinese drug companies for the production of APIs, excipients, and finished drug products. To source drug components and drugs from China, meeting Western GMP standards is critical. While Chinese GMP has come a long way, there are still differences between Chinese GMP and US GMP standards.
- [Korea’s Ministry of Food and Drug Safety (MFDS)](https://www.pacificbridgemedical.com/publication/koreas-ministry-of-food-and-drug-safety-mfds/): The Ministry of Food and Drug Safety (MFDS), formerly recognized as the Korean FDA, is the regulatory authority responsible for overseeing safety matters related to a wide range of products, including drugs, medical devices, food, functional food, and quasi-drugs. The MFDS regularly formulates new regulations, and it also aligns itself with many international standards. Notably, the MFDS staff actively engages in international harmonization efforts by participating in expert groups, contributing to the development of ICH guidelines, supporting the APEC Harmonization Center, and engaging in discussions on various topics and initiatives with members of the DIA.
- [Korea Drug Master File (DMF) Registration](https://www.pacificbridgemedical.com/publication/7412/): To learn more about how we can help you obtain a DMF in Korea, please contact us.
- [Malaysia’s Medical Device Authority and National Pharmaceutical Regulatory Agency](https://www.pacificbridgemedical.com/publication/malaysias-medical-device-authority-and-national-pharmaceutical-regulatory-agency/): Overview and History
- [China Drug Registration](https://www.pacificbridgemedical.com/publication/china-drug-registration/): China is the second-largest drug market in the world. Registering drugs in China is more accessible today than ever. That does not mean it is easy or straightforward. Before attempting to do so, international drug companies should research the prevalence of the disease their specific drug treats in China to make sure it will be welcomed by the Chinese government and people. Does your drug offer real advantages over alternative existing treatments in China?
- [Singapore’s Health Science Authority (HSA)](https://www.pacificbridgemedical.com/publication/singapores-health-science-authority/): The Health Sciences Authority (HSA) is a government organization in Singapore that falls under the Ministry of Health. The HSA performs three primary roles: it acts as the national regulatory approval authority for all health products, manages the national blood supply including the blood bank and transfusion medicine standards, and offers expertise in areas like forensic medicine, forensic science, and analytical chemistry testing.
- [China GMP Requirements and Audits for Drugs](https://www.pacificbridgemedical.com/publication/china-good-manufacturing-practices-gmp-for-drugs/): Contact us today for a free consultation with a China regulatory affairs consultant to discuss your specific needs.
- [China GMP Requirements and Audits for Medical Devices](https://www.pacificbridgemedical.com/publication/china-good-manufacturing-practices-gmp-for-medical-devices/): Contact us today for a free consultation with a China regulatory affairs consultant to discuss your specific needs.
- [Japan Drug GMP Requirements and Audits](https://www.pacificbridgemedical.com/publication/japan-gmp-requirements-and-audits/): Contact us today for a free consultation with a Japan regulatory affairs consultant to discuss your specific needs.
- [Taiwan Food and Drug Administration  (TFDA)](https://www.pacificbridgemedical.com/publication/taiwan-food-and-drug-administration-tfda/): Contact us today for a free consultation with a Taiwan regulatory affairs consultant to discuss your specific needs.
- [Japan’s Pharmaceuticals and Medical Devices Agency](https://www.pacificbridgemedical.com/publication/japans-pharmaceuticals-and-medical-devices-agency/): Contact us today for a free consultation with a Japan regulatory affairs consultant to discuss your specific needs.
- [China’s National Medical Products Administration (NMPA)](https://www.pacificbridgemedical.com/publication/chinas-national-medical-products-administration-nmpa/): Contact us today for a free consultation with a China regulatory affairs consultant to discuss your specific needs.
- [Singapore Pharmaceutical Registration](https://www.pacificbridgemedical.com/publication/singapore-pharmaceutical-registration/): To learn more about how PBM can help you register your drug products in Singapore, please contact us.
- [Japan Drug Master Files (DMF) for API, Excipient, and Drug Packaging Material Manufacturers](https://www.pacificbridgemedical.com/publication/japan-drug-master-files-for-api-excipient-and-drug-packaging-material-manufacturers/): Please feel free to contact us to obtain more information about Japan DMF.
- [Japan GMP for Foreign Drug Manufacturers](https://www.pacificbridgemedical.com/publication/japan-gmp-for-foreign-drug-manufacturers/): Contact us today for a free consultation with a Japan regulatory affairs consultant to discuss your specific needs.
- [China Medical Device Market Access](https://www.pacificbridgemedical.com/publication/china-medical-device-market-access/): Contact us today for a free consultation with a China regulatory affairs consultant to discuss your specific needs.
- [China Pharmaceutical Market Access](https://www.pacificbridgemedical.com/publication/china-drug-market-access/): Contact us today for a free consultation with a China reimbursement consultant to discuss your specific needs.
- [China DMF](https://www.pacificbridgemedical.com/publication/china-dmf/): For help registering your DMF in China, please contact us to discuss your needs in more detail.
- [CDx Registration in Korea, Taiwan, Singapore, Australia, and the Other Asian Markets](https://www.pacificbridgemedical.com/publication/cdx-registration-in-korea-taiwan-singapore-australia-and-the-other-asian-markets/): PBM can help you develop the best regulatory and reimbursement strategies in Asia. Please contact us to learn more.
- [Japan CDx Registration](https://www.pacificbridgemedical.com/publication/japan-cdx-registration-resource-center/): Pacific Bridge Medical has worked with a number of Western CDx companies to address the above issues and register CDx products in Japan. Please contact us to learn more.
- [China CDx Registration](https://www.pacificbridgemedical.com/publication/china-cdx-registration/): Please contact us to learn about how we can help you register your CDx product in China.
- [China Drug Master Files for API, Excipient, and Drug Packaging Material Manufacturers](https://www.pacificbridgemedical.com/publication/registering-excipient-components-china/): Contact us to learn how we can help you with DMF registration in China.
- [Is China Still A Good Opportunity For Device Manufacturers?](https://www.pacificbridgemedical.com/publication/is-china-still-a-good-opportunity-for-device-manufacturers/): Contact us to learn about how we can help you in the Chinese MedTech market. 
- [Growth of Medical 3-D Printing in Asia](https://www.pacificbridgemedical.com/publication/growth-of-medical-3-d-printing-in-asia/): Contact us today for a free consultation with an Asia regulatory affairs consultant to discuss your specific needs.
- [China: A Huge Medical Device Market with Prospects and Challenges](https://www.pacificbridgemedical.com/publication/china-a-huge-medical-device-market-with-prospects-and-challenges/): Contact us today for a free consultation with a China regulatory affairs consultant to discuss your specific needs.
- [Strategies You Cannot Overlook to Achieve Success in Japan’s Medical Device Market](https://www.pacificbridgemedical.com/publication/strategies-you-cannot-overlook-to-achieve-success-in-japans-medical-device-market/): Contact us today for a free consultation with a Japan regulatory affairs consultant to discuss your specific needs.
- [Doing a Medical Device Master File in Japan](https://www.pacificbridgemedical.com/publication/doing-a-medical-device-master-file-in-japan/): Contact us today to learn more about how Pacific Bridge Medical can help you file a device MF in Japan.
- [Doing a Medical Device Master File in China](https://www.pacificbridgemedical.com/publication/doing-a-medical-device-master-file-in-china/): With an experienced team of on-the-ground Chinese regulatory experts, PBM can be your local representative to submit your MF. Contact us if you want to learn more about doing a MF in China.
- [How Does The Third-Party Japanese DMAH System Work?](https://www.pacificbridgemedical.com/publication/how-does-the-third-party-japanese-dmah-system-work/): If your company wants to enter the Japanese market and is interested in our DMAH service, contact us today for a free consultation.
- [Registering Excipients in Japan via a Drug Master File (DMF)](https://www.pacificbridgemedical.com/publication/registering-excipients-in-japan/): Contact us today for a free consultation with our Japan DMF expert. 
- [Medical Devices Vulnerable as COVID-19 Deepens Cybersecurity Threats in Asia](https://www.pacificbridgemedical.com/publication/medical-devices-vulnerable-as-covid-19-deepens-cybersecurity-threats-in-asia/): This article was originally published on MedTech Intelligence.
- [With Diagnostics In High Demand During Pandemic, IVD Industry Expands Its Footprint In Asia](https://www.pacificbridgemedical.com/publication/with-diagnostics-in-high-demand-during-pandemic-ivd-industry-expands-its-footprint-in-asia/): This article was originally published on Medtech Intelligence
- [Asia 2020 Device Regulatory Update](https://www.pacificbridgemedical.com/publication/asia-2020-device-regulatory-update/): This article was originally published on MedTech Intelligence 
- [Japan Pharmaceutical Market Update 2020](https://www.pacificbridgemedical.com/publication/japan-drug-market-update-2020/): Background information

## Infographics
- [Malaysia Product Classification Flowchart Infographic](https://www.pacificbridgemedical.com/infographic/malaysia-product-classification-flowchart/): Malaysia Medical Device Authority product classification steps (click to download full size image).
- [Drug Pricing in China Infographic](https://www.pacificbridgemedical.com/infographic/drug-pricing-in-china-infographic/): Drug pricing in China is based on a combination of free-market and state-control mechanisms. (Click the image to download in full size.)
- [Timeline for a Drug to be Prescribed in China Infographic](https://www.pacificbridgemedical.com/infographic/timeline-for-a-drug-to-be-prescribed-in-china-infographic/): It takes up to 15 months for a drug to be prescribed after receiving the CFDA's approval. (Click the image to download in full size.)
- [Registration Timeline for Imported New Drugs in China Infographic](https://www.pacificbridgemedical.com/infographic/registration-timeline-for-imported-new-drugs-in-china-infographic/): For an imported new drug, it takes approximately 36-42 months from Investigational New Drug (IND) submission to New Drug Application (NDA) approval. (Click the image to download in full size.)
- [Classes of Drugs in China Infographic](https://www.pacificbridgemedical.com/infographic/classes-of-drugs-in-china-infographic/): This chart shows the classification system for pharmaceuticals in China. (Click the image to download in full size.)
- [The Business of Rx Commercialization in China Infographic](https://www.pacificbridgemedical.com/infographic/the-business-of-rx-commercialization-in-china-infographic/): This chart illustrates the Rx commercialization process in China. (Click the image to download in full size.)
- [State Agencies Governing the Pharmaceutical Industry in China Infographic](https://www.pacificbridgemedical.com/infographic/state-agencies-governing-the-pharmaceutical-industry-in-china-infographic/): Multiple government agencies are responsible for policy-making and for monitoring the pharmaceutical industry in China. (Click the image to download in full size.)
- [Medical Device Manufacturing Moving to Asia Infographic](https://www.pacificbridgemedical.com/infographic/medical-device-manufacturing-moving-to-asia-infographic/): Many Western medical device manufacturers are closing facilities located in the West (especially in the EU) and opening new facilities in Asia to reduce costs and get closer to growing markets. (Click the image to download in full size.)
- [Size and Growth of Global Medical Device Markets Infographic](https://www.pacificbridgemedical.com/infographic/size-and-growth-of-global-medical-device-markets-infographic/): The medical device markets in the U.S. and the European Union are growing slowly, and Western device companies are facing increasing cost pressures. However, the markets in developing countries are growing quickly, with some countries achieving high double digit growth. (Click the image to download in full size.)
- [Medical Device Submission Process in Singapore Infographic](https://www.pacificbridgemedical.com/infographic/medical-device-submission-process-in-singapore-infographic/): This chart shows the process for a full evaluation of a Class B, C, or D medical device in Singapore. (Click the image to download in full size.)
- [Classification of General Medical Devices in Singapore](https://www.pacificbridgemedical.com/infographic/classification-of-general-medical-devices-in-singapore/): Medical devices must be registered with Singapore's Health Sciences Authority (HSA) before they can be supplied in Singapore. (Click the image to download in full size.)
- [Major Health Authorities in Hong Kong Infographic](https://www.pacificbridgemedical.com/infographic/major-health-authorities-in-hong-kong-infographic/): Hong Kong's major health authorities oversee the regulation of medical devices and pharmaceuticals. (Click the image to download in full size.)
- [Medical Device Classification in India Infographic](https://www.pacificbridgemedical.com/infographic/medical-device-classification-in-india-infographic/): The Central Drug Standards Control Organization (CDSCO) released a draft document, Schedule M-III, which contains proposed official definitions for various types of medical devices in India. A four level medical device risk classification scheme was outlined in the proposed draft. (Click the image to download in full size.)
- [India’s Central Drug Standards Control Organization (CDSCO) Infographic](https://www.pacificbridgemedical.com/infographic/indias-central-drug-standards-control-organization-cdsco-infographic/): The Drug Controller General of India (DCGI) is the key official in the Central Drug Standards Control Organization (CDSCO). This chart shows the organizational structure of the CDSCO Medical Device and Diagnostic Division. (Click the image to download in full size.)
- [India’s Medical Device Market Infographic](https://www.pacificbridgemedical.com/infographic/indias-medical-device-market-infographic/): India's medical device market size, per capita spending, imports, annual growth rate, and projected growth rate up to 2015. (Click the image to download in full size.)
- [China Medical Device Registration Renewal Infographic](https://www.pacificbridgemedical.com/infographic/china-medical-device-registration-renewal-infographic/): Product registrations are valid for 4 years. Renewal applications must be submitted 6 months before the import license expires, and the process should be started 1 year in advance. The CFDA recently announced a simplified renewal process, shown in the chart above. (Click the image to download in full size.)
- [China Class II Product Registration Process & Timeline Infographic](https://www.pacificbridgemedical.com/infographic/china-class-ii-product-registration-process-timeline-infographic/): The approximate total timeframe for registering a new Class II medical device that does not require local clinical trials is 14-16 months. (Click the image to download in full size.)
- [Medical Device Classification in China Infographic](https://www.pacificbridgemedical.com/infographic/medical-device-classification-in-china-infographic/): Device classification is the basis for determining regulatory requirements. (Click the image to download in full size.)
- [China Medical Device Registration Agents Infographic](https://www.pacificbridgemedical.com/infographic/china-medical-device-registration-agents-infographic/): Three agents are required for medical device registrations in China: a legal agent, an after sales agent, and a registration agent. (Click the image to download in full size.)
- [CFDA Department of Medical Device Supervision Infographic](https://www.pacificbridgemedical.com/infographic/cfda-department-of-medical-device-supervision-infographic/): The CFDA's Department of Medical Device Supervision is responsible for the regulation of medical devices. This chart shows the divisions within the department and its affiliations. (Click the image to download in full size.)
- [Key Regulatory Bodies for Medical Device Registration in China Infographic](https://www.pacificbridgemedical.com/infographic/key-regulatory-bodies-for-medical-device-registration-in-china-infographic/): Breakdown of the Chinese regulatory authorities for medical devices and their responsibilities. (Click the image to download in full size.)

## News Briefs
- [China Clarifies Requirements for Medical Device Classification Changes](https://www.pacificbridgemedical.com/news-brief/china-clarifies-requirements-for-medical-device-classification-changes/): China’s National Medical Products Administration (NMPA) has issued a new announcement that refines how medical devices and in vitro diagnostic (IVD) reagents are classified and managed when classification changes occur. Announcement No. 52 establishes new guidance for handling classification adjustments. It is intended to address a long-standing regulatory challenge: determining what actions manufacturers must take when a product’s classification changes.
- [Japan Warns that Proposed US Drug Pricing Policy Threatens Drug Market Access](https://www.pacificbridgemedical.com/news-brief/japan-warns-that-proposed-us-drug-pricing-policy-threatens-drug-market-access/): Japan's government has sounded the alarm over the United States' most-favored-nation (MFN) drug pricing policy, warning it risks worsening the country's longstanding struggles with its drug lag problem. Officials fear that as pharmaceutical companies grow more cautious about entering the Japanese market, where prices could potentially be used as a reference point for US price negotiations, clinical trial activity may decline, and Japanese patient access to new therapies could suffer.
- [Hong Kong Updates Essential Document Requirements for Medical Device Listings](https://www.pacificbridgemedical.com/news-brief/hong-kong-updates-essential-document-requirements-for-medical-device-listings/): Hong Kong's Medical Device Division has updated its document checklist for medical device listing applications under the Medical Device Administrative Control System (MDACS). The MDACS framework requires all medical devices supplied in Hong Kong to demonstrate compliance with internationally adopted safety, quality, and performance standards.
- [Quick Japan Regulatory Updates (July 2026)](https://www.pacificbridgemedical.com/news-brief/quick-japan-regulatory-updates-july-2026/): Japan's health ministry is urging pharmaceutical companies to choose institutional review boards (IRBs) carefully, as the country prepares to overhaul its Good Clinical Practice rules. The forthcoming revision, due to be promulgated this summer, will allow trial sponsors to directly select a single IRB to cover multiple clinical trial sites. This replaces the current system where each institution runs its own IRB. The ministry acknowledged the change raises integrity concerns, particularly around sponsors cherry-picking favorable IRBs or conflicts of interest skewing reviews. To prevent this, companies will be required to document their IRB selection rationale, and IRBs themselves will need to publicly disclose member rosters and meeting records.
- [Thailand Tightens Medical Software Rules with UDI Requirement](https://www.pacificbridgemedical.com/news-brief/thailand-tightens-medical-software-rules-with-udi-requirement/): Thailand is raising the bar for medical device software. A revised labeling regulation taking effect June 20, 2026, brings stricter documentation standards and, notably, the country's first-ever unique device identification (UDI) requirement for software as a medical device (SaMD). The rule covers moderate and high-risk SaMD and puts Thailand in line with the ASEAN Medical Device Directive and the EU MDR.
- [Hong Kong to Streamline Approval of Innovative Drugs and Medical Devices](https://www.pacificbridgemedical.com/news-brief/hong-kong-to-streamline-approval-of-innovative-drugs-and-medical-devices/): Hong Kong's Hospital Authority has launched a new office dedicated to fast-tracking the introduction of innovative drugs and medical devices into the public health system. The Office for the Introduction of Innovative Drugs and Medical Devices began operations on June 8, with a mandate to streamline how cutting-edge treatments reach patients in public hospitals.
- [China Updates Good Clinical Practice Requirements for Drug Clinical Trials](https://www.pacificbridgemedical.com/news-brief/china-updates-good-clinical-practice-requirements-for-drug-clinical-trials/): China has revised its Good Clinical Practice (GCP) regulations for drug clinical trials, introducing new requirements focused on quality management, participant protection, investigator accountability, and the use of innovative technologies.
- [Quick Asia Regulatory Updates (July 2026)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-july-2026/): Korea's Ministry of Food and Drug Safety (MFDS) revised its digital medical device labeling guidelines on June 10. The update follows industry difficulties after the Digital Medical Products Act took effect in January 2025. Key changes include a grace period permitting previous labeling through January 23, 2027, and flexible guidance on recording version numbers and manufacturing dates for software products. Software disclosure requirements were also clarified, as key information must be disclosed via websites, user interfaces, or subscriber emails. Additionally, AI-enabled devices must now disclose learning methods, training data, and predicted performance ranges.
- [China Revises Drug Administration Law Implementing Provisions](https://www.pacificbridgemedical.com/news-brief/china-revises-drug-administration-law-implementing-provisions/): China's revised Implementing Provisions of the Drug Administration Law took effect on May 15, 2026. This marks the first major update to the regulations in more than two decades.
- [Indonesia Updates Rules for Drug Promotion and Advertising](https://www.pacificbridgemedical.com/news-brief/indonesia-updates-rules-for-drug-promotion-and-advertising/): Indonesia’s Food and Drug Authority (BPOM) issued Regulation No. 7 on Drug Promotion and Advertising on April 29, 2026. The new regulation outlines more detailed requirements for pharmaceutical promotion activities. Companies have until April 29, 2027, to make sure their existing advertisements comply with the new regulations.
- [Japan: Registering AI-based Medical Devices](https://www.pacificbridgemedical.com/news-brief/japan-registering-ai-based-medical-devices/): Japan continues to lag behind the United States in the registration of AI-based Software as a Medical Device (AI-based SaMD), particularly for products that continuously update after commercialization. Under Japan’s current regulatory framework, the Pharmaceuticals and Medical Devices Agency (PMDA) does not yet accommodate AI software that continuously changes its performance after approval.
- [China’s NMPA to Implement Revised Medical Device QMS Requirements](https://www.pacificbridgemedical.com/news-brief/chinas-nmpa-to-implement-revised-medical-device-qms-requirements/): China’s National Medical Products Administration (NMPA) has released updated Good Manufacturing Practice (GMP) rules. The new rules introduce a revised quality management system (QMS) framework and will take effect on November 1, 2026. The regulation applies to both domestic and foreign manufacturers supplying devices in China.
- [Japan Clarifies Revised Conditional Drug Approval Framework](https://www.pacificbridgemedical.com/news-brief/japan-clarifies-revised-conditional-drug-approval-framework/): Japan’s Ministry of Health, Labour and Welfare (MHLW) has issued a Q&A document clarifying how the revised conditional approval system under the amended Pharmaceuticals and Medical Devices (PMD) Act will be implemented as of May 1, 2026.
- [Quick Asia Regulatory Updates (June 2026)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-june-2026/): Singapore’s Health Sciences Authority (HSA) and China’s National Medical Products Administration (NMPA) have renewed their regulatory cooperation agreement for health products, signing an updated Memorandum of Understanding (MOU) in Beijing on May 11, 2026. The revised agreement expands cooperation into newer areas, including cell, tissue, and gene therapy products. Both agencies also said they plan to work more closely on regulatory pathways, pilot initiatives, staff exchanges, and the sharing of regulatory information and experience. The renewed partnership builds on an earlier agreement signed in 2021 and is expected to support more efficient review and market access processes for innovative therapies and medical technologies in both countries. Officials from both agencies said the collaboration is intended to strengthen regulatory capabilities while continuing to maintain product safety, quality, and efficacy standards.
- [China Proposes New Drug Reimbursement Rules and Pediatric Medicine Reforms](https://www.pacificbridgemedical.com/news-brief/china-proposes-new-drug-reimbursement-rules-and-pediatric-medicine-reforms/): China’s National Healthcare Security Administration (NHSA) has released the draft 2026 work plan for adjustments to the National Reimbursement Drug List (NRDL) and the Commercial Health Insurance Innovative Drug List (CHIDL), officially starting this year’s reimbursement review process. Several policy changes were included in the draft plan.  For example, previously, companies could only apply for NRDL consideration if their drug received approval by June 30 of that year. If approval came after that date, the company would generally need to wait until the following year’s NRDL cycle. Under the proposed rules, that cutoff would instead move to the date when the NHSA officially publishes its final work plan, which is expected later in the year. This change will give pharmaceutical companies more flexibility when preparing submissions. For the first time, drugs that have completed technical review but have not yet received formal marketing approval may pre-apply for NRDL consideration.
- [Japan Announces Mixed Drug Price Revisions for FY2026](https://www.pacificbridgemedical.com/news-brief/japan-announces-mixed-drug-price-revisions-for-fy2026/): Japan’s FY2026 drug price revision, which took effect in April 2026, brings another round of pricing cuts under the country’s National Health Insurance (NHI) system. Overall, drug prices were reduced by about 4%, with authorities continuing efforts to control healthcare spending as the use of high-cost therapies increases.
- [Korea Accelerates Review Pathways for Innovative Drugs and Medical Devices](https://www.pacificbridgemedical.com/news-brief/korea-accelerates-review-pathways-for-innovative-drugs-and-medical-devices/): Korea’s Ministry of Food and Drug Safety (MFDS) is expanding regulatory support for developers of cell and gene therapies by broadening its pre-consultation program to include products in the nonclinical stage. Previously, the service mainly focused on companies preparing for clinical trials. The National Institute of Food and Drug Safety Evaluation (NIFDS) has also recruited a new team of regulatory consultants with expertise in CMC, clinical development, and regulatory review in the cell and gene therapy area. The agency said the consultants will provide product-specific guidance throughout development, including support for IND filings and marketing approval applications. Officials expect the expanded program to improve access to tailored regulatory advice for companies developing advanced biopharmaceuticals, including cell and gene therapies and tissue-engineered products.
- [China Cracks Down on Medical Insurance Fraud](https://www.pacificbridgemedical.com/news-brief/china-cracks-down-on-medical-insurance-fraud/): China is tightening oversight of its medical insurance system in 2026 through new rules and a nationwide anti-fraud campaign. The measures, introduced by the National Healthcare Security Administration (NHSA), took effect on April 1. This will increase scrutiny in every aspect of the healthcare industry, but some of the changes will predominantly affect hospitals and pharmacies that participate in the public insurance system.
- [Japan’s PMDA Launches New Orphan Drug Designation Resource Page](https://www.pacificbridgemedical.com/news-brief/japans-pmda-launches-new-orphan-drug-designation-resource-page/): In May 2026, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) created a dedicated English-language webpage on orphan drug designation. The page is designed to be a central resource for sponsors seeking information on Japan’s orphan drug program, including designation requirements, incentives available and the overall application process.
- [India Strengthens Quality Surveillance for Medical Devices and Pharmaceuticals](https://www.pacificbridgemedical.com/news-brief/india-strengthens-quality-surveillance-for-medical-devices-and-pharmaceuticals/): India is taking efforts to strengthen the safety oversight of healthcare products. One key initiative is the establishment of a national registry for implantable medical devices, such as cardiac stents and orthopedic implants. The registry will allow regulators and healthcare providers to track implantable medical devices throughout their lifecycle and link them to patient outcomes. This is expected to improve traceability, support product recalls, and help flag potential safety concerns sooner.
- [Japan Introduces New Mechanisms to Increase Recruitment for Clinical Trials](https://www.pacificbridgemedical.com/news-brief/japan-introduces-new-mechanisms-to-increase-recruitment-for-clinical-trials/): Japan’s Ministry of Health, Labour and Welfare (MHLW) has issued a notification confirming that information used to recruit participants for clinical trials will now not be classified as “advertising,” as long as it is limited to necessary recruitment content. In the past, this was not allowed in Japan. Effective on March 30, this policy permits inclusion of investigational product names as long as communications remain factual and focused on recruitment only.
- [Korea Launches Funding Program to Accelerate AI Medical Device Commercialization](https://www.pacificbridgemedical.com/news-brief/korea-launches-funding-program-to-accelerate-ai-medical-device-commercialization/): Korea’s Ministry of Health and Welfare (MOHW) announced a new funding program on April 10, 2026. The initiative is designed to speed up the commercial rollout of AI-based medical devices. It focuses on the post-approval phase, where many products encounter challenges, as some devices are not adopted by hospitals even after receiving regulatory approval. Support for AI medical devices will cover clinical validation, real-world evidence generation, health economic studies, and reimbursement planning. The program is part of the broader AX-Sprint initiative, a 754 billion won (over 510 million USD) effort to scale AI applications across the Korean economy.
- [China’s NMPA Introduces New Post-market Surveillance Requirements for Medical Devices](https://www.pacificbridgemedical.com/news-brief/chinas-nmpa-introduces-new-post-market-surveillance-requirements-for-medical-devices/): China’s National Medical Products Administration (NMPA) has released six new guidelines to strengthen post-market surveillance and vigilance for medical devices. The updates set clearer expectations for quality management and require manufacturers and local agents (Marketing Authorization Holders) to have systems in place to monitor, assess, and respond to adverse events. They also include inspection guidance that gives companies a better idea of what regulators will focus on, especially when it comes to maintaining clear and traceable records throughout the product’s lifecycle.
- [Quick Asia Regulatory Updates (May 2026)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-may-2026/): On April 7, 2026, Beijing health authorities released a policy package with 32 measures to support innovative drugs and medical devices across the full lifecycle, from R&D to clinical use. Key actions include improving clinical trial infrastructure, accelerating regulatory review, and expanding manufacturing and reimbursement. The policy also promotes faster hospital adoption and introduces a dual-track reimbursement model, which combines public and commercial insurance to improve patient access. A strong emphasis is placed on AI integration, including better use of healthcare data and digital tools. This policy package aims to strengthen Beijing’s position as a life sciences hub by improving regulatory efficiency, especially for innovative products.
- [Japan and Singapore Strengthen Regulatory Cooperation to Streamline Access to Drugs](https://www.pacificbridgemedical.com/news-brief/japan-and-singapore-strengthen-regulatory-cooperation-to-streamline-access-to-drugs/): Singapore’s Health Sciences Authority (HSA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) signed a Memorandum of Cooperation in Tokyo on April 20, 2026. The agreement aims to bring the two regulators closer together in how they oversee drug products. At its core, the goal is to help patients get timely access to safe and effective medicines.
- [Hong Kong Begins New Drug Review Pathway](https://www.pacificbridgemedical.com/news-brief/hong-kong-begins-new-drug-review-pathway/): Hong Kong launched Phase 1 of its new “primary evaluation” regime for drug registration on March 31, 2026. The change supports the creation of the Hong Kong Center for Medical Products Regulation and moves the country closer to a fully independent drug review system by 2030.
- [China’s NMPA Outlines Long-Term Plan to Integrate AI into Drug Oversight](https://www.pacificbridgemedical.com/news-brief/china-nmpa-outlines-plan-to-integrate-ai/): China’s National Medical Products Administration (NMPA) has released a long-term strategy titled “Implementation Opinions on AI + Drug Regulation.” This ambitious regulation aims to integrate AI across the full pharmaceutical regulatory lifecycle by 2035.
- [Singapore Issues Cybersecurity and Data Security Guidelines for the Healthcare Sector](https://www.pacificbridgemedical.com/news-brief/singapore-issues-cybersecurity-and-data-security-guidelines-for-the-healthcare-sector/): Singapore’s Ministry of Health (MOH) has released new “Cybersecurity and Data Security Essentials” guidelines to support the rollout of the Health Information Act (HIA). The guidelines set out baseline requirements for healthcare providers handling patient data. They will be introduced in phases through early 2027.
- [Vietnam Consolidates Medical Device Rules](https://www.pacificbridgemedical.com/news-brief/vietnam-consolidates-medical-device-rules/): Vietnam’s Ministry of Health issued “Consolidated Document No. 08/VBHN-BYT” on medical device management on March 6, 2026. This brings together the provisions of Decree No. 98/2021 and its amendments, including Decree No. 07/2023, into one unified document. The consolidation simplifies how device companies should interpret and apply current rules. Instead of introducing new regulations, the document covers and provides additional details on the full regulatory lifecycle, including product classification, registration, licensing, distribution, and post-market surveillance. By replacing the need to review multiple legal texts, it provides medical device companies with a clearer and more efficient compliance framework.
- [Philippines Proposes New Post-Market Surveillance Rules for Medical Devices](https://www.pacificbridgemedical.com/news-brief/philippines-proposes-new-post-market-surveillance-rules-for-medical-devices/): The Philippine Food and Drug Administration (FDA) has released a draft circular introducing clearer and more detailed post-market surveillance (PMS) requirements for medical devices. The proposal aims to strengthen traceability and improve how medical device safety issues are monitored and addressed.
- [Japan’s MHLW Updates Pediatric Drug Development Guidance](https://www.pacificbridgemedical.com/news-brief/japans-mhlw-updates-pediatric-drug-development-guidance/): Japan’s Ministry of Health, Labour and Welfare (MHLW) has issued new notifications clarifying how pediatric drug development will be handled under amendments to the Pharmaceuticals and Medical Devices Act. These notifications will take effect on May 1, 2026.
- [Korea Introduces Regulatory Reforms for Medical Device Change Management](https://www.pacificbridgemedical.com/news-brief/korea-introduces-regulatory-reforms-for-medical-device-change-management/): Korea’s Ministry of Food and Drug Safety (MFDS) has issued a draft revision to the Enforcement Rule of the Medical Devices Act that would streamline device change procedures and update several regulatory requirements.
- [Quick Asia Regulatory Updates (April 2026)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-april-2026/): A new trade agreement between the United States and Taiwan includes measures to expedite the regulatory review of innovative pharmaceuticals and medical devices manufactured in the US. Under the agreement, approval from the US Food and Drug Administration may be used as key supporting evidence when applying for marketing authorization with the Taiwan Food and Drug Administration (TFDA). While Taiwan will continue to conduct its own regulatory review, this approach is expected to streamline the evaluation process and enable faster patient access to innovative therapies and medical technologies. The agreement also calls for greater transparency and predictability in reimbursement under Taiwan’s National Health Insurance system. These changes are expected to improve patient access to new treatments while strengthening pharmaceutical and medical device cooperation between the two countries.
- [China Introduces Market and Data Exclusivity in Major Drug Regulatory Reform](https://www.pacificbridgemedical.com/news-brief/china-introduces-market-and-data-exclusivity-in-major-drug-regulatory-reform/): China has introduced market exclusivity and data protection mechanisms for the first time under the revised Regulations for the Implementation of the Drug Administration Law of the People’s Republic of China. The revised regulation is set to take effect in May 2026.
- [Malaysia Initiates Early Regulatory Review for Innovative Medical Devices](https://www.pacificbridgemedical.com/news-brief/malaysia-initiates-early-regulatory-review-for-innovative-medical-devices/): Malaysia’s Medical Device Authority (MDA) has established an Innovative Medical Device Review (IMDR) program to assist developers of novel medical technologies seeking to align with regulatory expectations before formal product registration.
- [Korea Fast-Tracks Reimbursement for Rare Disease Therapies to Boost Patient Access](https://www.pacificbridgemedical.com/news-brief/korea-fast-tracks-reimbursement-for-rare-disease-therapies-to-boost-patient-access/): Korea is moving to significantly accelerate patient access to rare disease therapies. This is a result of a sweeping overhaul of its national drug pricing and reimbursement system, approved by the Health Insurance Policy Deliberation Committee.
- [China Expands UDI Requirements for Class II Medical Devices in 2027](https://www.pacificbridgemedical.com/news-brief/china-expands-udi-requirements-for-class-ii-medical-devices-in-2027/): China will expand its Unique Device Identifier (UDI) requirements to cover a wider range of medical devices. Under the updated framework that will go into effect on June 1, 2027, all Class II medical devices, including in vitro diagnostic (IVD) reagents, and all Class I IVD reagents must bear a UDI. Products manufactured before the implementation date will be exempt from this requirement.
- [Korea Advances AI-Driven Drug Review While Attracting Global Biopharma Investment](https://www.pacificbridgemedical.com/news-brief/korea-advances-ai-driven-drug-review-while-attracting-global-biopharma-investment/): Korea is developing an AI–supported system to assist regulatory drug reviews. The initiative, led by the Ministry of Food and Drug Safety (MFDS), includes a task force to build generative AI tools that can help analyze regulatory submissions, automate repetitive review tasks, and detect errors before applications are filed. The AI review system will initially support areas such as active pharmaceutical ingredient (API) standards and bioequivalence assessments, with plans to gradually expand its use across all drug approval processes by 2028. The government aims to shorten review timelines and ultimately reduce standard approval periods to about 240 days. The effort complements a broader national AI strategy for the pharmaceutical sector announced by the Ministry of Science. Korea hopes the initiative will increase its new drug pipeline tenfold and enable up to 300 investigational new drug (IND) applications generated with AI support over the next five years.
- [Japan Moves to Boost Drug Development and Address Shortages](https://www.pacificbridgemedical.com/news-brief/japan-moves-to-boost-drug-development-and-address-shortages/): Japan’s Ministry of Health, Labour and Welfare (MHLW) will expand the eligibility criteria for its “specific-use drug” designation to support the development of drugs addressing significant unmet medical needs. The revised rules, announced on February 27, will take effect on May 1 following amendments to the Pharmaceuticals and Medical Devices (PMD) Act. The program currently encourages development of treatments such as pediatric medicines and antibiotics targeting antimicrobial resistance (AMR), offering incentives including priority review, extended re-examination periods, and development subsidies. Under the revision, eligibility will expand to include new molecular entities (NMEs) for these categories. In addition, pharmaceutical companies will be able to directly request the designation through consultations with the MHLW. However, the existing pathway, where academic societies or healthcare professionals nominate candidates, will remain in place.
- [Singapore Strengthens Guidelines for Drug Product Defects and Recalls](https://www.pacificbridgemedical.com/news-brief/singapore-strengthens-guidelines-for-drug-product-defects-and-recalls/): In late January, Singapore’s Health Sciences Authority (HSA) published an updated guidance on defect reporting and recall procedures for therapeutic products in Singapore. The new guideline applies to therapeutic products, including biologics, as well as cell, tissue, and gene therapy products. It outlines what needs to be done when product defects are identified.
- [Japan Moves to Address Drug Gaps and Support Overseas Biopharma Trials](https://www.pacificbridgemedical.com/news-brief/japan-moves-to-address-drug-gaps-and-support-overseas-biopharma-trials/): On February 6, Japan’s Ministry of Health, Labour and Welfare (MHLW) designated 10 of 86 identified “drug loss” products (innovative products approved in the US and EU that are not available in Japan) as having high medical need. This designation enables the government to request development by pharmaceutical companies or invite new drug sponsors. The selected products span indications including advanced gastrointestinal tumors, cystic fibrosis, intra-abdominal and urinary tract infections, etc. Also, 4 of the 86 products were found not to meet the criteria for high medical necessity because of insufficient evidence of added benefit over existing therapies. Several other products were deferred,  pending further data collection from FY2026 onward.
- [China Tightens Contract Drug Manufacturing Rules](https://www.pacificbridgemedical.com/news-brief/china-tightens-contract-drug-manufacturing-rules/): On December 30, 2025, China’s National Medical Products Administration (NMPA) issued Announcement No. 134, which is expected to strengthen the oversight of local contract drug manufacturing. The regulation took effect immediately and provides a one-year rectification period. Companies that fail to comply may face suspension of contract manufacturing activities, reduction of manufacturing scope, or revocation of licenses. One of the main changes is that contract manufacturers are now required to conduct reverse due diligence. In the past, marketing authorization holders (MAH) were responsible for evaluating contract manufacturers prior to entering into a project with them. In short, contract manufacturers imposed very few requirements on MAHs.
- [Japan Clarifies Procedures for Medical Device Raw Material Changes](https://www.pacificbridgemedical.com/news-brief/japan-clarifies-procedures-for-medical-device-raw-material-changes/): In January 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) issued a new notice clarifying the regulatory procedures for changes to raw materials used in medical devices. The notice replaces the prior guidance from 2013 to determine when a raw material change may be submitted as a minor change notification, instead of requiring partial change approval or a new approval.
- [CDSCO Streamlines Medical Device Reviews Through Stricter Response Timelines and Pre-Filing Guidance](https://www.pacificbridgemedical.com/news-brief/cdsco-streamlines-medical-device-reviews-through-stricter-response-timelines-and-pre-filing-guidance/): India’s Central Drugs Standard Control Organisation (CDSCO) has announced that product applications will be rejected if applicants fail to respond to official regulatory queries within 90 days of receiving the first reminder. The CDSCO aims to clear long-pending applications across drugs, medical devices, and IVDs. On January 16, 2026, the CDSCO cited a significant backlog of applications, some of which have been pending for 8-10 years, largely due to unanswered inquiries on the SUGAM portal (the official online application portal). As a one-time measure, the CDSCO issued a final warning to applications pending for more than two years that have already received three reminders. If they do not receive responses by February 14, 2026, these applications will be rejected. Moving forward, the CDSCO will follow a structured reminder mechanism — a first reminder for unanswered inquiries, followed by a second and third reminder at 30-day intervals. If no response is received within 30 days of the third reminder, the application will be discarded.
- [China Regulatory Updates (March 2026)](https://www.pacificbridgemedical.com/news-brief/quick-china-regulatory-updates-march-2026/): On January 7, 2026, China’s National Medical Products Administration (NMPA) announced measures to expedite the approval of drugs already approved outside of China that are urgently needed in clinical practice. The Centre for Drug Evaluation (CDE) will assess the clinical demand of drugs on a case-by-case basis, instead of a predetermined list. In addition to a priority review to shorten technical review timelines, applicants may attend an early consultation with the CDE on clinical trials to determine if a Chinese clinical trial may be exempted. Requirements for registration testing for orphan drugs are also relaxed, as now only one batch of samples will be required. Pre-registration quality inspections may be remote or combined with post-marketing checks to further speed approvals.
- [Quick Asia Regulatory Updates (March 2026)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-march-2026/): In late December, Malaysia’s Ministry of Health (MOH) announced a new requirement regarding the use of a FarmaTag hologram security label on drug products. The measure is intended to strengthen labeling and authentication requirements.  Also, it will enhance safeguards against counterfeit medicines and improve product traceability in the Malaysian market. Its authentication function has been integrated since January 1, 2026 into the Malaysian MyUBAT mobile application, developed by the MoH to help patients manage their medicines. This will allow users to verify products digitally through the updated platform. Foreign companies selling pharmaceutical products in Malaysia should make sure that their labeling and verification processes comply with the updated requirements to maintain product integrity and compliance.
- [Thailand Issues Medical Device Labeling Regulation](https://www.pacificbridgemedical.com/news-brief/thailand-issues-medical-device-labeling-regulation/): Thailand’s Food and Drug Administration finalized its Medical Device Labeling Regulation (B.E. 2568) on December 22, 2025. The regulation consolidates prior fragmented rules into a single framework. Mandatory compliance needs to start by June 20, 2026. The new rules clarify labeling content, language requirements, and post-import obligations.
- [Korea Expands Expedited Review for Orphan Drugs](https://www.pacificbridgemedical.com/news-brief/korea-expands-expedited-review-for-orphan-drugs/): Korea’s Ministry of Food and Drug Safety (MFDS) is advancing a “full-cycle regulatory system” for rare disease drugs to reduce delays and improve patient access. Rare disease drug development is often hindered by small patient populations and limited clinical data, making trial-and-error particularly costly. Waiting until the final approval stage to address regulatory requirements can result in significant time and financial losses.
- [HSA Confirms Framework for AI-SaMD “Regulatory Sandbox” in Singapore](https://www.pacificbridgemedical.com/news-brief/hsa-confirms-framework-for-ai-samd-regulatory-sandbox-in-singapore/): On February 13, 2026, the Health Sciences Authority (HSA) released the outcome of its public consultation on a proposed “regulatory sandbox” for AI software as a medical device (AI-SaMD). The sandbox would exempt certain AI-SaMDs developed by public healthcare institutions from product registration under the Health Products Act.
- [India Eyes “Regulatory Sandbox” Model to Speed Pharma Approvals](https://www.pacificbridgemedical.com/news-brief/india-eyes-regulatory-sandbox-model-to-speed-pharma-approvals/): India’s Department of Biotechnology (DBT) is developing plans to introduce "regulatory sandboxes” for the pharmaceutical sector to fast-track approvals and shorten drug development timelines.
- [China to Lower Import Tariffs on Select Medical Products in 2026](https://www.pacificbridgemedical.com/news-brief/china-to-lower-import-tariffs-on-select-medical-products-in-2026/): According to the Customs Tariff Commission of the State Council, China will begin reducing its import tariffs on several medical goods starting in 2026. The purpose of this policy is to allow for increased access to sophisticated medical technology like artificial blood vessels, diagnostic testing products for certain infectious diseases, and other advanced and new medical goods.
- [Japan Issues New Pricing Rules for Conditionally Approved Regenerative Medicines](https://www.pacificbridgemedical.com/news-brief/japan-issues-new-pricing-rules-for-conditionally-approved-regenerative-medicines/): On January 14, Japan’s Central Social Insurance Medical Council (Chuikyo) implemented new pricing regulations for regenerative medicine products that are granted conditional and time-limited approval through a new pricing model. This new pricing model will be applied for the first time to the gene therapy product Elevidys developed by Chugai Pharmaceutical Corp.
- [Quick Asia Regulatory Updates (February 2026)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-february-2026/): On January 15, Singapore’s Health Sciences Authority (HSA) and the Indonesian Food and Drug Authority signed a Memorandum of Understanding (MoU) to improve regulatory cooperation. Both agencies have obtained the World Health Organization (WHO) Listed Authority status, which confirms that they have met the highest international regulatory standards as mandated by WHO. The two health authorities will work together to share information on drugs and complementary health products, including collaborative evaluation of products, clinical trial regulation, emerging technologies, staff training, and post-market safety. The MoU will enable both agencies to respond to health risks in a timely manner, strengthen both authorities’ capabilities, and make it easier for businesses seeking to establish new products in Singapore and Indonesia.
- [China Finalizes 2025 National Reimbursement Drug List and Launches First Commercial Insurance Drug List](https://www.pacificbridgemedical.com/news-brief/china-finalizes-2025-national-reimbursement-drug-list-and-launches-first-commercial-insurance-drug-list/): The National Reimbursement Drug List (NRDL) for 2025 has been announced by the Chinese government and includes 114 new entries, 50 of which are first-in-world innovative therapies. These additions show an increased focus from the government on making high-value medicines available to patients.
- [Malaysia Published Draft Change Management Guidance for Medical Devices](https://www.pacificbridgemedical.com/news-brief/malaysia-published-draft-change-management-guidance-for-medical-devices/): In December 2025, Malaysia’s Medical Device Authority (MDA) published for public comment its draft First Edition of Guidance on the management of changes to registered medical devices. This guidance is an important milestone in how modifications to registered medical devices will be governed under the Malaysian Medical Devices Act 2012 (Act 737).
- [Quick Asia Medical Device Regulatory Updates (February 2026)](https://www.pacificbridgemedical.com/news-brief/quick-asia-medical-device-regulatory-updates-february-2026/): India’s Central Drugs Standard Control Organization (CDSCO) has released the final list of risk classifications for oncology-related medical devices. The classification system, published on January 2, 2026, improves transparency concerning the regulation of cancer med-tech devices. It gives manufacturers of oncology devices clear guidance on the level of regulatory oversight required based on their device's intended use and level of risk. The list includes devices such as accelerator system components and alternating electric field cancer treatment systems. These devices are classified across risk tiers to align with India’s MDR 2017 framework. The CDSCO has stated that the risk classification system will continue to evolve over time.
- [Singapore HSA Updates Therapeutic Product Registration Rules](https://www.pacificbridgemedical.com/news-brief/singapore-hsa-updates-therapeutic-product-registration-rules/): The Singapore Health Sciences Authority (HSA) has introduced regulatory updates to help clarify and streamline the registration of Therapeutic Products, effective January 16, 2026.
- [India’s Health Ministry Halves Clinical Trial Approval Timeline For Drugs to 45 Days](https://www.pacificbridgemedical.com/news-brief/indias-health-ministry-halves-clinical-trial-approval-timeline-for-drugs-to-45-days/): In January 2026, India’s Ministry of Health and Family Welfare made major amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019. This has shortened the timeline for clinical trial approval from 90 to 45 working days, which will potentially improve the speed at which drugs are developed and tested in India.
- [Clinical Trials in Asia Gain Momentum](https://www.pacificbridgemedical.com/news-brief/clinical-trials-in-asia-gain-momentum/): Approximately 50% of global clinical trials are conducted in the Asia Pacific region today. The clinical trial landscape of Asia has been expanding beyond China in recent years. Although over 60% of the clinical trials in the region were initiated in China during 2024, China does not solely drive the region's growth. More countries in Asia have growing clinical research capacity and are capturing significant interest from foreign sponsors.
- [China Revises Pharmaceutical Implementing Regulations to Boost Innovation and Market Access](https://www.pacificbridgemedical.com/news-brief/china-revises-pharmaceutical-implementing-regulations-to-boost-innovation-and-market-access/): On January 27, 2026, China’s State Council issued revised Implementing Regulations of the Drug Administration Law of the People’s Republic of China, which will go into effect on May 15, 2026. The regulations refine key provisions of the Drug Administration Law, which has been in effect since December 2019, and provide clarification on pharmaceutical regulations in China.
- [Japan to Introduce Pathway for “Specific-Use Drug” Designations](https://www.pacificbridgemedical.com/news-brief/japan-to-introduce-pathway-for-specific-use-drug-designations/): Japan’s Ministry of Health, Labour and Welfare (MHLW) will introduce a new pathway from May 2026, allowing pharmaceutical companies to directly request an eligibility assessment from the Pharmaceuticals and Medical Devices Agency (PMDA) for designation as a “drug for specific use.” The designation targets therapies for high unmet medical needs, such as pediatric conditions and antimicrobial resistance, and provides incentives, including priority review and access to public support measures.
- [Korea and China Accelerate Support for Medical Device Innovation](https://www.pacificbridgemedical.com/news-brief/korea-and-china-accelerate-support-for-medical-device-innovation/): While in the past, the US, EU, and Japan dominated the global medical device market, things are changing as more new devices are being developed in Asia first, especially in China. Accordingly, Korea and China have recently announced new initiatives aimed at accelerating medical device innovation.
- [China Adds 55 Drugs to The New 11th VBP Round, Tightens Rules on Quality and Supply Stability](https://www.pacificbridgemedical.com/news-brief/china-adds-55-drugs-to-the-new-11th-vbp-round-tightens-rules-on-quality-and-supply-stability/): China's 11th round of national Volume-Based Procurement (VBP) came to an end in late October 2025 with all 55 tendered drug products awarded contracts across major therapeutic areas such as anti-infectives, oncology, diabetes, cardiovascular disease, lipid disorders, pain management, and allergy treatment. Participation reached a new high with over 46,000 healthcare institutions submitting volume forecasts and 445 drug companies placing 794 bids to win this business.
- [Malaysia and Thailand Launch Medical Device Regulatory Reliance Pilot](https://www.pacificbridgemedical.com/news-brief/malaysia-and-thailand-launch-medical-device-regulatory-reliance-pilot/): Malaysia’s Medical Device Authority (MDA) and Thailand’s Food and Drug Administration (Thai FDA) have recently signed a Confidentiality Agreement and launched a three-month regulatory reliance pilot to accelerate medical device approvals and reduce duplicate reviews in each country.
- [Singapore and the UK Initiate Fast-track Regulatory Pathway for Breakthrough Health Technologies](https://www.pacificbridgemedical.com/news-brief/singapore-and-the-uk-initiate-fast-track-regulatory-pathway-for-breakthrough-health-technologies/): The UK's Medicines & Healthcare Products Regulatory Agency (MHRA) and Singapore's Health Sciences Authority (HSA) have established a new "Regulatory Innovation Corridor" to speed up patient access to innovative healthcare solutions. Companies will be able to work with both regulators at the same time through a fast-track process, which will allow for early regulatory guidance, enhanced design of clinical studies if needed, and less duplication and delays.
- [China Tightens Oversight of Excessive Prescribing, Raising Risks for Multinational Drug Companies](https://www.pacificbridgemedical.com/news-brief/china-tightens-oversight-of-excessive-prescribing-raising-risks-for-multinational-drug-companies/): China has strengthened its regulation of excessive prescription practices through a new National Healthcare Security Administration (NHSA) notice issued on November 3, 2025, alongside the nationwide Insurance Fraud “Hundred-Day Campaign.” The measure aims to crack down on fraud, abuse, and improper use of medical insurance funds through high-technology supervision.
- [Korea Eases Path to Breakthrough Drugs with Flexible Incremental Cost-effectiveness Ratio](https://www.pacificbridgemedical.com/news-brief/korea-eases-path-to-breakthrough-drugs-with-flexible-incremental-cost-effectiveness-ratio/): Korea has unveiled major reforms to its national health insurance drug pricing system to improve patient access to innovative medicines, especially for severe and rare diseases. Several weeks ago, the government submitted its “Proposal for Improving the Drug Pricing System” to the Health Insurance Policy Deliberation Committee (HIPDC), focusing on raising and facilitating the better use of the Incremental Cost-effectiveness Ratio (ICER) threshold.
- [Singapore Initiates Health Information Bill](https://www.pacificbridgemedical.com/news-brief/singapore-initiates-health-information-bill/): The Parliament of Singapore made a considerable effort towards enhancing the country’s digital health infrastructure via the introduction of the Health Information Bill (HIB) on November 5, 2025. The Health Information Bill has been widely anticipated for several years and dates back to 2023, with the proposal put forth by the Singapore Ministry of Health.
- [Quick Asia Drug Regulatory Updates (January 2026)](https://www.pacificbridgemedical.com/news-brief/quick-asia-drug-regulatory-updates-january-2026/): Japan’s Cabinet Office has recently approved a 330 billion JPY (2.1 billion USD) support package to encourage drug discovery and strengthen the country’s biopharma sector. Key allocations include nearly 50 billion JPY (323 million USD) for bioclusters and biotech infrastructure, 20 billion JPY (129 million USD) for global clinical trials in rare diseases, 29 billion JPY (187 million USD) for cell and gene therapy manufacturing, and 16 billion JPY (103 million USD) for biosimilar production. The package also incorporates ongoing projects while earmarking new funds for the fiscal year ending March 31, 2026. The plan focuses on “health and medical security,” supporting drug discovery infrastructure, regenerative medicine, and domestic manufacturing systems. The initiative positions biopharma as a core growth industry, reinforcing Japan’s economic security priorities and continuity of the Liberal Democratic Party’s support for the sector.
- [Korea Starts Reforms to Fast-Track Healthcare Approvals and Improve Rare Disease Access](https://www.pacificbridgemedical.com/news-brief/korea-starts-reforms-to-fast-track-healthcare-approvals-and-improve-rare-disease-access/): Korea’s Ministry of Food and Drug Safety (MFDS) plans to make its approval system the world’s fastest by sharply reducing review timelines for drugs, biosimilars, and medical devices under its 2026 administrative plan. Biosimilar reviews will be shortened from up to 420 days to 240 days – supported by expanded parallel reviews, enhanced pre-application consultations, and dedicated review teams. The MFDS will also deploy AI-based review tools to streamline data assessment and documentation. Additional measures include a more relaxed requirement for medical device changes (only changes that may affect safety and efficacy need to be approved by the MFDS). In addition, the plan calls for regulatory support for AI and digital-based medical technologies to speed market entry and boost global competitiveness.
- [Japan’s SaMD Market Poised for Rapid Expansion](https://www.pacificbridgemedical.com/news-brief/japans-samd-market-poised-for-rapid-expansion/): Japan's market for Software as a Medical Device (SaMD) is on track for remarkable growth, expanding from approximately 20 million USD in 2024 to more than 95 million USD in 2033. From 2025 through 2033, the SaMD market is forecasted to grow at a 16.9% CAGR, spurred by the accelerated uptake of digital health services, AI-supported diagnostics, and remote patient monitoring applications.
- [China Issues New Draft Revision: Good Clinical Practice for Drugs](https://www.pacificbridgemedical.com/news-brief/china-issues-new-draft-revision-good-clinical-practice-for-drugs/): China's National Medical Products Administration (NMPA) has published the draft Good Clinical Practice for Drugs (2025) with fundamental changes to further enhance participant protection, data integrity, and trial quality. Published at the end of October, 2025, this draft condenses the current eight-chapter GCP regulations into six chapters, introduces a new section on Data Governance, and names the sponsor as the ultimately responsible entity. It also defines the Principal Investigator (PI) as the site-level responsible person. Comments are open to the public until the end of November.
- [Japan Drug Price Negotiations Continue for FY2026](https://www.pacificbridgemedical.com/news-brief/japan-drug-price-negotiations-continue-for-fy2026/): As mentioned last month, drug pricing negotiations are now underway in Japan, in line with the Fiscal System’s Council guidance for the FY2026 budget. In contrast to the Japan Pharmaceutical Association’s desire for higher prices, the Japanese Ministry of Finance (MOF) is seeking a tougher stance on high-priced pharmaceuticals. The MOF recommended the maximum use of the cost-effectiveness assessment (CEA) system and simultaneously called for a pro-innovation pricing system. Also, after the initial pricing, future drug pricing decisions should be made only with strong clinical and economic data.
- [China Amends Good Manufacturing Practice for Medical Devices](https://www.pacificbridgemedical.com/news-brief/china-amends-good-manufacturing-practice-for-medical-devices/): On November 4, the National Medical Products Administration (NMPA) released its revised Good Manufacturing Practice (GMP) for medical devices, which will come into effect on November 1, 2026. This is the first major revision of the GMP since 2014, and forms part of the general governmental measures to improve the regulation of medical devices and encourage high-quality development.
- [India Releases Draft Guidance on Medical Device Software](https://www.pacificbridgemedical.com/news-brief/india-releases-draft-guidance-on-medical-device-software/): For the first time, India’s Central Drugs Standard Control Organization (“CDSCO”) has issued a Draft Guidance on Medical Device Software to regulate software-based medical devices, including AI-based devices. This guidance aims to clarify the classification, licensing, validation, and post-marketing surveillance of Software in a Medical Device (SiMD) and Software as a Medical Device (SaMD).
- [China Introduces New Rules to Regulate Cutting-Edge Biomedical Technologies](https://www.pacificbridgemedical.com/news-brief/china-introduces-new-rules-to-regulate-cutting-edge-biomedical-technologies/): A new regulation issued by China's State Council outlines, for the first time, clear rules for the study and use of advanced biomedical technologies, including gene editing, CAR-T and NK cell therapies, as well as stem cell treatments.
- [Quick Asia Regulatory Updates (December 2025)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-december-2025/): Singapore’s Health Sciences Authority (HSA) has officially opened its new electronic Common Technical Document (eCTD) portal for test submissions. This represents an important move towards the process of digitalizing regulatory submissions for therapeutic products. The eCTD Specification Package version 1.0 will be available for test submissions from September 30, 2025, to March 27, 2026. During this time, it is recommended that companies submit test dossiers to become familiar with the use of the portal. The HSA has made it clear that the test submissions will not be reviewed, and all submissions will be discarded at the end of the testing period. Actual eCTD submissions to the portal can be made starting April 1, 2026.
- [Some Innovative Western Devices, Pause Before Japan Entry](https://www.pacificbridgemedical.com/news-brief/some-innovative-western-devices-pause-before-japan-entry/): Japan is the world’s third-largest device market. Similar to the drug lag, Japan is now beginning to see a device lag. The reason for this is that although Japan wants and needs innovative devices for its citizens, especially innovative devices that will reduce the Japanese Government’s healthcare expenditures, device reimbursement is now a “sticky” issue. To get into the higher functional reimbursement categories of C1 and C2, strong clinical evidence and strong support from a medical society are needed. However, please note that over the last 10 years, only about 14 innovative devices each year were allocated to the functional C1 and C2 categories. At the same time, of the innovative devices approved based on the cost-based calculation, only about 10% of these devices received a reimbursement price equal to or higher than the manufacturer’s requested prices.
- [Korea Expands Access to Cancer Clinical Trials for Early-Stage Patients](https://www.pacificbridgemedical.com/news-brief/korea-expands-access-to-cancer-clinical-trials-for-early-stage-patients/): Korea will significantly expand eligibility for cancer drug clinical trials, allowing patients who still have other standard treatment options to participate much earlier. The Ministry of Food and Drug Safety announced on Nov. 25 that participation would no longer be limited to terminal-stage patients if trials are medically appropriate for both the patient and physician.
- [India Clarifies Packaging Rules for Medical Devices](https://www.pacificbridgemedical.com/news-brief/india-clarifies-packaging-rules-for-medical-devices/): The Government of India has issued the Legal Metrology (Packaged Commodities – “LMPC”) Amendment Rules, 2025, a pivotal reform that exempts medical devices from the purview of the LMPC Rules, 2011. The amendment puts to rest long-standing issues of overlap created by the Medical Devices Rules, 2017, and is likely to ease the compliance burden of medical device manufacturers and importers.
- [Japan Medical Device Reimbursement Getting Tougher](https://www.pacificbridgemedical.com/news-brief/japan-medical-device-reimbursement-getting-tougher/): Ten to twenty years ago, Japan medical device reimbursement normally equaled the reimbursement in the US, or in a few cases, even higher. During this time, some device companies had 10% of their sales in Japan, with more than 10% of their overall profits there. However, those days are now over. A major consideration for device companies to bring their products to Japan is reimbursement.  Without a decent reimbursement, some device companies cannot make a profit. Today, Japan reimbursement closely follows the pricing in Europe and not the higher-priced markets of the US and Australia. Japan reimbursement is especially crucial because it is illegal for patients to supplement government reimbursement with out-of-pocket payments, which are allowed in most countries in the world.
- [China Promulgates 30-day IND Pathway for Innovative Drugs](https://www.pacificbridgemedical.com/news-brief/china-promulgates-30-day-ind-pathway-for-innovative-drugs/): In mid-September, China's National Medical Products Administration (NMPA) launched a 30-day review and approval pathway for investigational new drug (IND) applications to speed up clinical trial initiation for innovative pharmaceuticals. This pathway supplements the existing 60-day default approval pathway established in 2019.
- [Korea to Now Unveil Full Drug GMP Inspection Results](https://www.pacificbridgemedical.com/news-brief/korea-to-now-unveil-full-drug-gmp-inspection-results/): The Korean Ministry of Food and Drug Safety (MFDS) has made a major overhaul to its disclosure policies regarding Good Manufacturing Practice (GMP) inspection outcomes. The MFDS will now disclose results in full, instead of in the past, just issuing heavily redacted reports at the request of drug companies.
- [China Implements Regulations on Medical Device Self-Testing](https://www.pacificbridgemedical.com/news-brief/china-implements-regulations-on-medical-device-self-testing/): To register medical devices in China, type testing is required. Whereas in the past, this testing needed to be done in China, China has now allowed for testing overseas. Given the long time it may take for type testing in China (anywhere from 3-9 months), this may prove helpful to some foreign device companies looking to register and export to China. On the other hand, Chinese regulators will have the right to closely check the foreign device companies' QMS and testing standards, so how much of an advantage this will be may be unclear.
- [Japan Debating Many Drug Reimbursement Issues Now for FY 2026](https://www.pacificbridgemedical.com/news-brief/japan-debating-many-drug-reimbursement-issues-now-for-fy-2026/): Drug reimbursement is a key issue in Japan, especially as the country wants to promote innovative therapies and reduce the drug lag/loss there. Over the last few months, the MHLW, Central Social Insurance Medical Council (Chuikyo), the Japan Pharmaceutical Association, and other related groups have been discussing key drug pricing issues.
- [India to Extensively Revise Drug Quality Standards](https://www.pacificbridgemedical.com/news-brief/india-to-extensively-revise-drug-quality-standards/): India is moving toward an extensive revision of its legal drug-quality measures, which will be aligned with the various drug standards of the US, EU, and Japan. The Indian Pharmacopoeia Commission (IPC) will include new drug quality measures for 123 products and revise approximately 200 existing monographs, which define a drug's identity, strength, and purity.
- [Quick Asia Regulatory Updates (November 2025)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-november-2025/): Singapore's Health Sciences Authority (HSA) has strengthened international regulatory collaboration through two Memoranda of Understanding (MOUs) signed during the 16th International Conference on Medical Regulation 2025. On September 4, the HSA signed an MOU with Australia's Therapeutic Goods Administration (TGA) to facilitate information exchange, regulatory approval, and staff development. On September 5, the HSA signed a second MOU with Ireland's Health Products Regulatory Authority (HPRA) to help improve communication, regulatory policies, and post-market vigilance. The HSA anticipates that the collaborations will support the HSA's goals of improving approval efficiency and demonstrate Singapore's commitment to the safety of health products globally.
- [The Malaysia Medical Device Authority (MDA) issues new regulation to expedite product registration](https://www.pacificbridgemedical.com/news-brief/the-malaysia-medical-device-authority-mda-issues-new-regulation-to-expedite-product-registration/): Device registration in Malaysia is done by a Local Authorized Representative (LAR) for foreign device manufacturing companies without a physical presence in Malaysia. The normal device registration process includes going through a detailed conformity assessment before making a registration application submission. In October, the MDA promulgated a new Guidance Document for Class B, C, and D medical devices. Going forward, medical devices which already have approval from one of the following regulators - the FDA, TGA, EU NB, Health Canada, UK MHRA or Japan MHLW, are eligible for conformity assessment by way of verification. The benefit of conformity assessment by way of verification is a reduction of the CAB assessment time, government fees, etc.
- [Indonesia’s Halal Certification Deadlines](https://www.pacificbridgemedical.com/news-brief/indonesias-halal-certification-deadlines/): Indonesia requires most imported foreign products to meet its strict Halal requirements. The deadline for meeting Halal requirements has recently been extended. Different product categories have new certification deadlines. For our readers, these deadline extensions are important – 1. October 17, 2026, for natural drugs, quasi-drugs, chemical products, genetically engineered products, etc., 2. October 17, 2029, for OTC drugs and Class B medical devices, and 3. October 17, 2034, for RX drugs and Class C medical devices.
- [Thailand: Updates on Telemedicine and Advertising](https://www.pacificbridgemedical.com/news-brief/thailand-updates-on-telemedicine-and-advertising/): According to the recent Medical Facility Act in Thailand, telemedicine is now allowed and becoming more pervasive. Hospitals and clinics can diagnose, prescribe, and send out electronic prescriptions after a video call with a doctor is completed. Also, telepharmacy now permits a pharmacist to confirm prescriptions, discuss patients’ health concerns virtually, and distribute drugs if they have a license as a drug retailer from a faraway site. In short, telehealth now allows Thai patients to get doctor appointments more quickly, get access to remote specialists without travel, and ultimately improve their health.
- [Japan Dramatically Increasing its Drug GMP Inspections](https://www.pacificbridgemedical.com/news-brief/japan-dramatically-increasing-its-drug-gmp-inspections/): On July 7, Japan’s PMDA published its GMP annual report for 2024. Japan’s PMDA has reported that many foreign drug companies are not meeting Japan’s GMP standards. In 2024, there were 126 on-site GMP inspections and 2,049 desktop GMP inspections. These figures represent double the number of on-site inspections and four times the number of desktop inspections conducted in 2023.
- [Taiwan’s FDA Releases Updated Guidelines for AI Medical Devices](https://www.pacificbridgemedical.com/news-brief/taiwans-fda-releases-updated-guidelines-for-ai-medical-devices/): The Taiwan Food and Drug Administration (TFDA) has recently promulgated updated technical guidance on artificial intelligence-based medical devices, which came into effect on August 14, 2025. The new guidelines will replace the 2023 edition and incorporate additional clarification and detailed requirements for computer-aided detection and diagnosis (CADe and CADx) devices classified as Class II and Class III.  This guidance will apply to both incorporated systems and stand-alone software.
- [China’s 2025 Drug Reimbursement Update: Innovation and Competition](https://www.pacificbridgemedical.com/news-brief/chinas-2025-drug-reimbursement-update-innovation-and-competition/): China's 2025 revision of the National Reimbursement Drug List (NRDL) has been the most competitive in history, with a record-setting number of candidates qualifying for the first round of formal review. Through mid-August 2025, there are more than 300 drugs for new listings and over 200 drugs for renewals and re-negotiation. In addition, over 100 drugs are trying to make the new C-list, which targets innovative and expensive drugs not currently covered by the NRDL. The unprecedented number of drugs reflects intense negotiations now and in the future, as drug manufacturers strive to secure reimbursement under increasingly tight budget conditions.
- [Thailand FDA Streamlines Renewal Process for Class 2, 3, and 4 Medical Devices](https://www.pacificbridgemedical.com/news-brief/thailand-fda-streamlines-renewal-process-for-class-2-3-and-4-medical-devices/): The Thai FDA announced updated renewal procedures for Class 2, 3, and 4 medical devices, which came into effect on July 22, 2025. Renewal applications must be submitted on an annual basis, between October 1 and December 31. Devices that were originally registered with a Full Common Submission Dossier Template (CSDT) dossier will receive five-year automatic renewals once the renewal fee is paid, with the exception of HIV test kits, which must continue to submit test reports upon renewal. For devices that were registered with Partial 1 or 2 Pathways, which are simplified pathways for device registration in Thailand, renewal will be based on the device’s safety record following marketing: devices that do not have a serious adverse event or quality complaint will only require a Safety Declaration Form, while those with quality issues must submit additional supporting documents. It is anticipated that the new framework will reduce the administrative burden for compliant devices over their lifecycle, while still maintaining post-market safety assurance.
- [Quick Asia Regulatory Updates (October 2025)](https://www.pacificbridgemedical.com/news-brief/quick-asia-regulatory-updates-october-2025/): India has released a draft bill calling for greater accountability from clinical trial sponsors and contract research organizations (CROs). Companies will need to pay damages and treat participants who suffer from injuries during any trials. If the trial sponsors do not comply, companies would face a fine or even imprisonment. The draft also calls for the legal beneficiaries of participants to be paid in the event that the patient dies as a result of a trial. Apart from this, the bill also demands stricter punishment for selling counterfeit or substandard drugs, and the punishment could range from a minimum of 10 years of imprisonment, along with hefty fines. The government also intends to set up medical device test labs at both state and central levels and create two new advisory bodies — the Drugs Technical Advisory Board (DTAB) and Medical Devices Technical Advisory Board (MDTAB). The draft bill is available for public observation for the next 45 days.
- [China’s NMPA Implements Revisions to Clinical Trial Policies to Streamline Development](https://www.pacificbridgemedical.com/news-brief/chinas-nmpa-implements-revisions-to-clinical-trial-policies-to-streamline-development/): The National Medical Products Administration (NMPA) of China has issued revisions to its clinical trial policies in an effort to shorten drug development timelines and encourage innovation. The revised guidelines, which became effective on September 2, 2025, are expected to reduce approval timelines by 30% and to reduce the regulatory burden for drug companies.
- [India Seeks to Relax Clinical Trial Guidelines to Support Pharma Innovation](https://www.pacificbridgemedical.com/news-brief/india-seeks-to-relax-clinical-trial-guidelines/): India’s Union Health Ministry has suggested amending the New Drugs and Clinical Trial Rules, originally issued in 2019, to simplify approvals and encourage pharmaceutical innovation. The modification in the draft would permit drug companies to conduct some of the bioavailability and bioequivalence (BA/BE) tests — utilized to demonstrate that new formulations function in the same way as approved medicines — without authorization by the Central Drugs Standard Control Organisation (CDSCO). Instead, clinical trials in India could begin only with a notification, as long as they involve oral formulations that already hold approvals in the US, EU, UK, Japan, Australia, or Canada.
- [Korea Regulatory Updates (October 2025)](https://www.pacificbridgemedical.com/news-brief/korea-regulatory-updates-october-2025/): A draft bill has been introduced in Korea to increase the scope of devices that can receive a designation as "innovative medical devices". Innovative devices are those that would enhance the convenience and quality of diagnosis and treatment. At present, only devices with enhanced safety and efficacy can be designated as innovative, and usability is not taken into account. If the bill is passed, significant incentives such as reduced government fees, tax breaks, and participation in national R&D projects will be available to more device companies.
- [Malaysia to Use Real-World Evidence In Drug Listing Decisions](https://www.pacificbridgemedical.com/news-brief/malaysia-to-use-real-world-evidence-in-drug-listing-decisions/): Malaysia’s Ministry of Health (MOH) has recently announced that it will factor real-world evidence (RWE) in its decision-making for the inclusion of drugs into its national formulary – the “Blue Book.” This change signals a shift toward moving beyond reliance on clinical trial data alone and toward a closer alignment with value-based healthcare. The use of RWE will involve collecting treatment outcomes from hospitals and clinics, complementing the existing health technology assessment (HTA) framework, and ensuring that drug listings demonstrate both clinical effectiveness and cost-effectiveness. This ensures that public resources are allocated to therapies that demonstrate a proven value for patients.
- [Quick Asia Drug Regulatory Updates (October 2025)](https://www.pacificbridgemedical.com/news-brief/quick-asia-drug-regulatory-updates-october-2025/): On July 31, 2025, Taiwan's Ministry of Health announced a phased plan to digitize drug package inserts, moving everything to a digital and paperless format. By December 31, 2025, all prescription and non-prescription drug inserts must be structured electronically and uploaded to the Drug Package Insert Inquiry Platform. Digital format must be fully implemented by this deadline. QR codes with links to the electronic insert will replace paper inserts. Drug companies will be required to notify suppliers before the transition and provide printed copies upon request.

## Research Reports
- [Pacific Bridge Medical’s Report On Orphan Drugs And Rare Diseases In China](https://www.pacificbridgemedical.com/research-report/pacific-bridge-medicals-report-on-orphan-drugs-and-rare-diseases-in-china/): To download this report, please click on  PBM's Report on Orphan Drugs and Rare Diseases in China
- [Orphan Drugs in Asia Report 2017](https://www.pacificbridgemedical.com/research-report/orphan-drugs-asia-report-2017/): Following the example of the U.S. FDA's Orphan Drug Act established in 1983, some Asian countries have developed orphan drug legislation, such as Singapore's Orphan Drug Exemption to the Medicines Act and Japan's Orphan Drug Amendment to the Pharmaceutical Affairs Law. While laws on orphan drugs in Asia may provide benefits for companies registering new drugs, including marketing exclusivity, an expedited registration process, and a reduction in the number of clinical trials required, each registration process is unique and can pose a variety of challenges. This report reviews the orphan drug regulations in 10 Asian countries and discusses various business issues related to orphan drugs in the region. Lists of approved orphan drugs in Japan and Korea as well as a list of orphan drug associations are also included.
- [Japan Drug Regulatory Overview Report 2014](https://www.pacificbridgemedical.com/research-report/japan-drug-regulatory-report-2014/): This Japan drug regulatory PowerPoint presentation covers many basic issues for international drug companies looking to gain more knowledge about the Japanese drug market. It includes information on registering ethical, biological, orphan, and generic drugs in Japan. The presentation also provides information on drug classification, reimbursement, and clinical trials.
- [Sourcing and Manufacturing Medical Devices in Asia Report 2014](https://www.pacificbridgemedical.com/research-report/sourcing-manufacturing-medical-devices-asia-report-2014/): Sourcing medical devices in Asia has become a common practice as more companies are taking advantage of the lower overhead, lower labor costs and increasing technical capabilities available in the Asian countries. Medical device companies can buy and manufacture a wide array of components and medical devices from Asia at significantly lower costs and relatively high quality. This report helps manufacturers and distributors better understand medical device sourcing in Asia. The report contains guidelines on identifying manufacturers, performing due diligence, negotiating contracts, regulatory requirements, logistics, quality control, and other issues related to the sourcing equation. This report also offers advice about insurance, payment arrangements, freight forwarding, and customs.
- [Contract Research Organizations in Asia Report 2014](https://www.pacificbridgemedical.com/research-report/contract-research-organizations-asia-report-2014/): This report on Asian CROs provides a comprehensive list of contract research organizations in Asia. The countries covered include: Japan, Taiwan, Korea, Singapore, Hong Kong, India, China, Malaysia, Philippines, Indonesia, Thailand and Vietnam. Included for each CRO are contact information, description of services and further comments about the organization.
- [China Regulatory and Market Access Pharmaceutical Report 2014](https://www.pacificbridgemedical.com/research-report/china-pharmaceutical-report-2014/): China's pharmaceutical market is booming! The market is growing almost 15% annually and is expected to be about $100 billion dollars in 2017. However, drug regulations are complicated in China. In addition, once your drug is approved, what needs to be done to sell it in the Chinese market? This report covers the best way to register your drug there and optimize market access to increase sales in China. Topics that will be discussed include clinical trials, required drug documentation for approval, GCP, GMP, drug pricing, reimbursement, provincial bidding, hospital tenders, and more.
- [India Pharmaceutical Regulatory Report 2013](https://www.pacificbridgemedical.com/research-report/india-pharmaceutical-report-2013/): The India Pharmaceutical Regulatory Report comprehensively covers all aspects of India pharmaceutical regulations. It includes overviews of the laws and procedures on registration, manufacturing, distribution, price control, marketing, research and development, and intellectual property protection. It also includes an overview of the Indian pharmaceutical market and foreign involvement in the market up to 2012. As India's pharmaceutical market is poised for steady growth, reaching an estimated $13 billion, understanding of Indian regulatory issues is crucial for success.
- [India Medical Device Directory 2013](https://www.pacificbridgemedical.com/research-report/india-medical-device-directory-2013/): This is the first ever directory on Indian medical device companies. This Indian medical device directory has been compiled and verified by Pacific Bridge Medical. This directory provides contact information and company profiles for 242 credible India based medical device manufacturers, distributors and exporters. This directory is indexed alphabetically by company name and by product category.

## Webcasts
- [Japan Medical Device Reimbursement Strategy](https://www.pacificbridgemedical.com/webcast/japan-medical-device-reimbursement-strategy/)
- [AMDM Presentation: Companion Diagnostics (CDx) Registration in Asia](https://www.pacificbridgemedical.com/webcast/amdm-presentation-companion-diagnostics-cdx-registration-in-asia/)
- [RAPS Webcast: China Pharmaceutical Registration and Reimbursement](https://www.pacificbridgemedical.com/webcast/raps-webcast-china-drug-registration-and-reimbursement/)
- [Japan Medical Device Registration and Reimbursement](https://www.pacificbridgemedical.com/webcast/japan-medical-device-registration-and-reimbursement/): https://www.pacificbridgemedical.com/wp-content/uploads/2023/05/Japan-Med-Device-Registration-and-Reimbursement-final-version-2-1.mp4
- [China Medical Device Registration and Reimbursement](https://www.pacificbridgemedical.com/webcast/china-medical-device-registration-and-reimbursement/): https://www.pacificbridgemedical.com/wp-content/uploads/2023/05/China-Med-Device-Registration-and-Reimbursement-ver-3.0-1-1.mp4
- [2023 Asia Healthcare Market Update](https://www.pacificbridgemedical.com/webcast/2023-asia-healthcare-market-update/)
- [RAPS Webcast: Japan 2023 Medical Device Regulatory Update](https://www.pacificbridgemedical.com/webcast/raps-webcast-japan-2023-medical-device-regulatory-update/): The recording of the webcast can be accessed here.
- [2021 Asia MedTech Update – Taking Your Medical Device Products to the Asia Pacific Markets](https://www.pacificbridgemedical.com/webcast/2021-asia-medtech-update-taking-your-medical-device-products-to-the-asia-pacific-markets/): Spotify: https://open.spotify.com/episode/61krNTBfW9nKHadjtOOIuT?si=zGlmcBWnTUKGYT7qXOo1XQ&dl_branch=1 
- [2020 Asia MedTech Update for MDMA](https://www.pacificbridgemedical.com/webcast/2020-asia-medtech-update-for-mdma/): https://www.youtube.com/watch?v=7ryKWZ8HDN0&feature=youtu.be&ab_channel=MedicalDevicesMDMA
- [RAPS Wisconsin Chapter Webcast: Embracing The Growth – An Update on MedTech in Asia](https://www.pacificbridgemedical.com/webcast/raps-wisconsin-chapter-webcast-embracing-the-growth-an-update-on-medtech-in-asia/): https://attendee.gotowebinar.com/recording/5890292005019691021
- [China Medical Regulatory Updates 2015 Webcast: Devices, IVDs, and More](https://www.pacificbridgemedical.com/webcast/2015-china-medical-device-regulatory-webcast/): China's medical device and IVD market has grown to over $20 billion, the third largest in the world. The number of foreign medical device manufacturers registering their products in China has grown exponentially. To be successful in this fast growing market, view our webcast to learn about the new regulations in China. This webcast will also review ways to expedite registration in China.
- [India Medical Device Regulatory Update and New Post Market Requirements 2014 Webcast](https://www.pacificbridgemedical.com/webcast/2014-india-medical-device-regulatory-webcast/): The Indian medical device market is worth about $4.3 billion dollars. It is expected to grow to about $12 billion dollars by 2022. More and more Western device companies are registering their products in India. For registration renewals, the DCGI is now requiring that renewal dossiers have 3 years of post-market data. If your Indian office or Indian distributor is not keeping good track of PMS, you may not be able to renew your device license. Also, medical device manufacturers need to make sure their products are labeled properly.
- [China Medical Device Regulatory Updates 2014 Webcast](https://www.pacificbridgemedical.com/webcast/2014-china-medical-device-regulatory-webcast/): China's medical device market has grown to $13 billion, the second largest in Asia after Japan. The number of foreign medical device manufacturers registering their products in China has grown exponentially. View our webcast to learn about the new regulations in China. This webcast will also review ways to expedite registration in China.
- [Japan Medical Device Regulations Updates and Recent Revisions 2014 Webcast](https://www.pacificbridgemedical.com/webcast/2014-japan-medical-device-regulatory-webcast/): Japan is the second largest medical device market in the world. Getting through the registration process and selling your product on the market is not an easy task. This webcast will focus on key steps including PMDA consultation sessions, how to maximize foreign clinical data, and how to expedite product registration.
- [Japan Business Culture 2013 Webcast](https://www.pacificbridgemedical.com/webcast/2013-japan-business-culture-webcast/): With one of the world's largest economies, Japan is an attractive market for Western medical device, pharmaceutical and biotech companies. However, many Westerners struggle with understanding Japanese culture and business etiquette when they are registering their products, licensing their technology, or dealing with Japanese partners. Japan has distinct social norms and a group mentality that is hierarchical in nature. What are the cultural characteristics of Japanese companies? What are the most common errors that Western companies make when doing business in Japan? How can you successfully do business with Japanese people? Please view our Japanese Business Culture Update webcast to gain the cultural understanding needed when doing business in Japan.
- [Hong Kong Medical Device Regulatory Update 2012 Webcast](https://www.pacificbridgemedical.com/webcast/2012-hong-kong-medical-device-regulatory-webcast/): Like many other Asian countries, Hong Kong is developing a more regulated, harmonized system for medical device manufacturers and importers. Though registration is currently voluntary, manufacturers will soon be required to register their products. Get a head start by viewing our webcast and familiarize yourself with Hong Kong medical device regulations. Real case studies will be used to emphasize key points.
- [China Pharmaceutical Regulatory Updates 2012 Webcast](https://www.pacificbridgemedical.com/webcast/2012-china-pharmaceutical-regulatory-webcast/): China's pharmaceutical market is currently the ninth largest worldwide and worth approximately $25 billion. With analysts predicting this market to be the fifth largest by 2013, one cannot ignore China's potential. This webcast will provide an overview of drug registration in China as well as discuss the most recent China pharmaceutical regulations issues of the Chinese State Food and Drug Administration (SFDA).
- [Vietnam Medical Device Market Updates 2011 Webcast](https://www.pacificbridgemedical.com/webcast/2011-vietnam-medical-device-market-webcast/): The Vietnam medical device market is growing very quickly. To succeed there, foreign medical device companies need to understand the Vietnamese regulatory system and how to get product approval.
- [Singapore Medical Device Updates 2011 Webcast](https://www.pacificbridgemedical.com/webcast/2011-singapore-medical-device-webcast/): Singapore passed the Health Products Act in February 2007. This Act has been implemented in stages throughout the past few years. Under this Act, all Class A-D products require Singapore medical device registration with the Singapore HSA. Also, manufacturers, dealers, importers and wholesalers of medical products require comprehensive government licensing in order to do business. Make sure you know the newest regulations in order to remain in compliance with Singapore law! Companies without the proper Singapore medical device registration or licensing will not be allowed to import, manufacture, or sell medical devices in Singapore.
- [Japan Medical Device Reimbursement 2010 Webcast](https://www.pacificbridgemedical.com/webcast/2010-japan-medical-device-reimbursement-webcast/): Japan has the second largest medical device market in the world. How you determine whether product registration makes sense is largely a function of the device reimbursement. All too often, a medical device company will go through the regulatory hurdles and long approval times in Japan to then realize that they have not determined if their pricing strategy will work. This webcast will explain the reimbursement process, including reimbursement strategies as well as what key documents and information are necessary to submit to the PMDA. It will also explain the approximate timeframes for different reimbursement schemes.

## Presentation Slides
- [Japan Pharmaceutical Registration Update 2023](https://www.pacificbridgemedical.com/presentation/japan-pharmaceutical-registration-update-2023/): Please click here to access the presentation slides: Japan Pharmaceutical Registration Update 2023
- [Vietnam Medical Device Reimbursement](https://www.pacificbridgemedical.com/presentation/vietnam-medical-device-reimbursement/): Please click here to access the presentation: Vietnam Medical Device Reimbursement
- [DMF Registration in China](https://www.pacificbridgemedical.com/presentation/dmf-registration-in-china/): To view these presentation slides, please click on DMF Registration in China.
- [10 Things to Do and Not Do to Be Successful in Asia’s Medical Device Markets](https://www.pacificbridgemedical.com/presentation/10-things-not-successful-asias-medtech-markets/): There are several steps to consider when entering the Asian medical device market. This presentation covers 10 essential steps to help grow your business in Asia. Case studies will be used to demonstrate key points.
- [Drug Registration in India Presentation](https://www.pacificbridgemedical.com/presentation/drug-registration-india-presentation/): This presentation provides an overview of the regulatory framework and drug registration process in India.
- [2015 China Medical Device Update Presentation](https://www.pacificbridgemedical.com/presentation/china-medical-device-update-presentation-2015/): This presentation covers the latest updates on medical device business and regulatory issues in China. View the presentation to learn more about Chinese market trends, distributor search, product registration, manufacturing, and more.
- [Asia Medical Device Markets Overview Presentation](https://www.pacificbridgemedical.com/presentation/asia-medical-markets-overview-presentation-2015/): This presentation provides an overview of the Asian medical device markets and covers important regulatory issues for specific Asian countries, including China, Japan, India, Thailand, and Vietnam.
- [2014 India Medical Device Updates Presentation](https://www.pacificbridgemedical.com/presentation/india-medical-device-updates-presentation-2014/): India is one of the fastest growing medical device markets in the world. This presentation offers an overview of important issues such as distributor search in India, medical device regulations, registration requirements, intellectual property, and more.
- [Opportunities in the Asian Medical Device Markets Presentation](https://www.pacificbridgemedical.com/presentation/asian-medical-device-markets-presentation-2014/): There is a wealth of opportunities for healthcare companies looking to expand to the Asian markets. This presentation provides an overview of important business and regulatory issues to consider for medical device companies interested in Asia.
- [Japanese Business Culture Presentation](https://www.pacificbridgemedical.com/presentation/japanese-business-culture-presentation-2014/): Japan has unique social customs and a distinct group mentality that greatly affects how business is conducted there. Western medical companies looking to expand to Japan will first need to properly understand Japanese business culture and etiquette. This presentation covers various essential aspects of conducting business proceedings with Japanese people as well as important HR issues.
- [Doing Business in Singapore Presentation](https://www.pacificbridgemedical.com/presentation/doing-business-in-singapore-presentation-2013/): To be successful in the Singaporean market, medical companies will need to understand the local culture and learn how to conduct business properly there. View this presentation for a comprehensive overview of Singaporean business culture and HR issues.
- [Medical Device Strategies for Success in China, Japan, and India Presentation](https://www.pacificbridgemedical.com/presentation/medical-device-strategies-for-success-presentation-2011/): With the U.S. and European business climates in a downturn, the world is leaning toward Asia for growth. Tremendous opportunities abound in the China, Japanese, and Indian medical markets. Understanding how to enter, expand or deal with key regulatory issues in these markets is key to surviving in the competitive global market. From setting up your own branch in Japan to conducting clinical trials in India, this presentation will delve into the key business and regulatory issues in China, Japan, and India. Real case studies will be used to support main points.
- [China Distribution System – Drug/OTC/Device Presentation](https://www.pacificbridgemedical.com/presentation/china-distribution-system-presentation-2010/): Today, everyone knows that China's medical markets are the fastest growing in the world. But the vast territory and the various provincial markets can be difficult to maneuver. How do you find the right China medical device distribution network? Would a national distributor be sufficient, or should you pick several regional distributors? How are product prices set? Which medical products get reimbursement and how are margins determined? How can you win tenders? View our presentation to better understand distribution and pricing in China for your medical device, drug, or OTC product.
- [Quality Assurance for Medical Devices in China Presentation](https://www.pacificbridgemedical.com/presentation/medical-device-quality-assurance-china-presentation-2009/): More and more medical device companies are sourcing and manufacturing their products in China. However, given recent problems with heparin, di-ethylene glycol and melamine poisoning, quality issues have become paramount. What do you need to know about QA in China to be successful and avoid pitfalls? This presentation will go over the latest regulations for medical device QA, GMP, adverse event reporting, and additional plans for quality control. A Chinese case audit will help emphasize key issues.
- [Update on India’s Medical Device Markets Presentation](https://www.pacificbridgemedical.com/presentation/india-medical-device-markets-presentation-2009/): India combines many opportunities and many challenges for the medical device industry. India's medical device market is currently the fourth largest market in Asia. With projected growth rates of 12-16% for the next five years, one cannot ignore India's potential and vast market opportunity. This presentation will provide an overview of India's medical device market as well as discuss the most recent regulatory issues.
- [How Medical Companies can be Successful in China Presentation](https://www.pacificbridgemedical.com/presentation/how-to-be-successful-in-china-presentation-2009/): There is no doubt that China is and will continue to be a global hotspot for the medical industry. Yet many Western companies that rush haphazardly into China without fully understanding its business culture and mentality ultimately meet with failure. This presentation first provides crucial information on entering the Chinese medical market. It then goes one step further to give insight into communication and management techniques that have proven effective in the Chinese business context.
- [Japan Business Culture and Etiquette Presentation](https://www.pacificbridgemedical.com/presentation/japan-business-culture-presentation-2008/): With the third largest economy in the world, Japan is an attractive market for Western companies looking to expand internationally. To do successful business in Japan, however, Westerners need to understand Japanese culture and business etiquette. The strongly hierarchical group mentality and distinct social etiquette in Japan require careful consideration in your business proceedings with Japanese people. What messages are indirectly communicated via speaking manner and body language? How do Japanese companies balance business and social proceedings? What are common mistakes that Western companies make? What is the most successful approach to doing business with Japanese people? View this presentation to learn more about how to conduct business in Japan.
- [Doing Business in India Presentation](https://www.pacificbridgemedical.com/presentation/doing-business-in-india-presentation-2008/): The Indian economy is booming! India is becoming increasingly popular as a low-cost place to manufacture goods and outsource services. But without a full grasp of the local business environment, cost savings can be elusive. This presentation covers topics from joint ventures and foreign investment to recruiting strategies in India. What are the risks and benefits of doing business in India? What types of candidates are available to fill key jobs in India? How is the Indian culture different from East Asian and Western culture? View this presentation for the answers to these questions and more.
- [Understanding Asian Cultural Diversity for Medtech Companies Presentation](https://www.pacificbridgemedical.com/presentation/understanding-asian-cultural-diversity-presentation-2008/): Managing Asian cultural and business diversity can be very complex for Western companies. Each country has its own culture, history, ideology, language and philosophy: a strategy in Taiwan may not work in China, and vice versa. Understanding the local mentality, beliefs, and even linguistic traits can make a world of difference in managing Asian employees effectively. View this presentation to learn about business culture and strategies for the different Asian countries.